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Cervical cancer is primarily caused by infection with Human papillomavirus 
(HPV) and is a global concern, particularly in developing countries which 
contain ~80% of the cervical cancer burden. Current HPV L1 major capsid 
protein virus-like particle (VLP)-based vaccines are effective in the 
type-specific prevention of infection and associated disease. However, the 
high cost of the vaccines has limited their widespread application, and 
cytological screening programmes are still required to detect malignant 
lesions associated with the non-vaccine types, particularly in HIV-infected 
populations. Furthermore, the vaccines lack therapeutic efficacy in the 
treatment of established HPV infections and disease. As a result, there is an 
urgent demand for cheaper second-generation HPV vaccines, preferably 
novel vaccines which are therapeutic, and broadly protect against several 
HPV types.  
 
The objective of this study was to express novel HPV-16 L1-based chimaeras 
in plants using transient and transgenic tobacco expression systems, 
and investigate the immunogenicity of three L1 chimaeric candidate vaccines 
containing sequences of the L2 minor capsid protein. Eight L1 chimaera 
candidate vaccines were designed with cross-protective L2 epitopes and 
therapeutic E7 CTL epitope sequences replacing regions of the L1 C-terminal. 
The L1/L2 chimaeras contained epitope sequences derived from HPV-16 L2 
aa 108-120, 56-81 or 17-36 and BPV-1 L2 1-88 substituted into the helix 4 
(h4) region of L1 at aa 414. The L1/E7 chimaeras contained the HPV-16 E7 
CTL epitopes aa 49-57 and aa 86-93 (used in HPV-related cancer 
immunotherapy studies in mice and humans respectively) substituted in a 
similar L1 region at aa 417. Furthermore, two L1/L2/E7 chimaeras were 
analysed and contained the L2 aa 108-120 epitope at aa 414 and an 
additional E7 epitope in the coil between h4 and the β-J region at aa 433/434. 
 
All chimaeras were expressed in plants using an Agrobacterium-mediated 












expressed protein to the chloroplast. The L1/E7 and L1/L2/E7 chimaeras were 
poorly expressed in plants, with yields of 30 – 80 mg/kg plant tissue, and 
require further optimisation. Transient and transgenic plant expression studies 
suggest the insertion of two epitopes in the L1/L2/E7 chimaeras negatively 
affects chimaera expression. 
 
The L1/L2 chimaera with the BPV L2 aa 1-88 epitope replacing the C-terminal 
of L1 was not well-expressed and degradation was detected, suggesting 
expression of this chimaera is not viable in plants. Three L1/L2 chimaeras 
containing the L2 aa 108-120, 56-81 and 17-36 epitopes were 
highly-expressed with yields of ~1200 mg/kg plant tissue, and chimaeras 
assembled differently,  indicating that the length of the L2 epitope affects VLP 
assembly. The L1/L2 chimaera containing L2 aa 108-120 epitope was the 
most successful candidate vaccine. It assembled into small VLPs, elicited 
anti-L1 and L2 responses and antisera neutralised pseudovirions from 
homologous HPV-16 and heterologous HPV-52, which are detected in 
50-60% of cervical cancers and are highly prevalent in cervical lesions in 
South Africa. The other L1/L2 chimaeras containing longer L2 sequence 
replacements predominantly assembled into capsomeres and aggregates and 
elicited lower humoral immune responses. 
 
In summary, the expression of HPV-16 chimaera candidate vaccines in plants 
was investigated and optimized using several methods. The immunogenicity 
and the potential of HPV-16 L1/L2 chimaeras to display the L2 epitopes was 
analysed and the results demonstrated the importance of VLP assembly in the 
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Chapter 1: Literature Review 
1.1 Introduction 
Human papillomaviruses (HPVs) are small, double-stranded, non-enveloped 
DNA viruses that infect human squamous and cutaneous epithelial cells 
(zur Hausen, 2000). The virus genome is approximately 8 kb in size (Seedorf 
et al., 1985) and encodes six early genes (E1, E2, E4, E5, E6, and E7) and 
two late genes (L1 and L2). The structure and function of the encoded 




Figure 1: HPV-16 genome and encoded protein function. The transcriptional promoter is 
designated P97. AE and AL are the early and late polyadenylation sites, respectively. The 
viral long control region (LCR) contains transcriptional and replication regulatory elements. 
The HPV-16 genome contains six early genes, E1, E2, E4, E5, E6, E7, and two late genes, 
L1 and L2 (modified from Lin et al., 2010). 
 
 
The late genes encode the structural capsid proteins: the major capsid protein 
(L1) and the minor capsid protein (L2). The capsid shell comprises of 360 
copies of L1 assembled into 72 pentamers (capsomeres) with 36-72 copies of 
L2 (Buck et al., 2008) arranged in a T=7 icosahedral lattice (Trus et al., 1997; 












(VLPs), in the presence or absence of L2 (Kirnbauer et al., 1992). Although 
the VLPs lack the virus genome DNA, their morphological and immunological 
characteristics are very similar to those of native papillomaviruses (Kirnbauer 
et al., 1992, 1993; Rose et al., 1994a; Hagensee et al., 1993).  
 
The family Papillomaviridae consists of 16 genera, with 5 of these containing 
HPVs: the Alpha, Beta, Gamma, Mu and Nu papillomaviruses (de Villiers et 
al., 2004). HPVs comprise of more than 120 epitheliotropic genotypes, which 
are sub-grouped into cutaneous or mucosal types according to their ability to 
infect the skin or mucosa of the genital or the upper-respiratory tracts. 
Approximately 40 of these types specifically infect the genital tract (Muñoz et 
al., 2003), and 12 are classified as human carcinogens by the International 
Agency for Research on Cancer (IARC) (Bouvard et al., 2009). 
 
The HPV types that infect the genital mucosa are divided into two groups. The 
low-risk types, including HPV-6 and 11, cause benign condylomas. The 
high-risk types, such as HPV-16 and 18, are strongly associated with the 
development of malignant disease (Muñoz et al., 2003). HPV types are 
classified on the basis of L1 gene sequence homology. With rare exception, 
most of the known HPV types that infect the genital tract are members of the 
Alphapapillomavirus (A) genus (de Villiers et al., 2004).  
 
1.2 The global burden of cervical cancer 
Cervical cancer is the third most common cancer among women worldwide, 
with 529 000 incident cases and 275 000 attributable deaths in 2008 (Ferlay 
et al., 2010). More than 80% of cases arise in developing countries where 
health care resources are limited (Parkin and Bray, 2006). The global 
distribution of cervical cancer is shown in Figure 2, with majority of cases 














Figure 2: Distribution of cervical cancer deaths worldwide as reported through Globocan 
(Ferlay et al., 2010). 
 
Carcinoma of the cervix is associated with HPV in more than 99% of cases 
(Walboomers et al., 1999), and the causal association between HPV infection 
and cervical cancer has been well-described (zur Hausen et al., 1981). HPV 
has also been established as a cause of cancer of the penis, vulva, anus, 
vagina and oropharynx (Münger et al., 2004), and therefore HPV vaccine 
development is a prime priority for preventative cancer research. 
 
The majority of HPV infections, regardless of type, are transient and clear 
spontaneously, typically within 1 to 2 years (Schiffman et al., 2005), although 
resolution is less frequent and substantially delayed in immuno-compromised 
subjects (Koshiol et al., 2006). Approximately 10% of women fail to clear 
high-risk HPV-type infections and long-term persistent HPV infection is a 
prerequisite for the development of cervical cancer (Stanley, 2008). 
 
HPV-16 is the most prevalent genotype among women with invasive cervical 
cancers, followed by HPV-18, thus these types are the major etiological 
agents of cervical cancer and account for approximately 70% of diagnosed 
cervical cancers worldwide (Smith et al., 2007a, de Sanjosé et al., 2010). 












HPV-31, 33, 35, 45, 52 and 58, as consistently reported by the global IARC 
pooled analysis (>3000 cases, Muñoz et al., 2004), meta-analyses 
(>10,000 cases, Clifford et al., 2003; >14,500 cases, Smith et al., 
2007a; >30,800 cases, Li et al., 2011) and a recent cross-sectional 
world-wide study (>10,500 cases, de Sanjosé et al., 2010).  
 
HPV is highly prevalent in South Africa and is detected in 20-26% of women 
(Williamson et al., 2002; Mqoqi et al., 2004; Marais et al., 2008a). Cervical 
cancer is the second most common cancer among South African women and 
the most prevalent in black women (Mqoqi et al., 2004), with 6800 women 
diagnosed each year and 3700 annual deaths (Sinanovic et al., 2009).  
 
These statistics highlight the significant burden of HPV infection and its 
associated disease, particularly in developing countries with high morbidity 
and mortality rates (Cutts et al., 2007). Screening programmes have been 
ineffective in reducing the incidence of cervical cancer in developed countries 
(Lowy et al., 2008), and given that  prophylactic vaccines are an effective 
strategy to prevent HPV infections and associated disease (WHO, 2005), 
there is an urgent demand for HPV vaccines, both globally and locally in 
South Africa.  
 
1.3 Prophylactic HPV vaccines 
The L1 major capsid protein is the antigen of choice in the development of 
prophylactic (preventative) vaccines. Expression of L1 results in the 
spontaneous self-assembly of virus-like particles (VLPs) which are similar 
both morphologically and immunogenically to native virions (Zhou et al., 
1991a; Kirnbauer et al., 1992; Rose et al., 1994a) and thus retain 
immunogenic epitopes found on authentic virions without containing the 
infectious genome. 
 
Immunization with VLPs induces the production of neutralising antibodies 
(NAb) which protect animals from subsequent challenge with infectious virus 












al., 1996; Kirnbauer et al., 1996) and are predominantly directed against 
type-specific conformational epitopes (Christensen and Kreider, 1990; 
Kirnbauer et al., 1992; Roden et al., 1994; Rose et al., 1994b).  
 
The well-established link between HPV infection and cervical cancer 
(Wallboomers et al., 1999), as well as the high prevalence of HPV infection 
(Smith et al., 2007a), has lead to the development of prophylactic vaccines 
directed against the most relevant high-risk oncogenic HPV types 
(Christensen, 2005). Early adolescent females are the primary target of 
preventative HPV vaccines, as up to 48% of women will have evidence of 
cervical human papillomavirus (HPV) infection within 3 years after initiating 
sexual activity (Collins et al., 2002).  
 
Two HPV L1 VLP-based prophylactic vaccines have been licenced and are 
commercially available (reviewed by Lin et al., 2010). Gardasil® (Merck & Co., 
Inc.) is a quadrivalent HPV-6/11/16/18 vaccine, containing L1 VLPs of low-risk 
types 6 and 11, and the high-risk oncogenic types 16 and 18. The VLPs are 
produced in a Saccharomyces cerevisiae expression system and are 
adsorbed onto amorphous aluminum hydroxyphosphate sulfate (AAHS) 
adjuvant. CervarixTM (GalaxoSmithKline Biologicals) is a bivalent HPV-16/18 
vaccine containing L1 VLPs from HPV types 16 and 18, produced in 
recombinant baculovirus insect cells (Trichoplusia ni) and adjuvanted with 
3-O-desacyl-4´-monophosphoryl lipid A and aluminium hydroxide (AS04). The 
vaccines are expensive (US $300-360 for a 3 dosage regiment), administered 
by intramuscular injection and require refrigeration (Schiller et al., 2008). 
 
Vaccine safety, immunogenicity and efficacy has been demonstrated for both 
Gardasil® and CervarixTM in Phase II and III clinical trials (Harper et al., 2006; 
Villa et al., 2006; FUTURE II Study Group, 2007a; Garland et al., 2007; 
Paavonen et al., 2007), summarized and reviewed by Schiller et al. (2008). 
Prophylactic vaccine efficacy was defined by the absence of HPV 
vaccine-type infections and/or associated disease endpoints, particularly 
high-grade Cervical Intraepithelial Neoplasia (CIN2+) for both vaccines, as 












Neoplasia (VaIN) and genital warts, for the Gardasil vaccine. The study of 
primary efficacy was done using women who were both DNA and 
seronegative for HPV vaccine types prior to immunisation.  
 
Results show vaccines are well-tolerated, highly immunogenic and prevent 
vaccine-type infections and HPV-related CIN2+ and cervical adenocarcinoma 
in situ (AIS) in young women (Harper et al., 2004, 2006; Villa et al., 2005, 
2006; Ault et al., 2007a; FUTURE II Study Group, 2007a, 2007b; Garland et 
al., 2007; Joura et al., 2007, 2008; Paavonen et al., 2007, 2009). 
Furthermore, women previously exposed to one or more HPV vaccine types 
prior to Gardasil immunisation did not experience reinfection or reactivation of 
vaccine-type associated disease (Olsson et al., 2009). The sustained safety 
and protective efficacy for vaccine HPV type infections and associated 
disease has been demonstrated up to 6.4 years for Cervarix (Harper et al., 
2006; David et al., 2009) and 8.5 years for Gardasil (Villa et al., 2006; 
Rowhani-Rahbar et al., 2009) following vaccination.  
 
Low levels of cross-neutralising antibodies against closely-related HPV types 
are elicited by the L1 VLP vaccines (Brown et al., 2009; Ault, 2007b; Harper et 
al., 2004, 2006; Paavonen et al., 2007, 2009; Bonanni et al., 2009). In 
particular, cross-reactivity has been observed between HPV-16, 31, 33, and 
58 and between HPV-18 and 45, however the efficacy and duration of the 
cross-neutralising antibody responses are currently unknown (Kwak et al., 
2011). Cervarix has also shown cross-protection against incident infection 
with HPV-52 (Harper et al., 2004), although efficacy against HPV-52 may not 
be sustained over time (Harper et al., 2006), and recently cross-protection 
against individual HPV-31, 33 and 45 type-associated CIN2+ lesions has 
been reported by Paavonen et al. (2009).  
 
1.4 Limitations of current HPV vaccines 
It should be stated that the multi-national HPV phase II and III trials were not 
inclusive of all geographical regions, most noticeably Africa, and long-term 












and vaccine disease efficacy (Dillner et al., 2007; Schiller et al., 2008). Also, 
the initial trials were not representative of all gender and age populations, 
although other small-scale clinical trials analysing efficacy in males and 
mature women have recently been published (Reisinger et al., 2007; Block et 
al., 2006; Pederson et al., 2007; Muñoz et al., 2009; Olsson et al., 2009; 
Schwarz et al., 2007; Castellsagué et al., 2009; Bonanni et al., 2009).  
 
Despite the high efficacy of both vaccines, there are several important 
concerns including: (a) the vaccine type-restricted prophylactic efficacy, which 
limits protection in different populations given the geographical and regional 
variation in HPV type prevalence and distribution, (b) the lack of therapeutic 
efficacy and (c) the high cost of vaccines.   
 
1.4.1 Type-specificity of L1-based HPV vaccines 
Over a dozen high risk HPV genotypes are commonly associated with cervical 
cancers worldwide (Muñoz et al., 2004) and thus the development of vaccines 
protecting against multiple HPV types is a public health priority. Although 
cross-protective responses have been reported for the vaccines, in vitro 
neutralisation studies indicate that cross-neutralising antibody titres are low 
(Smith et al., 2007b). Furthermore, the limited cross-protective efficacy of 
vaccines is evident in analyses including lesions associated with non-vaccine 
types, particularly in intention-to-treat (ITT) groups which incorporates women 
with prevalent HPV infections and thus offer the best indication of vaccine 
protection in a partially-infected general population (Schiller et al., 2008).  
 
Data from the Gardasil FUTURE I and II trial indicated vaccine efficacy in the 
prevention of external genital lesions, CIN2/3 and AIS were 34%, 20% and 
17% respectively in ITT groups (Schiller et al., 2008). Paavonen et al. (2009) 
reported Cervarix efficacy was only 37-53% against CIN2+ lesions associated 
with non-vaccine oncogenic HPV types. Furthermore, cross-protection elicited 
by Gardasil was not effective against high-grade cervical lesions (CIN2+) 
associated with non-vaccine HPV types in the ITT group (Wheeler et al., 













An important consideration in HPV vaccine development, particularly in an 
African context, is the geographical and regional differences in HPV genotype 
prevalence and associated disease (de Sanjosé et al., 2010; Castellsagué et 
al., 2006; Smith et al., 2007a) and the prevalence of HPV in Human 
immunodeficiency virus (HIV)-infected populations (Clifford et al., 2006).  
 
Although HPV prevalence is highly variable among different populations, the 
most common high-risk HPV types in asymptotic women are HPV-16, 18, 52, 
31, 58, 39, 56 and 51 (Bruni et al., 2010), suggesting prophylactic vaccines 
should prioritise protection against these types. Sub-Saharan Africa has the 
highest HPV prevalence in the world, with a prevalence of 24% in comparison 
to the global estimate of 11% (Bruni et al., 2010). HPV-positive women in 
Africa are significantly less likely to be infected with HPV-16 and more likely to 
be infected with other HPV types than European women (Clifford et al., 2005), 
and contain a greater burden of non-vaccine type HPV infections (Bosch et 
al., 2009), indicating broadly protective vaccines are particularly essential in 
Africa. 
 
A recent study on the geographical HPV genotype distribution in cervical 
cancers was published by de Sanjosé et al. (2010). The global HPV type 
prevalence and African estimates are compared in Figure 3. The cumulative 
prevalence of the vaccine types HPV-16 and 18 in African cervical 
adenocarcinomas is 71% (similar to the global estimate). However, Africa has 
the lowest proportion of cervical cancer attributable to HPV-16, and the HPV 
types 18, 45, 35 and 51 are all more prevalent then global estimates. 
Furthermore, multiple HPV infections are detected in 26-48% of HPV-infected 
women in South Africa (Marais et al., 2008; Said et al., 2009) and 19% of 
cervical abnormities in Africa are associated with multiple HPV infections, 
which is more than double the global estimates of 9% (de Sanjosé et al., 














Figure 3: Global and African prevalence of HPV types in invasive cervical cancer globally. 
The data was taken from de Sanjosé et al. (2010) and modified. 
 
 
The high prevalence of HPV-35 in sub-Saharan Africa has been reported both 
for asymptotic women (Clifford et al., 2005) and in women with high-grade 
cervical cancer; specifically in South Africa (Allan et al., 2008; Said et al., 
2009), Nigeria (Clifford et al., 2005), Kenya (De Vuyst et al., 2003) and 
Mozambique (Castellsagué et al., 2001). Other non-vaccine types which were 
highly prevalent in cervical cancer include HPV-31, 33, 45, 52, 53 and 58 (Kay 
et al., 2003; Naucler et al., 2007; Allan et al., 2008; Marais et al., 2008a; 
Banura et al., 2008; Blossom et al., 2007; De Vuyst et al., 2003; Said et al., 
2009; Xi et al., 2003; Louie et al., 2009).  
 
A recent South African study demonstrated HPV-16, 18 and 35 prevalence 
was associated with increasing cervical disease severity (Allen et al., 2008). 
Importantly, HPV-16 only predominated in women with high-grade squamous 
intraepithelial lesions (HSILs), in whom HPV-35 was equally prevalent 
(18.9%). Furthermore, HPV-52 was the most prevalent in low-grade 
squamous intraepithelial lesions (LSILs, 17.5%) and highly prevalent with 
HPV-31 in HSIL (11.3%), thus the non-vaccine types HPV-31, 35 and 52 are 













Importantly, the efficacy of these vaccines has not been evaluated in 
immuno-compromised populations (Villa, 2011), particularly in HIV-infected 
women who have a higher risk of acquiring HPV infections and developing 
HPV-related diseases (Palefsky, 2006; Clifford et al., 2006; Moodley et al., 
2006; 2009; Baay et al., 2004; Adler et al., 2008; Louie et al., 2009). 
In particular, African HIV-positive women have the highest prevalence of HPV 
infection worldwide (Clifford et al., 2006) and several African studies have 
indicated HPV-16 does not predominate to the same extent as seen in 
HIV-negative women (Moodley et al., 2009; Sahasrabuddhe et al., 2007; 
Blossom et al., 2007; Singh et al., 2009; Banura et al.,  2008).  
 
In South Africa, Marais et al. (2008b) demonstrated HPV prevalence in HIV-
positive woman is more than double compared to HIV-negative women (50% 
and 24% respectively). Although HPV-16 is the most prevalent type in 
HIV-positive women with cervical cancer, other important types in South Africa 
include HPV-45 (Marais et al., 2008b), HPV-51 and 58 (Moodley et al., 2009) 
and HPV-52, 53 and 35 (Denny et al., 2008). As a result, broadly protective 
vaccines are a priority in these populations. 
 
1.4.2 The lack of therapeutic efficacy 
Another concern is the therapeutic treatment of HPV infections in women who 
have been previously exposed to HPV. Although HPV vaccination has been 
shown to induce cell-mediated immune responses traditionally involved in the 
eradication of infections (Giannini et al., 2006; Pinto et al., 2003; 2005; Emeny 
et al., 2002; Peng et al., 1998), neither Gardasil (FUTURE II Study Group, 
2007b) nor Cervarix (Hildersheim et al., 2007) demonstrated therapeutic 
efficacy against prevalent HPV infections or lesions, with no effect on the rate 
of viral clearance or HPV-related disease progression (Schiller et al., 2008).  
 
1.4.3 High vaccine costs 
HPV vaccines will potentially have the greatest impact in developing 
countries, which have the highest burden of HPV-related disease as a result 
of poor health resources (Parkin and Bray, 2006). One of the biggest hurdles 












as vaccine type-specificity does not eradicate the need for cytological 
screening programmes to detect cervical cancers caused by the non-vaccine 
HPV types (Kwak et al. 2011). In South Africa, estimates for a cost-effective 
vaccination and screening programme suggest a reduction of >60% is needed 
(Sinanovic et al. 2009). Therefore there is an urgent demand for cheaper 
second-generation HPV vaccines.  
 
1.5 Second-generation prophylactic HPV vaccines 
The necessity of further HPV vaccine development is called into question with 
two highly-effective prophylactic vaccines available. However, the cost and 
limited protection of the vaccines have provided an incentive for the 
development of improved second-generation HPV vaccines. 
 
1.5.1 Broadening protection using L2 cross-neutralising epitopes 
Although the immunogenicity and efficacy of HPV vaccines has been 
well-demonstrated, the cross-protection against other oncogenic HPV types is 
partial and limited to closely related genotypes. As a result of the 
type-restriction of vaccines, it remains important to broaden protection to 
include the remaining oncogenic HPV types.  
 
The L2 minor capsid protein has emerged as a candidate for the development 
of prophylactic HPV vaccines (Gambhira et al., 2006; Alphs et al., 2008; 
Karanam et al., 2009). The N-terminal region of L2 is of particular interest as it 
contains several epitopes (surface-exposed immunogenic regions displayed in 
a specific three dimensional conformation) which induce the production of 
cross-neutralising antibodies against a broad range of papillomavirus types 
(Roden et al., 2000; Kawana et al., 1999, 2001, 2003; Embers et al., 2004; 
Pastrana et al., 2005; Palmer et al., 2006; Gambhira et al., 2007a; Kondo et 
al., 2007, 2008; Alphs et al., 2008; Schellenbacher et al.,  2009) and elicits the 
production of neutralising antibodies which protect in vivo (Gaukroger et al., 













A structural sequence analysis shows the L2 amino acid (aa) 1-120 region to 
be highly conserved (Lowe et al., 2008). Several areas within this region are 
broadly neutralising and studies using overlapping L2 peptides have been 
utilized to map the important cross-neutralising epitopes (Pastrana et al., 
2005; Schellenbacher et al., 2009; Rubio et al., 2009; Rubio et al., 2011). 
Three highly-conserved neutralising epitopes within HPV-16 L2 N-terminal 
have been identified: aa 90-122, 56-81 and 17-38. 
 
(a) L2 epitopes within aa 90-122 
The first major region investigated for cross-neutralisation is aa 90-122. The 
cross-neutralising HPV-16 L2 epitope comprising of aa 108-120 has shown to 
generate sera which cross-neutralises HPV-6 (Kawana et al., 1999) and 
HPV-52 (Kawana et al., 2003). Additionally, fusion of the peptide to keyhole 
limpit haemocyanin (KLH) induced cross-neutralising antibodies against native 
HPV-11 virions (Slupetzky et al., 2007).  
 
Several L2 peptides overlapping this region were examined, including 
aa 90-111, 96-115 and 107-122. Only the L2 peptide composed of aa 96-115 
cross-neutralised HPV-31 and 58, suggesting the regions unique to this 
peptide (aa 96-107 and aa 111-115) are essential in the epitope, although 
mutating aa 101 and 112 had no affect on cross protection (Kondo et al., 
2007). A similar observation was reported by Embers et al. (2002), whereby 
the overlapping L2 region aa 107-112 of cottontail rabbit papillomavirus 
(CRPV) and rabbit oral papillomavirus (ROPV) did not contribute to 
cross-protective responses between these PV types. Furthermore, Kawana et 
al. (1999) demonstrated that HPV-16 L2 peptide aa 95-107 was not bound by 
HPV-16 L1/L2 VLP monoclonal antibodies (MAb) and Schellenbacher et al. 
(2009) recently demonstrated that peptides did not elicit neutralisation 
responses without the aa 113-115 region. Taken together, these studies show 
HPV-16 L2 aa 96-115 region contains a broadly neutralising epitope, with 
strong evidence suggesting the epitope occurs at aa 113-115. 
 
Despite these positive results, the HPV-16 L2 aa 108-120 peptide was not 












et al., 2002), in contrast to a longer L2 aa 11-200 peptide (Gambhira et al., 
2007a). This suggests there are other cross-neutralising epitopes within the 
conserved aa 11-107 region. Furthermore, Jagu et al. (2009) reported that the 
HPV-16 L2 peptide containing aa 89-200 did not cross-neutralise several 
heterologous HPV types, in contrast to the peptides aa 13-107 and aa 12-200 
(Jagu et al., 2009), suggesting important epitopes may occur between 
aa 13-89.  
 
(b) L2 epitopes within aa 56-81 
Another highly conserved L2 region comprises of aa 56-81. Kawana et al. 
(1998) first identified this epitope, demonstrating that the linear HPV-16 L2 
aa 69-81 peptide was bound by 7 of 11 anti-L2 MAb raised against HPV-16 
L1/L2 VLPs. The linear peptide containing aa 63-75 was also bound by 
1 linear MAb, suggesting that the aa 69-81 region contains the epitope for 
6 MAb, and the 7th MAb epitope is contained within aa 69-75. In addition, the 
peptide containing aa 69-81 cross-reacted with human sera raised against the 
L1 proteins of HPV-6, 16, 18 and 58 indicating that this region contains 
a common immunodeterminant which is exposed on the HPV virion surface. 
The peptide fused to KLH and inserted into BPV-1 L1 produced antisera 
which neutralised both HPV-16 PsV and HPV-11 authentic virions (Slupetzky 
et al., 2007).   
 
A longer L2 peptide containing aa 64-81 fused to bacterial thioredoxin (Trx) 
was also shown to be broadly cross-neutralising (Rubio et al., 2009). This 
region was mapped using three HPV-16 L2 peptides: aa 56-71, 61-75 or 
64-81 (Kondo et al., 2007). All peptide antisera neutralised HPV-16 and 
cross-neutralised HPV-18 and 58. However, only the aa 56-71 peptide 
cross-neutralised HPV-31 (Kondo et al., 2007; Conway et al., 2011), 
suggesting aa 56-61 are essential for this epitope and aa 75-81 may be 
redundant. Further work using the L2 aa 56-75 peptide inserted into HPV-16 
L1 showed the cross-protection was extended to HPV-52 (Kondo et al., 2008). 
The importance of the region comprising of aa 56-75 was further emphasized 
by Schellenbacher et al. (2009), who demonstrated the L2 aa 75-112 peptide 












(c) L2 epitopes within aa 17-36 
The L2 region composed of aa 17-36 has been shown to elicit 
cross-protection against 10 papillomavirus (PV) types to date, including high-
risk types HPV-16, 18, 31, 45, 52, 58, low-risk types HPV-6 and 11, non-
related type HPV-5 and the evolutionary divergent type BPV-1 (Gambhira et 
al., 2007b; Alphs et al., 2008; Schellenbacher et al., 2009). Furthermore, the 
RG-1 MAb generated against this peptide protected mice in a HPV-16 PsV 
challenge and depletion of the peptide-specific antibodies reduced or 
eliminated neutralisation of HPV-16 and 18, further evidence of the 
importance of this region in neutralisation (Gambhira et al., 2007b).  
 
Additionally, the L2 aa 18-38 peptide is cross-protective (Kondo et al., 2007; 
2008), creating doubts about the necessity of the aa 17 in the epitope. 
Schellenbacher et al. (2009) analysed HPV-16 L2 peptides composed of 
aa 17-36 or aa 18-31 inserted into the DE loop of BPV-1 L1. In comparison to 
L2 aa 18-31, the longer peptide (L2 aa 17-36) elicited higher titres of 
neutralising antibodies against HPV-5, 16, 18, 45 and 58, similar titres to 
HPV-52 and additionally neutralised HPV-11. This suggests the residues 17 
and 32-36 play a role in the cross-neutralisation of several HPV types, 
particularly HPV-11.  
 
Recent studies have examined the L2 peptide aa 20-38. The peptide was 
shown to be more effective than five other peptides covering the N-terminal aa 
1-120 of HPV-16 L2 in the cross-neutralisation of HPV-18, 31, 45 and 58 
(Rubio et al., 2009). Two cross-neutralising MAb targeted this peptide and the 
residues critically involved in binding were identified to be aa 21-30, which 
overlap the characterized RG-1 epitope and require the two cysteine residues 
(C22 and C28) to be present for binding (Rubio et al., 2011). As a whole, the 
L2 aa 17-36 epitope appears to have the greatest potential for broad 
cross-protection. 
 
(d) Other L2 epitopes 
Cross-neutralisation has been reported for L2 proteins from other PV types. 












cross-reactive against heterologous PV types CRPV and HPV, specifically 
HPV-6, 16, 18, 31 and native HPV-11 (Pastrana et al., 2005; Gambhira et al., 
2007a).  
 
1.5.2 L1/L2 chimaeras 
A major problem with L2 vaccines is lack of exposure on the surface of mature 
L1/L2 capsids (Buck et al., 2008) and the immunogenic subdominance of L2 
(Kirnbauer et al., 1992). Although L2 peptide/protein vaccines have been 
utilized, they have been shown to have low immunogenicity. A strategy to 
overcome these limitations is the fusion of L2 proteins or epitope peptides with 
L1 to produce L1/L2 chimaeric proteins.  
 
1.5.2.1 Engineering HPV L1-based vaccines 
The success of the L1 VLP vaccines has prompted the development of 
second-generation VLP-based vaccines incorporating polypeptides. L1 is 
considered an ideal carrier molecule for several reasons: (a) VLPs elicit 
immune responses without the use of an adjuvant (Ohlschläger et al., 2003; 
Wakabayashi et al., 2002; Reddy et al., 2004; Greenstone et al., 2008), 
(b) facilitate display of antigens to both the cellular and humoral arms of the 
immune system (Lenz et al., 2003; Da Silva et al., 2001), and (c) tolerate 
foreign peptides within the surface-exposed areas (Sadeyen et al., 2003; 
Varsani et al., 2003a). The L1 structure and the assembly into VLPs has been 
extensively studied (Chen et al., 2000; 2001; Modis et al., 2002; Bishop et al., 
2007a) and several groups have examined the display of peptides in various 
L1 surface regions to overcome the low immunogenicity of peptide antigens.  
 
1.5.2.2 Structural characteristics of L1 
L1 spontaneously forms capsomeres (Rose et al., 1993, Modis et al., 2002), 
and self-assembles into virus-like particles (VLPs), which may be either a 
spherical icosohedral lattice structure of T = 7 symmetry that is 
morphologically indistinguishable from native HPV virions (Kirnbauer et al., 
1992, 1993; Hagensee et al., 1993; Rose et al., 1994a), or a smaller T = 1 
“small VLP” particle comprised of 12 L1 pentamers (Chen et al., 2000). VLP 












helices 2, 3, and 4 in the C-terminal region of each L1 monomer (Chen et al., 
2000; Modis et al., 2002; Bishop et al., 2007a). The assembly of L1 into the 
higher-order structures is described in detail by Modis et al. 2002 and is 




Figure 4: Structural assembly of HPV-16 L1. Schematic diagrams of the L1 pentamer 
interactions are shown from A-C (modified from Modis et al., 2002). A) Individual pentamers 
consist of five monomeric subunits, represented by grey triangles. B) Assembly of 
12 pentamers into a T=1 small VLP occurs by the L1 C-terminal arms folded back toward the 
L1 monomers. C) Assembly of 72 pentamers into T=7 full-sized VLPs occurs by the L1 
C-terminal arms projecting outwards to neighbouring pentamers. Electron micrographs of the 
structures are shown from D-F (taken from Bishop et al., 2007a and Chen et al., 2000). 
D) HPV-16 L1 pentamers (10-20 nm), with an aggregate in the top left corner. E) T=1 small 
VLPs (35-40 nm), derived from N-terminal truncated HPV-16 L1. F) T=7 VLPs (55-60 nm) 
derived from full-length HPV-16 L1. Pentamers are also visible in the background of E and F. 
Scale bar represents 50 nm. 
 
 
1.5.2.3 Molecular basis of L1 type-specificity  
The L1 sequence is highly conserved amongst papillomaviruses (Bishop et 
al., 2007b), suggesting the type-specificity of the L1 immune response is 
related to the VLP structure (Figure 5). Several highly homologous regions 
comprise the inner core pentamer structure, and four or more hypervariable 
regions make up the hypervariable surface loops displayed on the outer face 














Figure 5: HPV L1 structure and sequences. A) Structural representation of a HPV-16 L1 monomer. The helix 4 domain and the surrounding residues 
(aa 401 – 439) is indicated with the white box (taken from Murata et al., 2009). B) HPV L1 pentamer, comprising of 5 L1 monomers with the surface loops 
indicated on the diagram (taken from Bishop et al., 2007b). C) L1 sequence alignment of L1 from HPV11, HPV16, HPV18, and HPV35. Conserved residues 
and non-conserved residues are shown in capital letters and lowercase letters respectively. Residues conserved among three HPV types are highlighted in 
gray shading. The arrows represent β sheets, the α helices indicated with thick bars. The five surface loops are labelled above the sequences (Taken from 













Conformational epitopes, predominantly responsible for the production of NAb 
(Christensen et al., 1994; Roden et al., 1996; White et al., 1998, 1999; 
Giroglou et al., 2001a), are located on the L1 surface loops BC, DE, EF, FG, 
and HI (Chen et al., 2000; Bishop et al. 2007a), specifically the FG and HI 
loops of HPV-16 (Roden et al., 1997; White et al., 1999; Christensen et al., 
2001). In a study done by Bishop et al. (2007b), the HPV-11, 16, 18, and 35 
L1 pentameric crystal structures revealed distinctive conformational 
differences in the surface loops containing known neutralising epitopes, thus 
explaining the type-restricted L1 immune response. 
 
1.5.2.4 Modifications affecting L1 assembly  
There are a number of studies describing the use of PV VLPs to deliver and/or 
display foreign epitopes, either by HPV L1 C-terminal fusion (Windram et al., 
2008; Müller et al., 1997; Kuck et al., 2006; Ashrafi et al., 2008; Paz De la 
Rosa et al., 2009), or by insertion of epitopes into the core sequences of the 
HPV-16 L1 (Slupetzky et al., 2001; Varsani et al., 2003a; Sadeyen et al., 
2003) with the intention of effectively displaying the peptide epitope on the L1 
surface and improving the elicited immune response. The modification of the 
PV L1 gene and its subsequent affect on L1 immunogenicity and assembly is 
an important factor to consider in the design of L1-based chimaeras. 
 
Several studies have identified HPV-16 L1 functional domains required for 
VLP assembly. These are the first 10 residues of the N-terminal (Chen et al., 
2000, 2001) and the last 30 residues of the C-terminal region, including the 
nuclear localization signal (NLS) located between aa 484-505 (Zhou et al., 
2001b; Varsani et al., 2006a). The N-terminal truncation has been shown to 
affect the assembly of VLPs into T=1 or T=7 particles in E. coli (Chen et al., 
2000). The 10 residue N-terminal truncation of HPV-16 L1 forms T = 1 small 
VLPs, while a 9 residue N-terminal or 30 residue C-terminal truncation does 
not affect assembly into T=7 particles (Figure 4). C-terminal deletions longer 
than 30 residues had been reported to render the protein unstable and 












In addition, the helix 4 (h4) appears to play a role in VLP assembly and is 
located between residues 414-426 (Varsani et al., 2003a). The removal of 
these motifs results in capsomere formation and prevents further 
self-assembly into VLPs (Bishop et al., 2007a). Varsani et al. (2006b) 
confirmed the importance of h4, as well as the C-terminal residues 428-465, 
which partially include the h5 helix.  
 
Another important consideration for assembly is the formation of disulphide 
bonds in higher-order structures. Disulphide bonds are present in T=7 VLPs 
between the highly conserved cysteine residue 175 and 428 (Li et al., 1998; 
Sapp et al., 1998; Fligge et al., 2001) via an invading C-terminal arm (Modis et 
al., 2002) and bonds do not occur in T=1 particles, where inter-pentameric 
interactions is mediated by helices h3, h4 and h5. Mutations of these 
cysteines results in the formation of capsomeres rather than VLPs (Li et al., 
1998; McCarthy et al., 1998; Sapp et al., 1998; Fligge et al., 2001; Varsani et 
al., 2006b). 
 
1.5.2.5 L1 surface display sites  
Several studies have examined the insertion of epitopes into the PV L1 
surface regions with the intention to enhance the immunogenicity of the 
peptide without compromising the structure and immunogenicity of the L1 
VLP. Large regions of the HPV L1 C terminal are surface-exposed and 
antigenic, especially the loop containing residues 420-429 (Modis et al., 
2002). 
 
Sadeyen et al. (2003) tested the insertion of a short hepatitis B core (HBc) 
antigen epitope into the surface-exposed loops BC, DE, EF, FG and HI of 
HPV-16 (Figure 5). The insertions did not affect VLP assembly but diminished 
the HPV-16 L1 response, particularly within the FG loop (also described by 
Slupetzky et al., 2001). The DE loop in particular has been used by several 
studies and has shown to elicit both anti-L1 responses and antibodies directed 
against the inserted peptide (Slupetzky et al., 2001). Although VLP assembly 












et al., 2003a; Sadeyen et al., 2003; Zhang et al., 2004; Schellenbacher et al., 
2009), the affect may be peptide dependent (Slupetzky et al., 2007; 
Schellenbacher et al., 2009).  
 
Varsani et al. (2003a) also examined other exposed C-terminal regions for 
epitope display, using a well-characterized cross-neutralising HPV-16 L2 
epitope comprising of aa 108-120 (Kawana et al., 1999) whose sequence 
replaced the h4 region (F-position) and a coil between the h4 region and the 
β-J sheet (E-position; Figure 5). The chimaeras successfully displayed the L2 
peptide, reacted with all L1 MAb and demonstrated both anti-L1 and L2 
immune responses, suggesting that both theses insertion sites have potential 
for epitope display. Despite the disruption of VLP assembly associated with 
the deletion of h4 (Chen et al., 2001; Bishop et al., 2007a; Murata et al., 
2009), the chimaera with L2 in the F-position elicited the highest anti-L2 
response, suggesting the peptide was efficiently displayed on the L1 
capsomere surface. Although h4 is not a surface loop, structural models 
predict this region projects outward from capsomeres and is highly exposed 
on the surface (Murata et al., 2009).  
 
The chimaera with the insertion of L2 in the E-position demonstrated lower L2 
immunogenicity, as this insertion region is less exposed (Varsani et al., 
2003a; Kondo et al., 2008). However the chimaera was capable of assembling 
into VLPs and induced higher anti-L1 responses than the chimaera with the 
h4 insertion. Although the production of neutralising antibodies was not 
evaluated, the results suggest that chimaeras with epitope insertions in these 
two regions were the most immunogenic and have potential for the further 
development of HPV L1-based vaccines.  
 
1.5.2.6 Immunodominance of L1  
An important factor to consider in L1-based vaccines is the 
immunodominance of L1 epitopes, which bias the immune response toward 
L1 and result in the exclusion of subdominant epitopes. The high 












spaced repetitive units of the antigen (Chackerian et al., 2002). Importantly, 
epitope immunodominance may be dependent on its presentation (Sandburg 
et al., 1998) and has been linked to the presence of tertiary or quaternary 
structures (Ito et al., 2003). L1 immunodominant responses have been 
reported for some chimaeric L1/E7 vaccines (Bian et al., 2008; Liu et al., 
2000), although the immonodominance has not negated humoral or cellular 
responses to inserted peptides, and studies have shown the immunogenicity 
of epitope peptides is improved by insertion into L1 (Qian et al., 2006; 
Slupetzky et al., 2007) 
 
In summary, vaccination with L2 protects animals from experimental viral 
challenge and elicited cross-protective responses (Roden et al., 2000) 
mediated by broadly neutralising antibodies that recognize conserved linear 
epitopes (Gaukroger et al., 1996;  Pastrana et al., 2005). Several 
cross-neutralising L2 epitopes have been mapped to the first 120 residues of 
the N-terminal, including HPV-16 L2 aa 90-122, 56-81, 17-36 and BPV-1 
aa 1-88. The use of these regions in second generation L1/L2 chimaera 
vaccines may improve the immunity of L2 and broaden the protection of 
L1-based vaccines.  
 
1.6 Therapeutic HPV vaccines 
The current treatment of HPV-induced lesions by surgical procedures or other 
methods is both invasive and inefficient (Govan, 2005) and both the current 
prophylactic vaccines lack therapeutic efficacy (Hildesheim et al., 2007; 
FUTURE II Study Group, 2007b). In light of the high prevalence of HPV 
infection and cervical cancer burden worldwide (Muñoz et al., 2004), there is 
an immediate need for therapeutic HPV vaccines to treat existing 
HPV-induced neoplastic lesions and induce regression of premalignant 
cervical dysplasias, a strategy which is less invasive, more specific and 
potentially more effective. 
 
Protection against the development of HPV-associated disease is thought to 












and thus an effective therapeutic vaccine requires the induction of strong 
cell-mediated immune responses against HPV-specific tumour antigens. 
Therapeutic vaccines have focused on the non-structural oncogenic HPV 
proteins, particularly E6 and E7, which are responsible for the induction and 
maintenance of cellular transformation and are constitutively expressed in 
HPV-infected premalignant and malignant tissues (review by zur Hausen, 
2000).  
 
The potential of therapeutic HPV vaccines to induce tumour regression has 
been tested directly in pre-clinical murine models; using transplantable 
tumours expressing HPV E7, or by the prevention of tumour formation in 
challenge experiments (Torréns et al., 2005). Studies have demonstrated that 
E7 peptides restricted by mouse H2-Db MHC class I molecules induce tumour 
regression in mice (Feltkamp et al., 1993; Torréns et al., 2005; Paz De la 
Rosa et al., 2009), and thus the use of mouse-restricted cytotoxic T-cell 
lymphocytes (CTL) epitopes in HPV candidate vaccines allows for the 
preclinical demonstration of therapeutic efficacy against E7-expressing 
transplantable tumours.  
 
Many HPV candidate vaccines have shown therapeutic efficacy in mice 
(De Bruijn et al., 1998; Revaz et al., 2001; Ohlschläger et al., 2003), including 
plant-derived E7-based vaccines (Franconi et al., 2002; Franconi et al., 2006; 
Massa et al., 2007). However, similar vaccines containing peptides restricted 
by human MHC class I molecules have not shown clinical success in human 
tumour regression (Steller et al., 1998; van Driel et al., 1999; Muderspach et 
al., 2000), suggesting tumour regression in mice is not necessarily indicative 
of therapeutic efficacy in humans (Frazer et al., 2011). 
 
More than 40 publications describe antigen-specific immunotherapy studies 
for the therapeutic treatment of persisting HPV infection or malignant lesions 
in humans (reviewed by Frazer et al., 2011). Four major classes of HPV 
immunotherapy vaccines have undergone trials: protein vaccines (Gambhira 












2000), polynucleotide vaccines (Trimble et al., 2009), and recombinant viral 
vectors (García-Hernández et al., 2006). 
 
The majority of the studies have focused on targeting E6 or E7 proteins and 
have demonstrated induction of antigen-specific humoral and cellular immune 
responses (Bodily and Laimins, 2011). Recently, a HPV vaccine has shown 
significant efficacy in human clinical trials and provided strong evidence of a 
therapeutic effect, thus stimulating further interest in the field. High-grade 
vulval intraepithelial neoplasia (VIN3) patients immunised with synthetic long 
overlapping peptides from HPV-16 E6 and E7, together with incomplete 
Freund‟s adjuvant, demonstrated a complete and durable regression of 
premalignant lesions in 47% of patients, with a further 31% showing a partial 
response (Kenter et al., 2009). The response was associated with a strong 
and broad HPV-specific T-cell type 1 (Th1) CD4+ and CD8+ response that 
peaked after the first vaccination (Kenter et al., 2009, Welters et al., 2010).  
 
1.6.1 HPV-16 E7 cytotoxic T-cell epitopes 
Protein-based vaccines are considered safer for clinical application compared 
with DNA or virus-based vaccines, although there are safety concerns 
regarding the use of the full length oncogenic proteins (Ohlschläger et al., 
2006). The use of specific T-cell epitopes overcomes these concerns and may 
improve vaccine efficacy by the removal of non-neutralising epitopes, or those 
which bias the humoral response toward epitopes of limited importance 
(Cleveland et al., 2000). 
 
Kast et al. (1994) identified four HPV-16 E7 human-restricted T-cell epitopes 
comprising of aa 11-20 (YMLDLQPETT), 12-20 (MLDLQPETT), 82-90 
(LLMGTLGIV) and 86-93 (TLGIVCPI). Further work by Ressing et al. (1995) 
indicated three of the peptides (aa 11-20, 82-90 and 86-93) stimulated the 
lysis of human cancer cells and they have all been subsequently investigated 
in clinical trials. The aa 11-20 and aa 86-93 epitopes were shown to elicit 
immune responses but no clinical effects was observed, either when used as 












universal T-helper epitope (Steller et al., 1998), or by immunization of both 
aa 12-20 peptides and the aa 86-93 fusion protein (Muderspach et al., 2000).  
 
In addition, Feltkamp et al. (1993) identified an E7 CTL epitope specific to 
H2-Db allele-restricted mice (binds specifically to H2-Db MHC class I 
molecules) which was comprised of aa 49-57 (RAHYNIVTF), and the elicited 
E7-specific CTL response protected mice from challenge with HPV-16 tumour 
cells. As a result, this epitope has been used successfully in several tumour 
regression and CTL response studies in mice (Peng et al., 1998; Liu et al., 
2000; Torréns et al., 2005; Daftarian et al., 2006; Kuck et al., 2006; Bian et al., 
2008; Paz De la Rosa et al., 2009).  
 
1.6.2 L1/E7 chimaera vaccines  
HPV vaccines that are both prophylactic and therapeutic will be particularly 
beneficial in the treatment and prevention of HPV infections. L1-based 
chimaeras containing E7 have the potential to be dual vaccines, utilizing the 
immunogenicity of L1 VLPs to enhance cellular immune responses against E7 
epitopes (Jochmus et al., 1999; Rudolf et al., 2001).  
 
Several E7 chimaeric vaccines have been comprised of fusion proteins, 
whereby either full length or N-terminal regions of E7 are fused to the L1 
C-terminal to create L1/E7 chimaeras (Müller et al., 1997; Jochmas et al., 
1999; Schafer et al., 1999; Kaufmann et al., 2001; Freyschmidt et al., 2004; 
Kuck et al., 2006; Kaufmann et al., 2007; Bian et al., 2008), or fused to the 
C-terminal of L2 to create L1/L2/E7 chimaeras (Greenstone et al., 1998; 
Rudolf et al., 2001; Wakabayashi et al., 2002; Da Silva et al., 2003; Qian et 
al., 2006; Xu et al., 2007).  
 
Phase I clinical trials for a L1/E7 fusion chimaera demonstrated the induction 
of L1 and E7-specific antibodies and cellular immune responses, although 
clinical efficacy was not significant (Kaufmann et al., 2007). However, both 












al., 2005) chimaeras induce human cellular immune responses in vitro, 
suggesting further research is needed.  
 
Studies have used E7 CTL epitopes in chimaeric VLPs (Peng et al., 1998; Liu 
et al., 2000; Paz De la Rosa et al., 2009) and the insertion of the HPV-16 E7 
mouse H2-Db-restricted CTL epitope (aa 86-93) into BPV-1 L1 C-terminal 
demonstrated efficacy in mice (Peng et al., 1998). Recently, Paz De la Rosa 
(2009) fused several HPV-16 E6 and epitopes to the HPV-16 L1 C-terminal 
and the chimaeric VLP (cVLP) induced HPV-specific humoral and cellular 
immune responses in mice. The E7 epitopes included the mouse-restricted 
epitope aa 49-57 and the human-restricted epitopes aa 86-93 and aa 37-54 
(T-helper epitope).  
 
Taken together, these studies indicate chimaeric VLP-based vaccines 
containing E7 CTL epitopes are a potential strategy for the development of 
duel prophylactic and therapeutic HPV vaccines. 
 
1.7 Reducing vaccine costs 
The high cost of vaccines has limited their global implementation, particularly 
in developing countries with the highest cervical cancer burden (Muñoz et al., 
2004). An attractive approach to reduce the cost of HPV vaccines includes: 
(a) the use of L1-based capsomere vaccines, and (b) alternative low-cost 
bacterial or plant expression systems. 
 
1.7.1 Capsomere-based vaccines  
The use of L1 capsomere-based vaccines is a potential strategy for the 
development of thermostable and cost-effective vaccines. Capsomeres induce 
high titres of anti-L1 neutralising antibodies and T-cell responses (Ohlschläger 
et al., 2003; Dell et al., 2006; Thönes et al., 2008), effectively display foreign 
antigens (Varsani et al., 2003a; Murata et al., 2009) and protect against viral 
challenge in animal models (Rose et al., 1998; Yuan et al., 2001). 












need for refrigeration. This could facilitate the introduction of HPV vaccines 
into low resource settings where they are needed the most.  
 
Although L1 capsomeres induce 20 to 40-fold lower humoral immune 
responses in comparison to VLPs (Thönes et al., 2008), the use of an 
adjuvant can potentially close this gap (Yuan et al., 2001; Schädlich et al., 
2009; Jagu et al., 2010) and both antigens induced similar CD8 T-cell 
responses after subcutaneous, intranasal, and oral immunization (Thönes et 
al., 2008). As a result, HPV capsomeres show potential as an alternative 
vaccine antigen. 
 
1.7.2 Plant expression systems  
Several hosts have successfully expressed HPV-16 L1, including bacteria 
(Chen et al., 2001), yeast (Carter et al., 1991), insect cells (Le Cann et al., 
1994), mammalian cells (McLean et al., 1990) and plants (Biemelt et al., 2003; 
Warzecha et al., 2003; Varsani et al., 2003b). Cell culture-derived vaccines, 
such as the current HPV vaccines produced in recombinant baculovirus and 
yeast systems, are associated with relatively high production costs, require 
expertise and are difficult to scale up (Tiwari et al., 2009; Daniell et al., 2009; 
Demain and Vaishnav, 2009), thus limiting their widespread application in 
developing countries. Similar problems are associated with mammalian cell 
systems and thus do not present a cost-effective alternative. Although 
bacterial systems have potential for low-cost production of antigens, they lack 
the eukaryotic post-translational machinery which is often necessary for 
human vaccine antigens, and E. coli-expressed HPV L1 exclusively 
assembles into capsomeres (Li et al., 2001; Yuan et al., 2001). Moreover, all 
these systems are amenable to contamination by micro-organisms, 
endotoxins or pyrogens, thus requiring extensive purification (Demain and 
Vaishnav, 2009; Tiwari et al., 2009).  
 
The use of plant expression systems for the large-scale production of foreign 
antigens has been proposed as a cost-effective alternative for vaccine 












system allows rapid scale-up and expression of recombinant proteins free of 
contamination by bacterial toxins or human pathogens (i.e. increased safety) 
and they contain eukaryotic protein modification machinery, allowing 
sub-cellular targeting, proper folding, and post-translational modifications 
(Fischer et al., 2004). The ability to rapidly scale-up production according to 
demand is particularly advantageous for rapid-response vaccine scenarios 
such as bio-terror threats or emerging diseases (Chichester et al., 2009; 
Rybicki, 2010). 
 
In particular, it has been proposed that plant production of human and animal 
vaccines may lower the cost of production significantly, especially for oral 
vaccination (reviewed by Fischer et al., 2004). However, research is moving 
away from the original concept of “edible vaccines” as a result of several 
practical and ethical issues, and it is generally accepted that plant-derived 
vaccines will need to processed and reproducibly formulated (Rybicki, 2010). 
Regardless, estimates suggest plants systems reduce vaccine production 
costs by 31% and thus provide cheaper production alternatives to 
well-established conventional HPV vaccines and new second-generation HPV 
vaccines (Rybicki, 2009; Rybicki, 2010). 
 
A variety of plants have been used to express human and animal vaccine 
antigens (detailed reviews by Rybicki, 2009; Rybicki, 2010; Lössl and Waheed 
2011). Plant-produced candidate vaccines have generated antigen-specific 
systemic and mucosal immune responses and conferred protection against 
challenge in animal model systems (Streatfield and Howard, 2003).  Several 
vaccines are at different stages of clinical trials (Rybicki, 2010; Obembe et al., 
2011) and two plant-derived proteins have been licenced (Website 1: 
http://www.molecularfarming.com): a transgenic tobacco-produced antibody 
(Pujol et al., 2005) and an injectible veterinary NDV vaccine for poultry 
(Website 2: http://www.dowagro.com/; Rybicki, 2009).  
 
A practical limitation of plant systems is low yields of recombinant protein, 
potentially a result of protein instability or low-level expression. There are 












expression and protein stability (reviewed by Fischer et al., 2004; Schillberg et 
al., 2005; Obembe et al., 2011). Strategies include the use of strong plant 
promoters, codon-optimization of the gene and introduction of 
a 5'-untranslated plant virus sequence or other translational enhancers. 
Furthermore, the co-expression of viral silencing suppressor proteins (Takeda 
et al., 2002; Voinnet et al., 2003) and the use of transcription factors (Yang et 
al., 2001) can further enhance transcript stability and transgene expression.  
 
The stability of recombinant proteins has been considered as the single most 
important factor limiting the yields in plant production systems (Schillberg et 
al., 2005) and poor protein folding and the resultant instability reduces the 
accumulation of heterologous proteins in plants (Ma et al., 2003). This 
problem has been effectively addressed by targeting the proteins to the 
secretory pathway (Franconi et al., 2006; Noris et al., 2011) or intra-cellular 
organelles (Maclean et al., 2007). 
 
Plant expression of recombinant proteins occurs as a result of the genetic 
transformability of plants (Bevan et al., 1983). Plant expression systems 
effective in the industrial-scale production of vaccines include: (a) stable 
transgenic or transplastomic expression in plants, (b) transient expression in 
plant virus-based or Agrobacterium tumefaciens-based plant systems, and 
(c) seed expression systems (reviewed in Rybicki, 2009).  
 
The two main strategies employed in the production of plant-derived HPV 
vaccine antigens are transgenic and transient expression. Several groups 
have expressed HPV-16 L1 VLPs in plants (Appendix A) using transient 
(Varsani et al., 2006a; Maclean et al., 2007; Regnard et al., 2010) and 
transgenic plant expression systems (Biemelt et al., 2003; Varsani et al., 
2003b; Liu et al., 2005; Fernández-San Millán et al., 2008; Lenzi et al., 2008; 
Waheed et al., 2011). Other HPV proteins such as CRPV and ROPV L2 
(Palmer et al., 2006), HPV-8 E7 (Noris et al., 2011) and HPV-16 E7 (Franconi 
et al., 2002, 2006; Massa et al., 2007; Venuti et al., 2009) have also been 













Plant-derived PV L1 and chimaeras of L1 self-assemble into higher-order 
structures, which are immunogenic and protective in animal models, thus 
demonstrating proof of efficacy. Furthermore, the first L1/E6/E7 chimaera 
expressed in plants has been recently described by Paz De la Rosa et al. 
(2009). Immunisation with the plant-derived cVLP demonstrated both antibody 
and CTL responses in mice, providing evidence of a successful dual HPV 
prophylactic / therapeutic candidate vaccine. 
 
There is a definitive trend toward the use of transient expression systems for 
the production of plant-expressed vaccine antigens (Rybicki, 2010), with 
several advantages including the rapid production of recombinant proteins 
days after molecular cloning (in comparison to several months required for 
transgenic regeneration), plants are unaffected by chromosome position 
effects due to transgene insertions, the system can be used in fully 
differentiated plant tissues and, most importantly, significantly higher protein 
levels have been obtained in comparison to stable nuclear transformation 
(Kapila et al., 1997; Varsani et al., 2006a; Fischer et al., 2004). 
 
Small-scale agroinfiltration using syringe injection has proved particularly 
useful in the optimisation of transient expression levels, as several gene 
constructs utilizing different gene modifications and sub-cellular targeting 
sequences can be simultaneously expressed and analysed (demonstrated by 
Maclean et al., 2007; reviewed by Rybicki, 2010). In addition, vacuum 
infiltration is useful in the large-scale production of proteins, allowing 
expression to be scaled up to industrial levels. This has been demonstrated 
by Medicago Inc. in Canada (Yusibov and Rabindran, 2008) and the 
Fraunhofer Institute for Molecular Biology and Applied Ecology and the 
Institute for Molecular Biotechnology at the RWTH Aachen University in 
Germany (Fischer et al., 2004). As a result, Agrobacterium-mediated transient 
expression systems have proved useful in both developmental research and 
in industrial applications. 
 
In conclusion, plant expression systems present an attractive cost-effective 












transgenic systems have been traditionally used for HPV-16 L1 expression, 
transient expression systems are more suitable for the rapid optimisation of 
protein expression in plants, a necessary process as the expression of 
recombinant proteins in plants appears to be empirical (Rybicki, 2009). 
 
1.8 Study objectives 
The first objective was to broaden the cross-protection of HPV L1-based 
prophylactic vaccines by creating four L1/L2 chimaera proteins containing a 
conserved cross-neutralising L2 epitope within HPV-16 L1. The L2 sequences 
replace the helix 4 (h4) sequence of HPV-16 L1, as this position has shown to 
induce high anti-L1 and L2 responses (Varsani et al., 2003a). The four L2 
epitopes are HPV-16 L2 aa 108-120 (Kawana et al., 1999), aa 56-81 (Kawana 
et al., 1998), aa 17-36 (Gambhira et al., 2007b), as well as BPV-1 L2 aa 1-88 
(Pastrana et al., 2005). 
 
The second objective was to improve the therapeutic efficacy of HPV 
L1-based vaccines by incorporating HPV-16 E7 CTL epitope sequences into 
the helix 4 of HPV-16 L1 to create two L1/E7 chimaeras. The two HPV-16 E7 
CTL epitopes used in this study are the mouse H2-Db-restricted E7 CTL 
epitope comprised of aa 49-57 (Feltkamp et al., 1993), which can be used to 
investigate tumour regression and CTL responses in mice, and the human 
HLA-A2-restricted E7 CTL epitope comprised of aa 86-93 (Kast et al., 1994). 
Another two L1/L2/E7 chimaera candicate vaccines were designed, consisting 
of HPV-16 L1 containing the HPV-16 L2 epitope aa 108-120 located in the 
helix 4, and either the mouse or human-restricted E7 CTL epitope in the coil 
between the helix 4 and β-J sheet, another insertion site described by Varsani 
et al. (2003a) which is useful for the display of foreign epitopes.  
 
The third objective was to optimize the Agrobacterium-mediated transient 
expression of the eight HPV candidate vaccines in Nicotiana benthamiana, 
either by targeting the protein to the chloroplast (Maclean et al., 2007) or by 
utilizing a self-replicative BeYDV-based vector (Regnard et al., 2010), both 












not been comparatively analyzed. All genes were human codon-optimised for 
high-level expression as described by Maclean et al., (2007) and the yields 
were quantified to determine the economic feasibility of using a tobacco 
transient expression system for HPV chimaera vaccine production. 
 
The fourth objective was to purify three plant-derived L1/L2 chimaeras from 
plants and examine the immunogenicity of the prophylactic L1/L2 chimaera 
candidate vaccines in mice. The elicited anti-L1 and L2 response was 
analysed and the cross-protective potential of the vaccines was determined 
using HPV-16, 18, 45 and 52 pseudovirion neutralisation assays. 
 
Finally, the study examined the transgenic expression of three HPV 
chimaeras: L1/L2, L1/E7M and L1/L2/E7M. The different chimaeras either 
contained the HPV-16 L2 epitope aa 108-120, the mouse-restricted HPV-16 
E7 CTL epitope comprising of aa 49-57, or both epitopes. These chimaeras 
were chosen to directly compare the effect of the L2 and E7 epitope insertions 
on chimaera expression. All chimaeras were targeted to the chloroplast and 
the expression of the three chimaeras was compared to yields obtained using 












Chapter 2: Transient plant expression of L1 chimaeras 
 
2.1 Introduction 
Cervical cancer is primarily caused by HPV infection and is the third most 
common cancer among women worldwide (Ferlay et al., 2010). As a result, 
HPV vaccine development is a priority for preventative cancer research. The 
L1 major capsid protein is the antigen of choice for prophylactic vaccines, as it 
is immunodominant and self-assembles into VLPs which are structurally and 
immunologically similar to authentic virions. Vaccination with VLPs elicits high 
titres of neutralisation antibodies (NAb) in both animals and humans and two 
multivalent HPV L1 VLP-based prophylactic vaccines have bee  licensed and 
are highly effective in the prevention of vaccine-type HPV-16 and 18 infections 
and associated disease (Schiller et al., 2008).  
 
Despite the high efficacy of current HPV vaccines, the type-specificity (Brown 
et al., 2009; Wheeler et al., 2009), the lack of therapeutic efficacy (FUTURE II 
Study Group, 2007b; Hildersheim et al., 2007) and the high cost of vaccines 
(Schiller et al., 2008) have limited their widespread application, particularly in 
developing countries with >80% of the cervical cancer burden (Parkin and 
Bray, 2006). Therefore, there is an urgent need for affordable 
second-generation HPV vaccines, which broaden protection to include 
multiple oncogenic HPV types, and improve the therapeutic efficacy to clear 
established HPV infections and cancerous lesions. 
 
Broad-spectrum prophylactic HPV vaccines can be developed using 
cross-neutralising L2 epitopes. The L2 epitopes can be incorporated into 
surface regions of L1 to create L1/L2 chimaeras displaying the L2 peptide on 
the surface of assembled L1. Three HPV-16 L2 cross-neutralising epitopes 
are of interest: aa 108-120 (Kawana et al., 1999, 2003), aa 56-81 (Kawana 
et al., 1998; Slupetzky et al., 2007; Kondo et al., 2007, 2008) and aa 17-36 
(Gambhira et al., 2007b; Kondo et al., 2007, 2008). Furthermore, Bovine 












cross-neutralising responses (Pastrana et al., 2005; Gambhira et al., 2007a) 
and was included in this study.  
 
The E7 non-structural protein is constitutively expressed in HPV-infected cells 
and elicits cellular immune responses against HPV-infected tumour cells (zur 
Hausen, 2000). Several HPV-16 E7 cytotoxic T-cell lymphocyte (CTL) 
epitopes have been identified (Feltkamp et al., 1993; Kast et al., 1994), and 
have demonstrated the regression of tumours in animals. As a result, the 
inclusion of these CTL epitopes within L1 may improve the cellular immunity 
of HPV vaccines and provides vaccines which are both prophylactic and 
therapeutic (Müller et al., 1997; Jochmus et al., 1999; Schafer et al., 1999; 
Kaufmann et al., 2001). 
 
The use of plant expression systems for the large-scale production of foreign 
antigens has been proposed as a cost-effective alternative for vaccine 
production (Fischer et al., 2004), with a definitive trend toward the use of 
transient expression for high-level protein expression and optimisation 
(Rybicki, 2009). The expression of papillomavirus antigens in plants is of 
particular interest in this study, specifically HPV-16 L1. Several groups have 
expressed HPV-16 L1 in plants (Appendix A), as well as HPV-11 L1 
(Warzecha et al., 2003; Kohl et al., 2007), canine oral papillomavirus (COPV) 
L1 (Azhakanandam et al., 2007), and cottontail rabbit papillomavirus (CRPV) 
L1 (Kohl et al., 2006).  
 
The transient expression of recombinant proteins in plants occurs either via 
plant tissue infiltration of Agrobacterium tumefaciens containing transgenes 
inserted into the transfer DNA (T-DNA) region of the Ti plasmid, or by use of 
infective virus-based vectors (Rybicki, 2009).  A coupled method has recently 
been developed, whereby viral vectors are integrated into modified 
A. tumefaciens Ti plasmids for the Agrobacterium-mediated delivery and 
release of a replicating viral vector into the host cell (Gleba et al., 2005; 
Rybicki, 2010). Successful amplification vectors have been derived from plant 












(Halley-Stott et al., 2007) and BeYDV-derived DNA replicon systems have 
shown rapid high-level transient expression for several vaccine antigens in 
N. benthamiana, including Norwalk virus capsid protein (NVCP), hepatitis B 
core antigen (HBc), HIV-1 p24 and HPV-16 L1 (Huang et al., 2009; Regnard 
et al., 2010).  
 
A practical limitation of plant systems is low yields of recombinant protein, 
potentially a result of protein instability or low-level expression (Fischer et al., 
2004; Obembe et al., 2011). It is estimated that plant-expressed recombinant 
protein yields need to be greater than 1% of the total soluble protein (TSP) to 
be economically viable (Fischer et al., 2004). This is particularly problematic 
for the expression of recombinant proteins using nuclear-transformed 
transgenic plants, as these systems are often associated with low yields of 
recombinant protein (Rybicki, 2009).  
 
HPV-16 L1 has been expressed transgenically in nuclear-transformed potato 
and tobacco plants (Biemelt et al., 2003; Varsani et al., 2003b; Liu et al., 
2005) and transiently in tobacco (Varsani et al., 2006a). Although transient 
expression of HPV-16 L1 using a simple tobacco mosaic virus (TMV)-derived 
vector (Varsani et al., 2006a) improved HPV-16 L1 yields 10-fold in 
comparison to previous transgenic studies (Varsani et al., 2003b), low 
expression levels of HPV-16 L1 (<1% TSP) were consistently reported for all 
studies (Appendix A) and the elicited immune responses were relatively weak.  
 
Human codon-optimisation of the L1 gene and targeting to the chloroplast 
have significantly improved HPV-16 L1 expression in both transgenic and 
Agrobacterium-mediated transient tobacco expression systems (Maclean et 
al., 2007). The higher accumulation of chloroplast-localised L1 in comparison 
to other intra-cellular compartments has also been demonstrated using 
transiently-expressed COPV L1 (Azhakanandam et al., 2007). Transient 
expression of the human codon-optimised HPV-16 L1 gene demonstrated 
>8500-fold increase in yield in comparison to previous TMV-based studies 












2007; Regnard et al., 2010). Expression levels were further improved by use 
of a self-replicative BeYDV-derived expression vector (Regnard et al., 2010), 
or by targeting the protein to the chloroplast (Maclean et al., 2007), to give the 
highest yields thus far in a tobacco transient expression system 
(530 - 550 mg/kg plant tissue; 17% TSP).  
 
A recent development in plant-derived HPV vaccines was the expression of 
the first HPV-16 L1 chimaera in plants. The L1/E6/E7 chimaera consisted of 
HPV-16 L1 C-terminally fused to several E6 and E7 epitopes and it was 
expressed in transgenic tomatoes (Paz De la Rosa et al., 2009). Although 
yields were low (0.05 – 0.1% TSP), the chimaera successfully assembled into 
immunogenic VLPs and demonstrated both antibody and CTL responses in 
mice, providing evidence of a successful dual HPV prophylactic / therapeutic 
vaccine.  
 
In addition, other viral coat fusion proteins containing HPV-16 L2 and E7 
epitopes have recently been expressed in plants. Cerovská et al. (2008) 
demonstrated a potato virus A coat protein (ACP) fused to a HPV-16 L2 
epitope (aa 108-120) and E7 epitope (aa 44-66) correctly assembled into ACP 
VLPs and the L2 epitope was detected on the surface of the VLPs. 
Furthermore, Morgenfield et al. (2009) expressed a fusion protein consisting 
of potato virus X (PVX) coat protein and HPV-16 E7 in transformed 
chloroplasts. These studies show promise for the development of HPV 
chimaera vaccines which display epitopes on the surface of a carrier protein 
such as HPV-16 L1.  
 
In conclusion, L1-based chimaeric proteins containing cross-neutralising L2 
epitopes and therapeutic E7 CTL epitopes may broaden the protection and 
improve the therapeutic efficacy of current HPV L1 VLP vaccines. Plant 
expression systems present a cost-effective alternative for the production of 
HPV vaccines and plant-derived HPV L1 and L1-based chimaeras 
self-assemble into immunogenic VLPs. HPV-16 L1 yields were significantly 












the protein to tobacco chloroplasts in Agrobacterium-mediated transient 
expression systems. Similar high yields were obtained using the 
agroinfiltration-delivered self-replicative BeYDV-derived expression vector.  
 
In this study, eight HPV L1-based chimaeras were expressed in tobacco using 
an Agrobacterium-mediated transient system. Injection agroinfiltration was 
used for the rapid optimisation of protein expression and several methods 
were analysed to obtain commercially-viable yields in plants. 
 
2.2 Materials and Methods 
2.2.1 Plant expression vectors 
Three binary Agrobacterium plant expression vectors were used to optimize 
HPV chimaera expression: pTRAc and pTRAkc-rbcs1-cTP (provided by Prof.  
Rainer Fischer; Fraunhofer Institute for Molecular Biology and Applied 
Ecology, Germany) and the Bean yellow dwarf geminivirus (BeYDV) vector 
pRIC3 (created by Richard Halley-Stott). Two are non-replicative vectors 
which target the expressed protein to either the cytoplasm (pTRAc) or 
chloroplast (pTRAkc-rbcs1-cTP) (Maclean et al., 2007), and the third is a 
self-replicating cytoplasm-targeting vector (pRIC3). The pRIC3 vector is a 
third-generation pRIC vector (Regnard et al., 2010), which has been reduced 
in size and has shown similar amplification of transgene expression in planta.  
 
The vectors contain a number of elements necessary for protein expression in 
plants (Figure 1). The pTRAkc-rbcs1-cTP vector (Figure 1A) is a derivative of 
pTRAc (Figure 1B), and contains the chloroplast-transit peptide sequence of 
the potato rbcS1 gene. The pRIC3 (Figure 1D) contains the BeYDV 




















Figure 1: Plasmids used to create the HPV chimaera plant expression constructs. C) HPV 
chimaera genes from pGA4 constructs were directionally subcloned into the Agrobacterium plant 
expression vectors: A) pTRAkc-rbcs1-cTP, B) pTRAc and D) pRIC3. The vector elements 
necessary for plant expression are shown in the figure. P35SS: CaMV 35S promoter containing 
duplicated transcriptional enhancer, CHS: chalcone synthase 5‟ untranslated region, pA35S: 
CaMV 35S polyadenylation signal for foreign gene expression, ColE1ori: E. coli origin of 
replication, RK2ori: Agrobacterium origin of replication, bla: ampicillin / carbenicillin-resistance 
gene, and LB/RB: left and right borders for T-DNA integration. The pTRAc vector contains SAR: 
tobacco Rb7 scaffold attachment regions flanking the expression cassette. In addition, the 
pTRAkc-rbcs1-cTP vector contains npt II: the kanamycin-resistant gene, Pnos/pAnos: 
promoter / polyadenylation signal of the nopaline synthase gene and rbcs1-cTP: 
Solanum tuberosum chloroplast-transit peptide sequence of the Rubisco small-subunit gene 
rbcS1. The pRIC3 vector contains LIR: BeYDV long intergenic region, SIR: BeYDV short 














2.2.2 Synthesis of the L1 chimaeras 
Three types of HPV-16 chimaeras were analyzed: the L1/L2, L1/E7 and 
L1/L2/E7 chimaeras. The structure of these chimaeras is shown in Figure 2. 
The chimaeras consist of a South African HPV-16 L1 isolate gene sequence 
(SALI: GenBank accession no. AY177679) with an L2 or E7 epitope located in 
the h4 helix at aa 414, or in the coil between the h4 helix and ß-J structural 
region at aa 433/434 (denoted the “F-position” and “E-position” respectively by 
Varsani et al., 2003a).  
 
 
Figure 2: The amino acid location of the HPV L2 and E7 epitopes in HPV-16 L1 for L1/L2, 
L1/E7 and L1/L2/E7 chimaeras. The L1 C-terminal region containing the h4 helix (F-position) 
and coil between the h4 and the ß-J structural region (E-position) was targeted in the 
production of the chimaera genes. 
 
 
The eight HPV-16 L1 chimaeras used in this study are described in Table 1. 
These chimaeric genes were designed by Dr Inga Hitzeroth (Plant Vaccine 
Group, UCT), human codon-optimised and synthesized in silico by GENEART 
AG (Regensburg, Germany) using high throughput gene assembly. 
Synthesized L2 or E7 epitope sequences replaced the L1 sequence in the E-














Table 1: Summary of the HPV-16 L1 chimaeric constructs 
Construct Inserted epitope L1 position of epitope 
Sequence 
substitution (aa) 
L1/L2(108-120) HPV-16 L2 aa 108-120 F-position aa 414-426 13 
L1/L2(56-81) HPV-16 L2 aa 56-81   aa 414-439 26 
L1/L2(17-36) HPV-16 L2 aa 17-36   aa 414-433 20 
L1/L2 BPV(1-88) BPV-1 L2 aa 1-88   aa 414-505 88 
L1/E7M* HPV-16 E7 aa 49-57 F-position aa 417-425 9 
L1/E7H** HPV-16 E7 aa 86-93   aa 417-424 8 
L1/L2/E7M* HPV-16 L2 aa 108-120 F-position aa 414-426 13 
  HPV-16 E7 aa 49-57 E-position aa 433-441 9 
L1/L2/E7H** HPV-16 L2 aa 108-120 F-position aa 414-426 13 
  HPV-16 E7H aa 86-93 E-position aa 434-441 8 
* M = mouse-restricted E7 CTL epitope,  
**H = human-restricted E7 CTL epitope,  
 
2.2.3 Subcloning of the L1 chimaera genes 
The HPV-16 L1/L2, L1/E7 and L1/L2/E7 chimaera sequences were excised 
from pGA4 vectors using 3‟ XhoI and either 5‟ BspHI, MluI or HindIII restriction 
enzyme (RE) sites that flank the chimaeric genes (Figure 1C). The HPV 
genes were directionally subcloned into the plant expression vectors, using 
AflIII and XhoI for pTRAc (Figure 1B), MluI and XhoI for pTRAkc-rbcs1-cTP 
(Figure 1A), and HindIII and XhoI for pRIC3 (Figure 1D). DH5-α chemically 
competent E. coli cells (E.cloniTM, Lucigen) were transformed with the 
chimaera plasmid constructs and recombinants were selected using 
ampicillin resistance (100 μg/ml). The pTRAc HPV-16 L1/L2 chimaera 
constructs L1/L2(108-120), L1/L2(56-81) and L1/L2(17-36) were provided by 
Mark Whitehead (Plant Vaccine Group, UCT). The plasmid constructs used in 
this study are summarized in Table 2. 
 










pTRAc L1/L2 Non-replicative Cytoplasm M. Whitehead 
pTRAkc-rbcs1-cTP L1/L2 Non-replicative Chloroplast This study 
  L1/E7       
  L1/L2/E7       
pRIC3 L1/L2 Self-replicative Cytoplasm This study 
  L1/E7       












2.2.4 Identification of recombinant L1 chimaeras 
L1 chimaera recombinant clones were screened by colony PCR, using pTRAc 
vector-specific primers and chimaera-specific primers binding to different L2 
or E7 epitopes (Table 3). PCR was performed using GoTaq Flexi DNA 
Polymerase kit (Promega) as per the manufacturer‟s instructions using 1 μM 
of each primer in a final MgCl2 concentration of 3 mM.  
 
 
Table 3: Primers used in PCR and sequencing of the HPV chimaeras  
Primer 
target 
Chimaera detected Primer name Primer sequence PCR 
product (kb) 
pTRAc  All chimaeas pTRAc Fwd 5'-CATTTCATTTGGAGAGGACACG-3' ~1.7 
vector   pTRAc Rvs 5'-GAACTACTCACACATTATTCTGG-3'  
L1/L2 All L1/L2 chimaeras ModNew Fwd 5'-CGACGACCTGTACATCAAGG-3' - 
chimaeras L1/L2(108-120) VEET Rvs 5'-GATGAAGCTGGTCTCCTCC-3' 0.41 
 L1/L2(56-81) SAF2 Rvs 5'-GGATGTAGCCGGTCCTGC-3' 0.44 
 L1/L2(17-36) QLYK Rvs 5'-ACCTTGGGGATGATGTCAGG-3' 0.44 
 L1/L2 BPV(1-88) SALIBPV Rvs 5'-TATCTAGGGCTTCCTCCAGC-3' 0.56 
E7 L1/E7M RAHY Fwd 5'-CCACTACAACATCGTGACCTTC-3' 0.22 
chimaeras L1/L2/E7M     0.17 
 L1/E7H TLGI Fwd 5'-CTGGGCATCGTGCCCTATC-3' 0.23 
 L1/L2/E7H     0.18 
 All E7 chimaeras EndMod Rvs 5'-CATCACAGCTTCCGTTTCTTCC-3' - 
 
 
2.2.4.1 Colony PCR using vector-specific primers 
The pTRAc vector-specific primers (designed by Mark Whitehead) bind 
upstream and downstream of the multiple cloning site (MCS) to detect the 
gene insertions. The PCR profile consisted of an initial denaturation step at 
95°C for 3 min, followed by 25 cycles at 95°C for 30s, 59°C for 30s and 72°C 
for 3 min, and a final elongation step at 72°C for 3 min.  PCR products were 
separated on a 0.8% TBE agarose gel and detected using ethidium bromide.  
 
2.2.4.2 Colony PCR using epitope-specific primers 
HPV L2 or E7 epitope-specific primers (designed by Marieta Burger) were 
used to verify the correct chimaera insert in recombinant pTRAkc-rbcs1-cTP 
and pRIC3 clones. The PCR profile consisted of an initial denaturation step at 
95°C for 2 min, followed by 25 cycles at 95°C for 30s, 55°C (L1/L2 chimaeras) 












at 72°C for 3 min. PCR products were separated on a 1.2% TBE agarose gel 
and detected using ethidium bromide.  
 
2.2.4.3 Restriction enzyme digestion 
Recombinants were verified by restriction enzyme digestion using RE sites 
which flank the 1.5 kb chimaera gene insert (EcoRI / XhoI for 
pTRAkc-rbcs1-cTP clones, or HindIII / XhoI for pRIC3 clones). Recombinant 
DNA (~500 µg) was digested for 1-2 hrs at 37°C, using 1U enzyme per 
reaction as per manufacturer‟s instructions (Roche/Fermentas). Digested DNA 
was separated on a 0.8% TBE agarose gel and stained with ethidium 
bromide.  
 
2.2.4.4 Sequencing of L1 chimaeras 
The HPV chimaera gene insert in pTRAkc-rbcs1-cTP recombinants were 
sequenced using the pTRAc vector-specific primers. Sequences were aligned 
with the HPV chimaera sequences using DNAMAN multiple alignment 
software. 
 
2.2.5 Agrobacterium transformation 
Agrobacterium tumefacien  GV3101::pMP90RK cells were made 
electrocompetent using the method described by Shen and Forde (1989). 
Transformation of Agrobacterium was performed as described by Maclean 
et al. (2007) and recombinant clones were screened by antibiotic selection 
(50 μg/ml Carbenicillin, 50 μg/ml Rifampicin and 30 μg/ml Kanamycin). 
Successful transformation was confirmed by colony PCR and restriction 
enzyme digestion (as described in Section 2.2.4). 
 
2.2.6 Agroinfiltration of N. benthamiana 
A. tumefaciens recombinant chimaera cultures, as well as A. tumefaciens 
LBA4404 cultures containing the pBIN-NSs plasmid encoding the tomato 
spotted wilt virus (TSWV) NSs silencing suppressor (Takeda et al., 2002), 












Agrobacterium cells were diluted in infiltration media (10 mM MgCl2, 10 mM 
MES, 3% sucrose and 150 µM acetosyringone in water, pH 5.6) to give a final 
OD600 of 0.25 for individual Agrobacterium chimaera strains and a combined 
OD600 of 0.5 for the constructs co-infiltrated with A. tumefaciens LBA4404 
(pBIN-NSs). The strains were incubated at 22°C for 2 hrs to allow for 
expression of the vir genes prior to infiltration.  
 
Six-week old N. benthamiana leaves were agroinfiltrated by injecting the 
bacterial suspension into the abaxial air spaces from the ventral side of the 
leaf (Maclean et al., 2007). The plants were grown under conditions of 16 hr 
light, 8 hr dark at 22°C for the desired time period. Chimaera expression time 
trials were conducted 1-9 days post-infiltration (dpi), and chimaeras were 
either co-expressed with or without the NSs silencing suppressor. Separate 
plants were used for each chimaera, and separate leaves on the same plant 
were infiltrated with either pTRAc, pTRAkc-rbcs1-cTP or pRIC3 chimaera 
constructs for the comparative vector expression. 
 
2.2.7 Protein extraction from plants 
Leaf discs, cut using the cap of an eppendorf tube, were harvested from 
agroinfiltrated leaves (~10 mg per disc, 3 discs per construct) and ground in 
liquid nitrogen. Leaf mat rial was resuspended in 250μl per disc of 1.5M NaCl 
high salt PBS (HS PBS) extraction buffer containing protease inhibitor 
(EDTA-free Complete Protease Inhibitor; Roche). The crude plant extract was 
clarified twice by centrifugation at 13,000 rpm for 5 min and the supernatant 
was stored at -20°C. 
 
2.2.8 Western blot detection of plant-expressed L1 chimaeras 
The plant extracts were incubated at 95°C for 5 min in loading buffer 
(Sambrook et al., 1989), separated by a 10% SDS-PAGE gel and transferred 
onto a nitrocellulose membrane by semi-dry electroblotting. The membrane 
was blocked in blocking buffer for 30 min at room temperature (5% skim milk, 












primary antibody, diluted in blocking buffer. HPV-16 L1 protein was detected 
with either mouse monoclonal (MAb) CamVir1 (1:10000; Abcam, UK), which 
binds to the L1 linear epitope GFGAMDF located at aa 230-236 (McLean et 
al, 1990), or H16.J4 (1:2500) which binds a linear epitope located at 
aa 261-280 within the FG loop of the L1 protein (Christensen et al., 1996). 
Both binding sites are not destroyed by the L2 or E7 epitope insertions.  
 
Membranes were washed with blocking buffer for 4x 15 min, and 
incubated in secondary goat-anti-mouse-alkaline phosphatase conjugate 
(1:10000; Sigma) diluted in blocking buffer for 2 hrs at room 
temperature. Membranes were finally washed with wash buffer (0.1% 
Tween-20 in 1x PBS, pH 7.6) for 4x 15 min and developed with Nitro blue 
tetrazolium chloride/5-broma-4-chloro-3-indoyl phosphate substrate 
(NBT/BCIP substrate; Roche). Chimaera expression was compared by 
measuring the density of the bands detected on anti-L1 western blots using 
GeneTools (SYNGENE).  
 
2.2.9 Chimaera quantification by capture ELISA 
The L1 chimaeras extracted from N. benthamiana were quantified by capture 
ELISA using a modified polyvinyl alcohol (PVA)-blocking ELISA method 
(Studentsov et al., 2002). Briefly, a 96-well Maxisorp microtitre plate was 
coated with 1:2000 mouse anti HPV-16 L1 MAb (either CamVir1 or H16.J4) 
overnight at 4°C a d blocked with PVA. Plant extract was added to the wells 
and incubated for 1 hr at 37°C. This was followed by a washing step and the 
addition of rabbit anti-HPV-16 polyclonal serum (1:1000). The plate was 
incubated overnight at 4°C and HPV-16 L1 protein was detected with swine 
anti-rabbit horseradish peroxidase (HRP) conjugate (1:5000; DAKO) and 1.2-
phenylenediamine dihydrochloride substrate (OPD; DAKO; Denmark).  
 
The commercial HPV vaccine Cervarix was used as a positive ELISA control 
and as a HPV-16 L1 VLP standard. Each sample was analysed in triplicate 












protein present in each sample (mg) was expressed as chimaera per kilogram 
of plant tissue (mg/kg).  
 
Total soluble protein (TSP) for each crude leaf extract was determined using 
the Lowry protein assay (Biorad DC Protein Assay; Microplate Assay 
Protocol) as per the manufacturer‟s instructions using a Bovine plasma 
gamma globin IgG protein standard (Bio-Rad). The relative chimaera yield 
was calculated where the ELISA-quantified chimaera protein (mg) was 
expressed as a percentage of TSP, in order to account for differences in leaf 
tissue mass and protein extraction efficiency.  
 
2.2.10 Statistical analysis of chimaera expression yields 
Statistical differences in chimaera expression using the different plant 
expression vectors were determined using ANOVA and the Fischer LSD Post 
Hoc test. Differences were reported at statistically significant at p < 0.01. 
 
2.2.11 Chimaera assembly 
Assembly of the HPV proteins into higher-order immunogenic structures was 
assessed using a H16.J4 and H16.V5 capture ELISA as described above. 
The H16.J4 MAb binds to a L1 linear epitope comprising of aa 261-280 
(Christensen et al., 1996) and thus gives the total HPV protein present in the 
plant extract. H16.V5 binds to a conformational L1 epitope (Christensen et al., 
1996, 2001) containing essential aa 260-290 and specifically binding L1 
residues Phe-50, Ala-266, and Ser-282 (White et al., 1999), thus it was used 
for the detection of assembled HPV protein. In order to compare the assembly 
of chimaeras expressed using different vectors, the amount of assembled 














2.3.1 Verification of L1 chimaera clones 
The L1 chimaeras (Table 1) were successfully cloned into the 
pTRAkc-rbcs1-cTP and pRIC3 plant expression vectors and transformed into 
E. coli and Agrobacterium GV3101.  
 
The pTRAkc-rbcs1-cTP recombinant clones were screened by colony PCR 
using pTRAc-specific primers binding upstream and downstream of the MCS 
(Figure 3A), or chimaera-specific primers binding to different L2 or E7 
epitopes (Figure 3B). All chimaeras produced fragments of the expected size 
(Table 3), with 1.7 kb fragments for the constructs in Figure 3A and 
0.2 - 0.6 kb fragments for the individual chimaeras in Figure 3B.  
 
Clones were further verified by restriction enzyme (RE) digestion using EcoRI 
and XhoI RE sites which flank the chimaera gene insert. As expected, all 
chimaeras contained a 1.5 kb gene insert (Figure 4). Clones were sequenced 
and individual chimaeras were confirmed using DNAMAN multiple sequence 















Figure 3: L1 chimaeras cloned into pTRAc-rbcs1-cTP were identified by colony PCR using 
A) vector-specific primers and B) L2 or E7 epitope-specific primers. Labels:  M = DNA marker 
with size in kb indicated on the left. –ve control = no template water control with the 
appropriate primer set. pTRAkc-cTP (-) = non-recombinant vector control. 
+ve control = parental pGA4 chimaera clones. 1 = Recombinant clone tested. Black arrows 
represent the L1 chimaera PCR products. White arrow represents the ~0.2 kb PCR product 















Figure 4: L1 chimaera recombinant clones were verified by EcoRI / XhoI restriction enzyme 
digests. M = DNA marker with size in kb indicated on the left. pTRAkc-cTP 
control = non-recombinant vector. Black arrows indicate the ~1.5 kb L1 chimaera insert and 
the ~7.7 kb linearized vector. White arrows represent dditional bands caused by EcoRI star 
activity.   
 
 
The pRIC3 recombinant clones were similarly verified by colony PCR using 
the chimaera epitope-specific primers and HindIII / XhoI restriction enzyme 
digestion (Figure 5). All chimaeras produced the 0.2–0.6 kb chimaera-specific 
PCR bands (Figure 5A) described in Table 3 and the 1.5 kb gene fragment in 
the RE digests (Figure 5B). Thus all the HPV chimaeras were successfully 

















Figure 5: L1 chimaeras cloned into pRIC3 were identified by colony PCR and verified by RE 
digestion. A) Colony PCR using L2 or E7 epitope-specific primers, black arrows represent the 
L2 or E7-epitope specific PCR products. B) HindIII / XhoI RE digests, black arrows 
represent the ~1.5 kb L1 chimaera gene insert and the ~6 kb linearized pRIC3 vector. Labels: 
M = DNA marker with size in kb indicated on the left. –ve control = no template water control 
with the appropriate primer set. +ve control = parental pGA4-HPV chimaera clones. 













2.3.2 Optimisation of L1 chimaera expression in N. benthamiana 
 
2.3.2.1 Co-expression with the NSs silencing suppressor 
Chloroplast-targeted HPV-16 L1/L2 expression in N. bethamiana was 
examined in a 1-9 day post-infiltration (dpi) time trial. Chimaeras were 
expressed either with (+) or without (-) the NSs silencing suppressor protein to 
examine its effects on chimaera expression. Expression was analysed by 
western blotting using the anti-L1 MAb CamVir1. All the L1/L2 chimaeras were 
detected, with the predicted ~56 kDa L1 band (Figure 6), although L1/L2(108-
120) runs higher than the other chimaeras.  
 
All chimaeras showed a prolonged increase in expression when co-infiltrated 
with the silencing suppressor protein NSs (Figure 6A-D), suggesting it was 
effective in preventing post-transcriptional gene silencing and enhancing 
protein accumulation in plants. ELISA detection using the linear-epitope 
specific MAb H16.J4 confirmed the results, with up to a 16-fold increase in 
L1/L2 yields (data not shown). Chimaera expression without NSs was 
detected 1-3 dpi and peaks 3-5 dpi, while chimaeras co-expressed with NSs 
was detected at 3 dpi and expression peaked at 5-7 dpi. There was a small 
decrease in expression between 5-9 dpi, suggesting there is a slow decline in 
expression levels (ELISA results, data not shown). As a result, all chimaeras 
were co-expressed with NSs in further experiments.  
 
Several high molecular bands were detected for the L1/L2(17-36) chimaera, 
suggesting the chloroplast signal sequence (cTP) may not have been cleaved 
or the chimaera may have been glycosylated. However, L1/L2(17-36) 
analysed on subsequent western blots did not display these high molecular 
weight bands, suggesting the protein was partially denatured in Figure 6C.  
 
The L1/L2 chimaera containing the BPV L2 aa 1-88 epitope had low 
expression levels in comparison to the chimaeras containing HPV-16 L2 
epitopes. The bands on the L1/L2 BPV (1-88) western blots were only visible 












development time required for the other chimaeras (Figure 6A-C). ELISA 
quantification estimated L1/L2 BPV(1-88) achieved maximum yields of 40 
mg/kg plant tissue, while high expression yields of 1000 - 4600 mg/kg were 
estimated for the other L1/L2 chimaeras (data not shown).  In addition, the 
L1/L2 BPV(1-88) plant extract contained a characteristic ~45 kDa band 
(Figure 6D) associated with L1 degradation, suggesting L1/L2 BPV(1-88) is 
unstable in this expression system. These results were confirmed by several 




Figure 6: Chloroplast-targeted L1/L2 chimaera expression time trial 1-9 days post-infiltration 
(dpi) in N. benthamiana, either with (+) or without (-) the NSs silencing suppressor. The L1/L2 
chimaeras A) L1/L2(108-120), B) L1/L2(56-81), C) L1/L2(17-36) and D) L1/L2 BPV (1-88) in 
crude leaf extracts were detected by CamVir1 western blot analysis. Equal volumes were 
loaded and blots were developed for 15 minutes (A-C) and for 16 hours (D). M = protein 
marker with the size in kDa indicated on the left. NSs negative control = pBIN-NSs infiltrated 
crude plant extract (5 dpi). Positive controls: N. benthamiana (+) = plant-derived HPV-16 L1. 
The black arrows indicate the position of the L1/L2 chimaeras (~56 kDa) and the grey arrow 
indicates degraded protein.  
 
 
2.3.2.2 Effect of chloroplast targeting on L1/L2 chimaera yield 
Targeting of HPV proteins to the chloroplast can significantly improve plant 












chloroplast-targeting, the pTRAc (cytoplasmic-targeting) and the 
pTRAkc-rbcs1-cTP (chloroplast-targeting) L1/L2 chimaera constructs were 
co-infiltrated with pBIN-NSs in N. benthamiana in a 3-9 dpi time trial (Figure 
7). The L1/L2 BPV(1-88) chimaera was not included in this study, as it shows 
very low expression in N. bethamiana when compared to the other L1/L2 










Figure 7: Expression of cytoplasm-targeted L1/L2 chimaeras in N. benthamiana when 
co-infiltrated with the pTRAc chimaera constructs and pBIN-NSs. L1/L2(108-120), 
L1/L2(56-81) and L1/L2(17-36) chimaeras were detected with H16.J4 in crude 
N. benthamiana leaf extracts 3 dpi. M = protein marker with the size in kDa indicated on the 
left. pTRAkc-cTP (+) = chloroplast-targeted pTRAkc-rbcs1-cTP L1/L2(108-120) with 
pBIN-NSs at 3 dpi (positive control). Equal volumes were loaded but pTRAkc-rbcs1-cTP 
L1/L2(108-120) extract was diluted 3-fold to prevent the over-exposure of bands. The arrow 
indicates the position of the L1/L2 chimaeras (~56 kDa).  
 
 
Western blots and ELISA data consistently demonstrated low expression for 
the cytoplasm-targeted L1/L2 chimaeras, with maximum expression of 
chimaeras 3 dpi and yields of 20-45 mg/kg plant tissue (data not shown).  An 
example of a western blot is shown in Figure 7. Expression of 
cytoplasm-targeted L1/L2(108-120), L1/L2(56-81) and L1/L2(17-36) was 
weakly detected in comparison to the chloroplast-targeted L1/L2(108-120) 
chimaera diluted 3x prior to loading and included as a positive control. 
Comparison of chimaera yields indicates that L1/L2 chimaera expression was 
increased 40 - 80 fold when targeted to the chloroplast. Taking these results 
















2.3.2.3 Transient expression of the E7 chimaeras 
Chloroplast-targeted L1/E7 and L1/L2/E7 chimaeras, co-expressed with NSs, 
were examined in a 1-9 day post-infiltration (dpi) time trial. All the E7 
chimaeras were successfully expressed in N. benthamiana (Figure 8), 
although yields were low. Maximum yields of 10-40 mg/kg plant tissue was 
obtained 3-5 dpi and ELISA results demonstrated both the L1/E7 chimaeras 
are expressed to higher levels than the corresponding L1/L2/E7 chimaeras 
(data not shown), suggesting the insertion of the second epitope negatively 
affects chimaera expression. 
 
Two bands were detected for the L1/E7 chimaeras: the ~56 kDa band and an 
unidentified ~65 kDa band (Figure 8A). Repeated L1/E7 time trial analyses 
demonstrated only the 56 kDa L1 band, suggesting the L1/E7 chimaera was 
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Figure 8: Chloroplast-targeted E7 chimaera expression time trial 3-9 days post co-infiltration 
with the Agrobacterium chimaera strain and pBIN-NSs in N. benthamiana. CamVir1 western 
blot detection of A) L1/E7 and B) L1/L2/E7chimaeras in crude N. benthamiana leaf extracts 
3-9 dpi. M = protein marker with the size in kDa indicated on the left. Positive 
control (+) = crude insect-cell produced L1/E7M or L1/L2/E7M. The black arrow indicates the 
position of the E7 chimaeras (~56 kDa). The grey arrow is caused by insufficient denaturation 















2.3.2.4 Optimisation using the self-replicative pRIC3 plant expression vector 
In an attempt to improve chimaera yields, particularly for the low-expressing 
L1/L2 BPV(1-88) and E7 chimaeras, the plant expression vector pRIC3 
(self-replicative, cytoplasm-targeting vector) was compared to 
pTRAkc-rbcs1-cTP (non-replicative chloroplast-targeting vector) in a 
3-9 dpi time trial in the presence of NSs (Figure 9). The pRIC vector has been 
shown to improve yields for several proteins, including HPV-16 L1 (Regnard 
et al., 2009). 
 
Western blot analysis of L1/L2 expression is shown in Figure 9A. Maximum 
chimaera yields for both vectors were obtained 3-5 dpi. The three L1/L2 
chimaeras containing the HPV-16 L2 epitopes aa 108-120, 56-81 and 17-36 
were better expressed using the chloroplast-targeting pTRAkc-rbcs-cTP 
vector compared to the self-replicative pRIC3 vector. L1/L2 BPV(1-88) was 
not highly expressed for either vector and degradation was visible for both 
constructs. Western blot detection of L1/E7 and L1/L2/E7 expression showed 
similar expression profiles for both vectors, with maximum expression 3-5 dpi 
(data not shown). 
 
ELISA quantification shows the self-replicative pRIC3 vector did not improve 
expression yields for majority of the chimaeras. Yields were up to 3-fold higher 
using the pTRAkc-rbcs1-cTP vector, suggesting chloroplast-targeting is more 
effective in the high-expression of chimaeras than the pRIC3 vector, which 
ultimately targets the expressed protein to the cytoplasm. The only exception 
was low-expressing L1/L2/E7M, which gave similar yields using either vector 
(Figure 9B). The L1/L2 BPV(1-88) expression levels were similar to the NSs 
negative control, suggesting plants are not a viable system for the production 


















Figure 9: Comparative expression time trial 3-9 days post-infiltration (dpi) of N. benthamiana 
using the vectors pTRAc-rbcs1-cTP and pRIC3. A) CamVir1 western blot analysis of the 
L1/L2 chimaeras. Similar volumes were loaded for all samples, although the high-expressing 
L1/L2 chimaera samples were diluted 8-fold compared to the low-expressing L1/L2 
BPV(1-88). M = protein marker with the size in kDa indicated on the left. NSs negative 
control = pBIN-NSs infiltrated crude leaf extract 5 dpi. The black arrow indicates the HPV 
chimaeras (~56 kDa). The grey arrow indicates degraded chimaeras. B) Capture ELISA 
quantification of all the HPV chimaeras using CamVir1. The highest yield obtained for each 
chimaera, occurring either 3 or 5 dpi, is shown for the two vectors. The error bars indicate 
the standard deviation. 
 
 
The results from the expression optimization using the pTRAkc-rbcs1-cTP and 
pRIC3 vectors are summarised in Table 4. The L1/L2(108-120), L1/L2(56-81) 
and L1/L2(17-36) were highly-expressed, with yields 3-20 fold higher than the 












preliminary time trials are: co-expression with NSs (Figure 6), extraction 5 dpi 
(Table 4) and use of the pTRAkc-rbcs-cTP vector to target the expressed 
L1/L2 protein to the chloroplast (Figure 7 and 9; Table 4). 
 
 
Table 4: Summary of L1 chimaera expression and optimization 
 












L1/L2(108-120) 5 pTRAkc-rbcs1-cTP 600 3.7 1.8 
L1/L2(56-81) 5 pTRAkc-rbcs1-cTP 280 1.7 2.4 
L1/L2(17-36) 5 pTRAkc-rbcs1-cTP 440 2.9 1.8 
L1/L2 BPV(1-88) 5 pTRAkc-rbcs1-cTP - - - 
L1/E7M 3-5 pTRAkc-rbcs1-cTP 80 0.6 2.8 
L1/E7H 3 pTRAkc-rbcs1-cTP 80 0.4 1.2 
L1/L2/E7M 3-5 pRIC3 30 0.3 0.9 
L1/L2/E7H 3-5 pTRAkc-rbcs1-cTP 90 0.8 1.6 
 
 
2.3.3 Comparative vector expression of L1/L2 chimaeras 
Three high-expressing L1/L2 chimaeras were chosen as vaccine antigens for 
the mouse immunogenicity studies: L1/L2(108-120), L1/L2(56-81) and 
L1/L2(17-36). A final expression study including three biological repeats was 
performed to confirm the L1/L2 results and obtain statistically valid data. All 
three vectors (pTRAc, pTRAkc-rbcs1-cTP and pRIC3) were directly compared 
for expression of each of the L1/L2 vaccine antigens, HPV-16 L1 was included 
as a positive control (pTRAc and pTRAkc-rbcs1-cTP constructs were 
available) and NSs-infiltrated plants served as the negative control. 
Chimaeras were co-expressed with NSs and extracted 5 dpi.  
 
2.3.3.1 Effect of expression on plants 
Examination of the infiltrated leaves prior to extraction 5 dpi (Figure 10) 
suggested that the self-replicative pRIC3 vector had adverse effects on the 
health of the plant. Leaves infiltrated with pRIC3 were yellow/brown in colour 
and necrosis of the leaf tissue was visible in the infiltrated areas. This was 
observed to a lesser degree in the pTRAc leaves, which also targeted 












be the healthiest, resembling the leaves of the NSs-infiltrated negative control 
and the uninfiltrated leaves, suggesting accumulation of the chimaras in the 
chloroplast has less of an impact on plant health. Infiltration appears to have 
no observable effect on plant health, as the NSs-infiltrated leaf looked similar 
to the uninfiltrated leaf (excluding the syringe injection markings). These 
results were consistently observed for all the time trials. 
 
 
Figure 10: Photographs of infiltrated leaves prior to chimaera extraction at 5 days 
post-infiltration. Three plant expression vectors were used to express the L1/L2 chimaera 
vaccine antigens: pTRAc, pTRAkc-rbcs1-cTP and pRIC3. HPV-16 L1 was expressed as a 
positive expression control and NSs-infiltrated plants served as the negative expression 
control. The uninfiltrated leaf was used as a health indicator for the observable effects of 
infiltration and protein expression using the vectors. 
 
 
2.3.3.2 Western blot detection of the HPV proteins 
HPV protein was detected by anti-L1 western blotting (Figure 11). The NSs-
infiltrated plant extract (negative control) was not detected and plant-derived 
HPV-16 L1 (positive control) was detected using the chloroplast-targeting 
vector. Expression using the different vectors was directly compared with 
pTRAkc-rbcs1-cTP consistently giving the highest expression yields, followed 














































Figure 11: Western blot of the L1/L2 chimaeras expressed using 3 plant expression vectors: 
pTRAc, pTRAkc-rbcs1-cTP and pRIC3. Chimaras were co-expressed with NSs, extracted 
5 dpi and detected with CamVir1. HPV-16 L1 was expressed as a positive expression control 
for pTRAc and pTRAkc-rbcs1-cTP (pRIC3 construct not available) and the negative 
expression control was NSs-infiltrated plants. Equal volumes of sample were loaded. 
M = protein marker with the size of the protein indictated in kDa on the left. The black arrows 
indicate the the L1/L2 chimaeras or HPV-16 L1 (~56 kDa). 
 
 
2.3.3.3 ELISA quantification of the HPV proteins 
Capture ELISA was used to quantify the HPV chimaeras using CamVir1. The 
L1/L2 chimaera and HPV-16 L1 yields are shown in Figure 12. Statistical 
differences in chimaera expression using the 3 plant expression vectors were 
determined using ANOVA and the Fischer LSD Post Hoc test. Differences 
were reported at statistically significant at p < 0.01.  
 
Chloroplast-targeted expression of the L1/L2 chimaeras and HPV-16 L1 using 
pTRAkc-rbcs1-cTP gave significantly higher yields than the NSs-infiltrated 
negative control (p = 0.000 - 0.002), and the cytoplasm-targeting pTRAc 
vector (p = 0.000 - 0.004). In addition, pTRAkc-rbcs1-cTP significantly 
improved L1/L2(56-81) expression compared to pRIC3 (p = 0.006). The 
pRIC3 vector did not statistically improve expression of any of the chimaeras 














Figure 12: Comparison of the L1/L2 chimaeras expressed using 3 plant expression vectors: 
pTRAc, pTRAkc-rbcs1-cTP and pRIC3. Proteins were co-expressed with the NSs, extracted 
5 days post-infiltration and HPV protein yield was determined by capture ELISA using 
CamVir1. HPV-16 L1 was expressed as a positive expression control. Statistical analysis by 
ANOVA and the Fisher LSD Post-Hoc test showed significant differences in chimaera yields 
and yields that are significantly different at p = 0.01 are denoted with a star. The error bars 
indicate the standard deviation. 
 
 
In comparison to the optimization experiments (Figure 6-9, Table 4), the 
comparative time trial demonstrated similar trends in chimaera expression. 
The chloroplast-targeted L1/L2 chimaeras gave the highest yields 
(1040 - 1310 mg/kg; 2 - 3% TSP), improving chimaera expression by up to 
28-fold in comparison to the cytoplasm-targeting vector pTRAc (50 – 260 
mg/kg; <1% TSP) and up to 7-fold in comparison to the self-replicative vector 
pRIC3 (190 - 660 mg/kg; <1% TSP).  
 
Cytoplasm-targeted chimaera yields were improved up to 4-fold using the 
self-replicative vector pRIC3 in comparison to the non-replicative pTRAc 
vector. This suggests self-replication of the vector improves chimaera 
expression, although targeting to the chloroplast appears to be a superior 
strategy to increase chimaera expression in plants.  
 
Although chloroplast-targeted HPV-16 L1 demonstrated higher average yields 












were not statistically significant, indicating the L2 epitope substitutions do not 
appear to affect the expression and accumulation of recombinant protein in 
chloroplasts. However, western blotting (Figure 7 and 11) and ELISA 
expression data (Figure 12) consistently revealed higher levels of 
cytoplasm-localised L1/L2(108-120) and L1/L2(17-36) than L1/L2(56-81), 
suggesting L1/L2(108-120) and L1/L2(17-36) chimaeras with shorter L2 
sequence replacements (13 and 20 aa respectively) may be better expressed 
and have a greater stability than L1/L2(56-81) with a 26 aa sequence 
replacement. 
 
2.3.3.4 Assembly of the HPV proteins 
Chimaera assembly into higher-order structures such as capsomeres or VLPs 
was assessed using H16.J4 (linear epitope-specific MAb) and H16.V5 
(conformational epitope-specific MAb) capture ELISA. The amount of 
V5-detected conformational HPV protein was expressed as a percentage of 
the J4-detected total HPV protein for each of the vector constructs 
(Figure 13). 
 
A low percentage of the expressed chimaeras assembled into 
H16.V5-detected higher-order structures. The NSs plant extract, used as a 
negative control, did not bind H16.J4 or H16.V5 MAb (data not shown). The 
low-expressing pTRAc chimaeras appear to have the highest proportion of 
assembled protein (11-18%), followed by the high-expressing 
pTRAkc-rbcs1-cTP chimaeras (5-9%). The pRIC3 chimaeras did not contain a 
high percentage of assembled protein (< 2%). Although the pTRAkc-rbcs1-
cTP chimaeras did not contain the highest percentage of assembled protein, 
higher expression yields results in up to 40x and 4x more assembled protein 
than pTRAc and pRIC3 respectively. This provides further evidence that 
pTRAkc-rbcs1-cTP is the best vector to use for the production of 














Figure 13: Assembly of L1/L2 chimaeras expressed using 3 different plant expression 
vectors:  pTRAc, pTRAkc-rbcs1-cTP and pRIC3. Proteins were co-expressed with the NSs 
silencing suppressor and extracted 5 dpi. Chimaeras assembled into higher-ordered 
structures such as capsomeres or VLPs (detected by conformational-specific H16.V5 MAb) 
is expressed as a percentage of the total chimaera protein (detected by the linear-specific 
H16.J4 MAb). HPV-16 L1 was expressed as a positive expression control and the negative 




2.4.1 Optimisation of L1 chimaera transient expression in plants 
All the L1 chimaeras were successfully expressed in plants using an 
Agrobacterium-mediated transient system (Figure 6-9). Several methods were 
used to optimize chimaera expression in plants; including use of a NSs 
silencing suppressor, use of an agroinfiltration-delivered self-replicative viral 
vector and targeting of the expressed protein to the chloroplast.  
 
2.4.1.1 Co-expression with the NSs silencing suppressor 
Agrobacterium-mediated transient expression typically peaks 60-72 hours 
(~3 days) post-infiltration and then declines rapidly as a result of triggering 
post-transcriptional gene silencing (PTGS) in the host plant (Voinnet, 2001). 
PTGS is an adaptive anti-viral plant defense mechanism, where foreign RNA 
molecules are recognized and degraded in a sequence-specific manner 












plant viruses have evolved proteins that suppress various steps of the 
mechanism (Voinnet, 2001). Although PTGS responses reduce transgene 
mRNA accumulation in the plant cytoplasm and limit the efficiency of 
Agrobacterium-mediated transient expression (de Carvalho et al., 1992; Van 
Blokland et al., 1994), co-expression of proteins with viral silencing 
suppressors has been shown to repress PTGS responses and allow high level 
transient expression, resulting in higher yields (50-fold in some instances) and 
prolonged expression of the transgene (Voinnet et al., 2003).  
 
Co-infiltration with the tomato spotted wilt virus (TSWV) silencing suppressor 
NSs suppresses PTGS and increases transient expression (Takeda et al., 
2002). This effect was similarly observed in the transient expression of the 
L1/L2 chimaeras (Figure 6). Chimaeras typically displayed maximum 
expression levels 3-5 dpi without the presence of viral silencing suppressors. 
However, co-expression with NSs displayed a prolonged increase in the 
expression of the chimaeras, whereby expression levels were increased by up 
to 16-fold and peaked 5-7 dpi. 
 
2.4.1.2 The use of a self-replicative BeYDV vector 
Cytoplasmic HPV-16 L1 yields have been improved by 50% using a 
self-replicative pRIC vector (Regnard et al., 2010). As a result, a 
third-generation pRIC3 vector was examined as a potential strategy to 
improve chimaera yields. Three L1/L2 chimaeras were examined: L1/L2(108-
120), L1/L2(56-81) and L1/L2(17-36). All chimaeras demonstrated higher 
expression levels using pRIC3 (self-replicative vector), in comparison to 
pTRAc (non-replicative vector), suggesting transgene amplification improves 
L1/L2 yields in the plant cytoplasm (Figure 11 and 12). However, chloroplast-
targeting was more effective in the high-level accumulation of L1/L2 
chimaeras (Figure 12) and visible necrosis of the leaf tissue was observed in 
pRIC3-infiltrated leaves, suggesting the self-replication of the vector 















2.4.1.3 Chloroplast-targeting of L1 chimaeras 
L1 chimaeras were targeted to the chloroplast using the pTRAkc-rbcs1-cTP 
vector. The chloroplast transit peptide (cTP) is fused to the expressed 
chimaera and is cleaved by the chloroplast stromal processing peptidase 
(SPP) upon entry into the organelle (Robinson and Ellis, 1984). There are 
several factors responsible for the high level accumulation of protein in 
chloroplasts: (a) protection from cellular proteases, (b) different protein 
hydrolyzing machinery in the plastids and (c) protective plasmid-specific 
chaperones which assist in the correct folding of L1 and thus improve protein 
stability (Fernández-San Millán et al., 2008). Previous studies have shown 
that targeting HPV-16 L1 to the chloroplast produces higher yields than 
targeting to the cytoplasm or ER (Maclean et al., 2007). In this study, 
chloroplast-targeting was highly effective and increased L1/L2 chimaera yields 
by 40 to 80-fold in comparison to chimaeras targeted to the cytoplasm (Figure 
7 and 11).  
 
The chloroplast-targeted chimaeras detected in the anti-L1 western blots 
produced bands of ~56 kDa (Figure 6-9), suggesting the signal peptide was 
effectively removed from the accumulated protein. Although L1/L2(108-120) 
runs higher than the other chimaeras on the western blot (Figure 6 and 8), this 
phenomenon is not caused by insufficient cleavage of the signal peptide, as 
the cytoplasm-localised L1/L2(108-120) expressed with pTRAc (Figure 7), and 
insect cell-expressed L1/L2(108-120) analysed in parallel (data not shown), 
showed a similar banding pattern. 
 
Higher molecular weight bands of ~65 kDa were detected for L1/L2(17-36) 
and the L1/E7 chimaeras (Figure 6 and 8), possibly as a result of 
glycosylation or insufficient denaturation of chimaeras. A glycosylated form of 
HPV-16 L1 produced in baby hamster kidney cells (BHK) was described by 
McLean et al. (1990), whereby CamVir1 detected 2 bands for L1: the 56 kDa 
L1 major band and a minor band of ~64 kDa. The additional band was 
subsequently removed from cell lysates when infected in the presence of the 
N-glycosylation inhibitor tunicamycin. Although plants do contain glycosylation 












~56 kDa band, suggesting the L1/L2(17-36) and L1/E7 chimaeras were 
partially denatured in initial experiments rather than glycosylated (L1/L2: 
Figure 9A and 11, L1/E7: data not shown).  
 
2.4.1.4 Direct comparison of plant expression vectors 
Two strategies have increased plant-expressed L1 yields to a maximum of 
530 - 550 mg/kg: targeting the protein to the chloroplast (Maclean et al., 2007) 
or the use of an agroinfiltration-delivered self-replicative BeYDV-derived 
expression vector (Regnard et al., 2010). This was the first study which 
directly compared these strategies using the L1-based chimaeras. Chimaera 
expression levels using the plant expression vector pRIC3 (self-replicative, 
cytoplasm-targeting vector) was directly compared to pTRAkc-rbcs1-cTP 
(non-replicative, chloroplast-targeting vector) in the presence of NSs (Figure 
9). Expression using the pTRAc (non-replicative, cytoplasm-targeting vector) 
was included for comparative purposes and HPV-16 L1 was used as a 
positive control (Figure 11 and 12). 
 
Chloroplast-targeting produced the highest yields for the majority of chimaeras 
(Figure 9 and 11-12) and improved L1/L2 chimaera expression by up to 7-fold 
relative to pRIC3, and 28-fold relative to pTRAc, both which target the 
expressed protein to the cytoplasm (Figure 12). Statistical analysis revealed 
that the chloroplast-targeted L1/L2 yields were significantly higher than the 
cytoplasm-targeted L1/L2 yields (p < 0.01). However, yield differences 
between chloroplast-targeted chimaeras and chimaeras expressed using the 
self-replicative pRIC3 vector were only significant for L1/L2(56-81). These 
results provide evidence that pTRAkc-rbcs1-cTP is the best vector to use for 
the high-level production of HPV chimaeras. 
 
2.4.2 Expression of the L1/L2 chimaeras 
 
2.4.2.1 Highly-expressed L1/L2 chimaeras containing the HPV-16 L2 epitopes  
The L1/L2(108-120), L1/L2(56-81) and L1/L2(17-36) chimaeras were 












(Table 4). As a result, these three L1/L2 chimaeras were chosen as vaccine 
antigens for the mouse immunogenicity studies.  
 
Chloroplast-targeted L1/L2 chimaeras consistently demonstrated the highest 
chimaera yields of ~ 1200 mg/kg plant tissue (2-3% TSP). Although HPV-16 
L1 demonstrated higher yields than the L1/L2 chimaeras, the differences were 
not statistically significant (Figure 12). This indicates the L2 epitopes do not 
significantly affect the expression and accumulation of HPV protein in 
chloroplasts. Furthermore, the chimaera yields are ~2-fold higher than 
published HPV-16 L1 yields produced using an Agrobacterium-mediated 
tobacco expression system (Maclean et al., 2007; Regnard et al., 2010) and 
the production of these chimaeras is commercially viable (>1% TSP; Fischer 
et al., 2004). 
 
Assembly into higher-order structures is associated with a lower susceptibility 
to proteolysis (Chen et al., 2000) and it was hypothesized that the high 
accumulation of L1/L2 may be a result of assembly. The 
conformational-specific H16.V5 MAb binds assembled protein (Christensen 
et al., 1996) and can be used to detect assembly into higher-order structures 
(Carter et al., 2003; Wang et al. 2003; Ryding et al., 2007). All 
plant-expressed L1/L2 chimaeras and the HPV-16 L1 control appeared to 
contain a low proportion of assembled protein (<20% TSP), suggesting 
majority of the protein exists as unassembled L1 monomers. However, both 
the L1/L2(56-81) and L1/L2(17-36) chimaeras contain L2 sequences 
overlapping the L1 C-terminal region aa 428-483 shown to be critical for the 
binding of H16.V5 (Varsani et al., 2006b), suggesting this MAb may not be 
suitable for detection of chimaera assembly and cannot be used for 
comparable quantification. Electron microscopy will provide further insights 
into chimaera assembly and is analyzed in Chapter 3. 
 
2.4.2.2 Instability of the L1/L2 chimaera with the BPV L2 aa 1-88 epitope  
The L1/L2 BPV(1-88) chimaera had low expression levels in comparison to 
the chimaeras containing the HPV-16 L2 epitopes (Figure 6) and the E7 












similar to the NSs negative control (Figure 9), although L1/L2 BPV(1-88) was 
detected on western blots probed with H16.J4 MAb and has achieved low 
yields of 40 mg/kg plant tissue (Figure 6, ELISA data not shown). In addition, 
the chloroplast-targeted L1/L2 BPV(1-88) was partially degraded (Figure 6D), 
which has been described in several HPV L1 expression studies (Hagensee 
et al., 1993; Sasagawa et al., 1995; Li et al., 1997; Kohl et al., 2007) 
 
These results provide evidence that L1/L2 BPV(1-88) is not well-expressed 
and stable in this plant expression system. The L1/L2 BPV(1-88) chimaera 
contains the largest L2 sequence replacement and the 88 residue epitope 
replaced the entire C-terminal of L1 (Figure 2, Table 1). The HPV L1 
C-terminal plays a role in VLP assembly (Zhou et al., 1991b; Varsani et al., 
2006b; Bishop et al., 2007a), and deletion of this L1 region prevents assembly 
into higher-order structures which are less susceptible to degradation (Chen 
et al., 2000). Taken together, the sequence replacement of the L1 C-terminal 
with foreign epitope sequences is not an effective strategy for HPV chimaera 
expression and plants are not a viable system for L1/L2 BPV(1-88) 
expression.  
 
2.4.3 Expression of the E7 chimaeras 
The L1 chimaeras containing E7 epitopes had relatively low expression levels 
(Figure 9B) with maximum yields of 30 - 80 mg/kg plant tissue (0.3 - 0.8% 
TSP) were obtained (Figure 8, Table 4). Furthermore, expression was not 
improved using pRIC3 except for the lowest-expressing L1/L2/E7M chimaera 
(Figure 9B). These yields are lower than the >1% TSP threshold for the 
commercial production of recombinant proteins in plants (Fischer et al., 2004), 
suggesting further optimization or an alternative expression system is required 
for economically feasible vaccine production. 
 
In addition, the number of epitope insertions appears to affect expression. The 
L1/L2/E7 chimaeras and the L1/L2(108-120) chimaera all contain the L2 aa 
108-120 epitope in the h4 region of L1. However, the L1/L2/E7 chimaeras, 












L1/L2(108-120), providing evidence that a second 8-9 residue epitope 
substitution into L1 negatively impacts chimaera expression (Table 4).  
 
2.4.4 Conclusions 
All the L1 chimaeras were expressed in plants using an 
Agrobacterium-mediated transient system and co-expression of the NSs 
silencing suppressor. Although the use of a BeYDV-based self-replicative 
vector (pRIC3) increases the accumulation of L1/L2 chimaeras in the 
cytoplasm in comparison to a non-replicative vector (pTRAc), 
chloroplast-targeting is the best strategy for the high-level accumulation of 
chimaeras in plants.  
 
L1/L2(108-120), L1/L2(56-81) and L1/L2(17-36) were highly expressed, 
producing yields which were viable for commercial production (>1% TSP) and 
were ~2-fold higher than the maximum HPV-16 L1 yields reported in similar 
plant expression studies. As a result, these three L1/L2 chimaeras were 
selected for subsequent analysis in mouse immunogenicity studies.  
 
Several factors should be considered in the future design of HPV chimaeras. 
The L1/E7 and L1/L2 chimaeras containing different epitopes inserted into 
similar L1 regions showed differential expression levels, providing further 
evidence that the expression of recombinant proteins in plants is empirical. 
Furthermore, comparison of the L1/L2(108-120) and L1/L2/E7 chimaeras 
suggests that a second 8-9 residue epitope in the E-position of L1 negatively 
effects chimaera expression, although this may be dependent on the size or 












Chapter 3: Purification and assembly of HPV antigens 
 
3.1 Introduction 
The L1 major capsid protein spontaneously self-assembles into virus-like 
particles (VLPs), which form the basis of the current prophylactic HPV 
vaccines (Schiller et al., 2008). Recombinant VLPs have been expressed in 
several diverse host systems including mammalian (Mossadegh et al., 2004), 
insect (Kirnbauer et al., 1992), yeast (Neeper et al., 1996), bacteria (Zhou et 
al., 1991a) and plants (Liu et al., 2005), with VLP sizes varying from 25-65 nm 
(Mach et al., 2006; Maclean et al., 2007; Kim et al., 2007, 2010, Park et al., 
2008; Woo et al., 2008), depending on the modification of the L1 gene (Chen 
et al., 2000) and the expression host (Varsani et al., 2006b). 
 
The HPV-16 L1 C-terminal helix 4 (h4) plays a role in VLP assembly and is 
located between residues 414-426 (Varsani et al., 2003a). The removal of 
these motifs results in capsomere formation and prevents further 
self-assembly into VLPs (Bishop et al., 2007a). Varsani et al. (2006b) 
confirmed the importance of h4, as well as the C-terminal residues 428-465. 
Furthermore, there are disulphide bonds between highly conserved cysteine 
residues 175 and 428, and mutations of these cysteines results in the 
formation of capsomeres rather than VLPs (Li et al., 1998; McCarthy et al., 
1998; Sapp et al., 1998; Fligge et al., 2001; Varsani et al., 2006b). 
Capsomeres are thermastable, immunogenic and protect against viral 
challenge in animals (Rose et al., 1998; Yuan et al., 2001; Thönes et al., 
2008; Schädlich et al., 2009; Jagu et al., 2010) and thus also have potential 
for development as cost-effective HPV vaccines. 
 
Commercial HPV vaccines (currently expressed in yeast or insect cells) are 
expensive (Schiller et al., 2008), partially as a result of costly production and 
purification protocols (Tiwari et al., 2009). In addition, complicated purification 
methods and extensive pre-treatment can affect the stability and recovery of 
assembled L1 protein (Shi et al., 2005; Kim et al., 2010) and denatured L1 do 












1995; Suzich et al., 1995). As a result, the production of vaccine antigens 
using low-cost expression systems and simple production and purification 
processes remain high priorities in any commercial protein production system. 
 
Ultracentrifugation using sucrose or caesium chloride (CsCl) density gradients 
and size-exclusion chromatography has been used routinely for the 
small-scale purification of VLPs, either for immunogenic experiments in 
animals or for analytical studies (Chen et al., 2001; Aires et al., 2006; Kim et 
al., 2007; Park et al., 2008, Woo et al., 2008; Schädlich et al., 2009). 
Specifically, CsCl centrifugation and sucrose sedimentation analysis are 
standard techniques for the quantitative separation and purification of 
plant-derived L1 protein (Biemelt et al., 2003; Maclean et al., 2007; 
Fernández-San Millán et al., 2008). However, these methods are unsuitable 
for industrial-scale production of VLPs, as they cannot be used to process 
large amounts of protein and require a great deal of time and labour. 
Furthermore, additional chromatography steps are required for commercial 
vaccine production, as contaminants are not completely removed by these 
methods (Kim et al., 2010).  
 
Conventionally, several chromatography steps are required to attain highly 
purified protein, a strategy which is time consuming and result in the loss of 
the target protein (Park et al., 2008; Kim et al., 2010; Baek et al., 2011). 
Recent studies have shown the recovery, yield and purity of HPV L1 protein is 
improved using cation-exchange chromatography (Kim et al., 2010; Baek et 
al., 2011) or heparin chromatography (Kim et al., 2010). Purification of 
recombinant HPV L1 using one-step chromatography methods may reduce 
time, costs and labour needed for L1 purification and thus facilitate the 
production of HPV vaccines.  
 
Purification of HPV L1 using heparin chromatography is based on evidence 
that cell-surface heparan sulphate proteoglycans (HSPG) are the primary 
attachment receptors for several HPV types (Joyce et al., 1999; Giroglou et 
al., 2001b; Combita et al., 2001; Drobni et al., 2003; Shafti-Keramat et al., 












is a competitive inhibitor of HPV pseudoinfection (Joyce et al., 1999, Giroglou 
et al., 2001b; Combita et al., 2001; Selinka et al., 2002) and selectively binds 
assembled L1 protein (Fleury et al., 2009).  
 
At least two L1 sequences interact with heparin: a C-terminal linear motif 
comprising of basic residues (Joyce et al., 1999; Bousarghin et al., 2003; 
Fleury et al., 2009) and a conformational binding site containing lysine 
residues on the assembled L1 surface (Rommel et al., 2005; Knappe et al., 
2007; Fleury et al., 2009). HPV-16 L1 contains two basic C-terminal regions: 
aa 473-488 (GLKAKPKFTLGKRKAT) and aa 492-505 (SSTSTTAKRKKRKL). 
These regions contain a high proportion of positively-charged amino acids 
which comprise the nuclear localization signal (NLS) and bind DNA (Zhou et 
al., 1991b; Sun et al., 1995, 2010). 
 
The importance of the C-terminal in heparin binding is of particular interest for 
L1 chimaeras containing C-terminal modifications. HPV-16 L1 deletion 
mutants that lacked the basic C-terminal sequences self-assembled into VLPs 
(Touzé et al., 2000; Fleury et al., 2009) and bound heparin similarly to 
wild-type VLPs (Fleury et al., 2009). Furthermore, heparin binding is lost when 
VLPs are denatured, confirming that heparin binds to a conformational motif 
on assembled L1, and that this motif is not present in the C-terminal (Giroglou 
et al., 2001b; Rommel et al., 2005; Wang et al., 2005; Fleury et al., 2009).  
 
In conclusion, several methods have been used to purify HPV L1 protein, 
including sucrose and/or CsCl density gradients and various chromatography 
techniques. Multiple purification steps and extensive pre-treatment affects the 
stability of the protein and denatured L1 is inefficient in the production of 
neutralising antibodies. As a result, purification of recombinant HPV L1 protein 
using a simple one-step chromatography method would be ideal for the rapid 
and cost-effective production of HPV vaccines.  
 
This study describes the purification of plant-expressed HPV-16 L1 and three 












Several size-based purification methods were examined, as well as cation-
exchange chromatography and heparin chromatography. 
 
 
3.2 Materials and Methods 
 
3.2.1 Large-scale transient expression and extraction of antigens 
N. benthamiana plants (2-4 weeks old) were vacuum-infiltrated with 
A. tumefaciens LBA4404 (pBIN-NSs) encoding the NSs silencing suppressor 
protein and the Agrobacterium GV3101 strain encoding HPV-16 L1 or the 
L1/L2 chimaeras,  as described by Maclean et al. (2007). The plants were 
grown for 5 days in 16 hr light, 8 hr dark, at 22 °C.  
 
The infiltrated leaves were harvested, weighed and ground in liquid nitrogen 
using a mortar and pestle. PBS extraction buffer, containing 0.5M NaCl and 
protease inhibitor (Roche Complete EDTA-free), was added at a ratio of 1:4 
(w/v) and samples were homogenized in a Waring blender for 10 min on ice. 
The homogenate was sonicated on ice for 6x 20s intervals of sonication and 
rest (Macrotip sonication; Level 8; Heat Systems – Ultrasonics, Inc. Sonicator 
Cell Disruptor Model W-225 R), and the lysate was filtered through a double 
layer of Miracloth (CALBIOCHEM). The crude extract was clarified twice by 
centrifugation at 13,000 rpm for 10 min. Pellets were resuspended in 1ml PBS 
and stored at -70ºC. The supernatant and pellet were examined by western 
blotting to check for localization of the HPV antigen to the supernatant. 
 
3.2.2 Pilot purification of HPV antigens 
Several methods were examined for the purification of plant-expressed L1 
vaccine antigens (Appendix B). Size-based methods such as cross-flow 
microfiltration and ultracentrifugation using sucrose and caesium chloride 
density gradients were tested, as well as single-step cation-exchange and 
heparin chromatography for the rapid purification of L1 and L1-based 
chimaeras. L1 protein extracted in PBS containing 0.5M NaCl was diluted 10x 












to allow L1 binding to the columns. Ultrafiltration was utilized to concentrate 
antigens and desalt chromatography fractions for downstream application in 
mouse immunogenicity studies.  
 
References for the methods used in the pilot purification experiments are 
given in Appendix B. Overall, purification using heparin chromatography and 
diafiltration using Macrosep® ultrafiltration spin tubes were the best strategies 
to obtain partially-purified L1 and L1-based chimaeras, and these methods 
were used to prepare the vaccine antigens for subsequent mouse 
immunological experiments.  
 
 
3.2.3 Purification of vaccine antigens 
 
3.2.3.1 Sample preparation 
HPV-16 L1 and L1-based chimaeras were expressed in N.bethamiana and 
extracted as described in Section 3.2.1 using LS PBS as the extraction buffer. 
The double-clarified crude supernatant for L1/L2(108-120), L1/L2(56-81), 
L1/L2(17-36), HPV-16 L1 and the NSs-infiltrated plant extract (Vaccines 1-5 
respectively) was filtered through a 0.22 µm Millipore filter prior to 
chromatography to remove any debris. 
 
3.2.3.2 Heparin chromatography 
Chromatography was performed using an ÄKTA Explorer System 10. The 
procedure was followed as recommended in the GE Healthcare column 
instruction manual and a flow rate of 0.5 ml/min was maintained. The column 
was equilibrated with 10 column volumes (cv) of low salt wash buffer (LS 
PBS: 10mM NaCl PBS) prior to loading the sample. The crude extract (10-20 
ml) was loaded on a pre-packed 1ml HiTrap Heparin cation-exchange column 
(GE Healthcare, Amersham Biosciences AB, Sweden) and the column was 
washed with 10 cv of LS PBS wash buffer. The elution profile for each HPV 
antigen was optimized in a pilot experiment using a linear ionic strength 












containing 1.5M NaCl was applied to the column. Once it had been 
established that all antigens eluted when <50% HS PBS was applied to the 
column, a 50% step elution gradient (0.75M NaCl) was applied for purification 
of the vaccine antigens. The step elution gradient was 10 cv of 50% HS PBS, 
followed by 10 cv of 100% HS PBS. The column was finally washed with 5 cv 
of distilled water and 5 cv of 20% ethanol. Fractions (1ml) were collected and 
analyzed by western dot blots.  
 
3.2.3.3 Western dot blot detection of purified HPV antigens 
The dot blots were performed as described in Chapter 2 (Section 2.2.8). 
CamVir1 (1:10000) was used to detect L1 and Cervarix was used as a 
positive control. Eluted fractions containing a high concentration of purified 
antigen were pooled and stored at -70ºC. For the NSs-infiltrated plant extract 
(V5: negative control), the fractions which corresponded with the eluted 
protein peak were pooled and tested on the L1 positive control vaccine (V4) 
dot blot, to confirm it did not contain L1. 
 
3.2.3.4 Desalting of purified antigen samples by ultrafiltration 
The purified antigens in the 50% HS PBS elution buffer (0.75M NaCl), were 
desalted prior to mouse vaccinations. Ultafiltration spin tubes with 10kDa 
MWCO filter (Macrosep® Centrifugal Devices, 10K Omega, PALL Life 
Sciences) were used to concentrate and desalt the purified L1 fractions 
rapidly by centrifuging the samples at 7000g for 15-30 min. The retentate 
containing the L1 antigens was diluted in LS PBS and re-concentrated by 
ultrafiltration several times as per the manufacturer‟s instructions until the 
samples contained a NaCl concentration similar to that found in commercial 













3.2.4 Analysis of antigen purity 
 
3.2.4.1 Coomassie staining and western blot detection of HPV antigens 
to assess purification 
The crude extract and purified sample for each of the vaccine antigens was 
compared by Coomassie staining and western blot analysis. Samples were 
prepared as described in Chapter 2 (Section 2.2.8) and equal volumes were 
loaded into two 10% SDS-PAGE protein gels. One gel was stained with 
Coomassie solution overnight at room temperature and destained 2x 2hr at 
37ºC. The other gel was blotted onto nitrocellulose membrane and probed 
with CamVir1. 
 
3.2.4.2 Total soluble protein quantification 
The negative control vaccine (V5: NSs-infiltrated plant extract) cannot be 
quantified by anti-L1 western blotting. As a result, the amount of total soluble 
protein (TSP) was determined for each vaccine antigen using the Biorad 
Lowry protein assay (described in Chapter 2, Section 2.2.9) to ascertain that 
the TSP was similar for all vaccines. 
 
3.2.4.3 Detection of HPV antigens by capture ELISA to determine 
enrichment of antigen relative to the TSP 
A capture ELISA was performed as described in Chapter 2 (Section 2.2.9), 
using the linear epitope-specific monoclonal antibody (MAb) H16.J4. The HPV 
antigen yields determined by ELISA were compared to corresponding TSP 
yields in both the crude and purified samples to determine antigen 
enrichment. 
 
3.2.5 Western blot quantification of purified vaccine antigens 
A dilution series of the vaccine Cervarix (containing 40 ug/ml of insect 
cell-produced HPV-16 L1) was used to quantify the plant-produced HPV 
antigens (V1-4). Several dilutions of the antigen were analyzed to ensure 
quantification occurred within the linear range of the standard curve. Equal 












SDS-PAGE gels, proteins were blotted onto nitrocellulose membrane and the 
HPV antigens were detected with CamVir1 (1:10000). 
 
Densitometry (GeneTools, Syngene, Synoptics Ltd) was used to quantify the 
antigens (as done by Aires et al., 2006; Bazan et al., 2009) and the amount of 
HPV protein present in the samples was determined using the standard curve 
generated by the Cervarix dilution series. Quantified HPV antigens were 
stored at -70ºC. 
 
3.2.6 Structural analysis by transmission electron microscopy 
Aliquots of the purified vaccine antigens were pre-treated as if they were 
being prepared for mouse vaccinations. The antigens were defrosted 
overnight at 4ºC, resuspended in PBS to the required concentration and 
incubated at 37ºC for 30 min.  
 
To determine the affect of purification, the pre-treated purified antigens and 
the crude plant extracts for each antigen were diluted 10x in PBS, 
immunotrapped using CamVir1 (1:1000), a linear epitope-specific HPV-16 L1 
antibody which binds both L1 monomers and assembled L1 protein (McLean 
et al., 1990), and captured on glow-discharged carbon-coated copper grids. 
The proteins were negatively stained with 2% uranyl acetate and viewed on a 





3.3.1 Purification of plant-expressed HPV antigens 
 
3.3.1.1 Detection of HPV antigens in the clarified extract 
The localisation of L1 and the L1/L2 chimaeras to the clarified supernatant 
was confirmed by western blot analysis. The Coomassie-stained protein gel 
indicated the abundant presence of Rubisco in the supernatant and the 















Figure 1: Localisation of the HPV antigens to the supernatant in the clarified plant extract. 
A) Coomassie-stained protein gel and B) Western blot detection of HPV-16 L1/L2(108-120) 
using the anti-L1 antibody CamVir1. Labels:  M = Protein marker with size in kDa indicated on 
the left. S = supernatant. P = pellet resuspended in PBS. The black arrow indicates the HPV 
chimaera and the white arrow indicates the plant protein Rubisco. 
 
 
3.3.1.2 Pilot purification of HPV antigens 
Appendix B described the results from the pilot purification experiments using 
Coomassie-staining of proteins, as well as anti-L1 western blotting and 
capture ELISA using CamVir1 (data not shown). Purification using size-based 
techniques was largely unsuccessful and not reproducible between the 
vaccine antigens, as the L1/L2 chimaeras appear to assemble into a variety of 
structures in contrast to L1. In addition, protein degradation was detected and 
thus purification using chromatography was examined as an alternative 
method. 
 
Although cation-exchange chromatography using the HiTrap SPFF or POROS 
50HS column was unsuccessful in the purification of the L1-based chimaeras, 
heparin affinity chromatography purified all the vaccine antigens. The 
concentration and removal of salt in the chromatography fractions was 
examined using two ultrafiltration-based methods, either by cross-flow 
filtration or centrifugation spin columns. Although cross-flow ultrafiltration was 
effective, the method was costly with regard to time and significant protein 












Thus, heparin chromatography and centrifugation ultrafiltration were 
considered the best strategies to purify the vaccine antigens for subsequent 
mouse immunological experiments.  
 
3.3.1.3 Purification using heparin chromatography 
Vaccine antigens were purified from the clarified crude plant supernatant by 
heparin chromatography using a high NaCl gradient for elution of the HPV 
antigens. The step elution gradient was optimised for each HPV antigen using 
a linear 0-100% 1.5M NaCl gradient. An example of this is shown in Figure 
2A. All HPV antigens eluted between 0.45 - 0.75M NaCl (data not shown). As 
a result, a 50% (0.75M NaCl) step gradient was used to purify the vaccine 
antigens for the mouse immunogenicity study. An example of this step 
gradient elution with HS PBS is shown in Figure 2B. Detection of the purified 
HPV antigens in the eluate fractions was determined using CamVir1 dot blots. 
 
In Figure 2, the elution of unbound protein is shown by a broad absorbance 
peak during the LS PBS wash. An absorbance peak was detected when the 
HS PBS elution buffer was applied to the column (a broad peak for the linear 
gradient in Figure 2A and a sharp peak for the step gradient in Figure 2B), 
and these fractions contained the purified HPV antigens. The chromatograms 
for the other vaccine antigens were similar, including the graph for the 
NSs-infiltrated plant extract (negative control). This indicates that the HPV 
antigens were co-purified with other contaminating plant proteins.  
 
The fractions containing the partially-purified HPV antigens (or co-eluted plant 
proteins for the negative control) were pooled and then desalted using 
ultrafiltration spin columns. Western dot blots indicated that the HPV antigens 
















Figure 2: Purification of the plant-produced HPV antigens using heparin cation-exchange 
chromatography. A) L1/L2(56-81) purification using a 0-100% linear high salt elution gradient 
to determine the concentration of NaCl needed to elute the chimaera. B) L1/L2(108-120) 
purification using a 50% and 100% step high salt elution gradient. The elution of purified HPV 
antigens were detected in the i) chromatograms and in the ii) anti-L1 CamVir1 western dot 
blots. Labels:  Fr = fractions. C = crude plant extract. D = crude sample diluted 10x in 1x PBS. 
UB = the unbound proteins eluted with the low salt wash buffer. +ve control = Cervarix. 
The dotted box indicates which fractions were pooled and desalted. 
 
 
3.3.1.4 Purity of the vaccine antigens 
The purity of the vaccin  antigens was examined by comparing the purified 
sample to the crude plant extract. This was done using Coomassie staining, to 
indicate total protein present in the samples (Figure 3A), and western blot 
analysis, to detect the HPV antigens and indicate the loss in antigen yield 
(Figure 3B). Note that the L1/L2(108-120) chimaera (V1) runs higher than the 














Figure 3: Purity of the plant-produced vaccine antigens. A) Coomassie-stained protein gel. 
B) Western blot detection of HPV antigens. M = Protein marker with size in kDa indicated on 
the left. C = clarified crude plant extract. P = purified antigen. V1 = L1/L2(108-120), 
V2 = L1/L2(56-81), V3 = L1/L2(17-36), V4 (+) = HPV-16 L1 and V5 (-) = NSs-infiltrated plant 




Figure 3 shows the purified samples were enriched with L1 as a result of the 
purification procedure. The Coomassie-stained gel shows a large decrease in 
the total protein in the purified samples, while the western blot results indicate 
that there is only a small decrease in antigen yield after purification. The L1 
antigen was not detected in the negative control (V5: NSs-infiltrated plant 
extract).  
 
Samples were only partially-purified, as additional Coomassie-stained protein 
bands were detected in Figure 3A for purified antigens V1 and V3 (more 
concentrated than V2 and V4), thus demonstrating that the purified samples 
contain several contaminating plant proteins. Also, although the NSs negative 
control (V5) was not detected on the western blot, several similar Coomassie 















3.3.1.5 Enrichment of HPV antigens in purified samples 
The TSP of the purified antigens was determined to: (a) ensure that the TSP 
was similar for the NSs negative control (containing plant proteins which were 
co-purified with the HPV antigens) in comparison to the other vaccine 
antigens, and (b) to determine HPV antigen enrichment after purification. The 
TSP for the purified HPV vaccine antigens (V1-4) was similar, however the 
TSP for the NSs plant extract negative control (V5) was almost 2-fold higher, 
possibly as a result of more eluate fractions being pooled or greater 
ultrafiltration concentration (data not shown). As a result, it was diluted 
accordingly in 1x PBS. 
 
Capture ELISA, using the linear-specific H16.J4 MAb was used to estimate 
the amount of HPV antigen present in the crude and purified samples. To 
determine the effect of purification on the TSP and the enrichment of HPV 
antigens, the H16.J4-detected HPV yield was directly compared to the TSP 
yield for both the crude and purified samples (Figure 4). 
 
Figure 4 demonstrates that purification of the plant extracts reduced both the 
TSP and total HPV protein, as expected. However, relative to the TSP, there 
is up to a 5-fold enrichment of HPV antigen in purified samples (V1-4), 
suggesting that heparin chromatography is effective in removing a large 
proportion of contaminating protein. The NSs-infiltrated plant extract (V5) 
showed a similar decrease in TSP with purification and the amount of TSP in 
the “purified” negative control lies within the levels obtained for the HPV 














Figure 4: Total soluble protein (TSP) and total HPV protein in the crude and purified 
samples. TSP was determined using the Lowry assay and HPV protein was detected with 
H16.J4 (linear epitope-specific). V1: L1/L2(108-120), V2: L1/L2(56-81), V3: L1/L2(17-36), 
V4: HPV-16 L1 (positive control), V5: NSs plant extract (negative control). The error bars 




3.3.2 Western blot quantification of purified HPV antigens 
HPV antigens were quantified by western blotting using densitometry and the 
commercial vaccine Cervarix as the standard. An example of the western 
blots and standard curves used to quantify the HPV antigens are shown in 
Figure 5A-C. 
 
Some L1 protein degradation, visible as a ~45 kDa band (Baek et al., 2011), 
was detected in some of the purified antigen batches, particularly after several 
freeze-thaw cycles. However, only the full-length 56 kDa L1 band was 















Figure 5: Western blot quantification of HPV antigens using the commercial vaccine Cervarix 
for A) V1: L1/L2(108-120), B) V2: L1/L2(56-81) and C) V3: L1/L2(17-36) and V4: HPV-16 L1. 
The i) western blots were used to generate a ii) Cervarix (HPV-16 L1) standard curve. Labels:  
M = Protein marker with siz  in kDa indicated on the left. The star indicated the antigen 
dilution which falls within the range of the standard curve. 
 
 
3.3.3 Structural analysis of purified vaccine antigens 
The structural assembly of L1 and the L1/L2 chimaeras in both the crude and 
purified samples was analysed by immunocapture transmission electron 
microscopy (Figure 6). Antigen purification resulted in the removal of 
contaminating background protein, particularly for L1/L2(108-120) and the 
negative control (Figure 6A and E respectively). In comparison to the negative 
control (NSs-infiltrated plant extract), all the HPV antigens appeared to 
contain secondary HPV structures, either capsomeres (~10 nm), capsomere 













Purified L1/L2(108-120) assembled into small chimaeric VLPs (cVLP) which 
were regular in shape but varied in size (25-40 nm), while L1/L2(56-81) only 
appeared to contain capsomeres (Murata et al., 2009) and some aggregates, 
although VLP-like structures were visible in the crude extract. Purified 
L1/L2(17-36) contained a mixed population of amorphous cVLPs and a high 
proportion of capsomere aggregates in contrast to the crude extract, 
suggesting purification promoted the formation of higher-order structures. 
Purified V4, the HPV-L1 positive control, assembled into distinct VLPs 
















Figure 6: Transmission electron micrographs of CamVir1-immunotrapped crude and purified 
vaccine antigens A) V1: L1/L2(108-120), B) V2: L1/L2(56-81), C) V3: L1/L2(17-36), D) V4: 
HPV-16 L1 (positive control), E) V5: NSs plant extract (negative control). Grids were viewed 
on a Zeiss 912 Omega Cryo EFTEM. Left scale bar = 50 nm, right scale bar = 200 nm. Blue 
arrows indicate HPV-16 capsomeres (~10 nm), white arrows represent capsomere 













Stringent purification is necessary for the commercial production of vaccines, 
although the stability of L1 is negatively affected by multiple purification steps. 
Heparin affinity chromatography can be utilized to selectively purify 
assembled L1, and a purification strategy using a one-step chromatography 
method would be ideal for the rapid and cost-effective production of HPV 
vaccines. This study reports the purification of plant-expressed HPV-16 L1 
and three L1/L2 chimaeras using heparin chromatography for subsequent 
immunogenicity studies in mice.  
 
3.4.1 Optimisation of L1/L2 chimaera purification 
HPV-16 L1 and the L1-based chimaeras were localized to the crude extract 
supernatant (Figure 1) and were purified using a variety of methods 
(Appendix B). Although size-dependent purification methods have been used 
to purify plant-expressed HPV L1 (Biemelt et al., 2003; Maclean et al., 2007; 
Fernández-San Millán et al., 2008), these methods were inefficient for L1/L2 
chimaera purification and were non-reproducible between antigens. The 
L1-based chimaeras were broadly detected in several fractions using both 
sucrose and CsCl density gradient ultracentrifugation, indicating that the L1/L2 
chimaeras assembled into heterologous higher-order structures, such as 
capsomeres, aggregates and VLPs. Furthermore, the extent of assembly 
appeared to differ between the chimaeras and the L1 positive control. This 
was confirmed by transmission electron microscopy (Figure 6), which showed 
distinct differences between the different L1/L2 chimaeras and the L1 control. 
 
Chromatography was the next strategy to selectively purify HPV L1; either on 
the basis of surface charge, or by affinity for the proteoglycan heparin. The 
use of cation-exchange chromatography for the purification of 
yeast-expressed HPV L1 has been demonstrated using P-11 
phosphocellulose (Kim et al., 2009, 2010) or a POROS 50HS column (Cook et 
al., 1999). In contrast, the plant-expressed L1/L2 chimaeras were not purified 
efficiently using either the strong cation-exchange HiTrap SPFF column or the 












bind to either column, although a small proportion of protein bound strongly 
and irreversibly to the POROS 50HS resin. This phenomenon has been 
described by Cook et al. (1999), whereby 10% of HPV-11 L1 did not bind the 
resin and 45-65% could not be recovered without stripping the POROS 50HS 
column using 0.5M NaOH.  
 
As a result, cation-exchange chromatography was not pursued further, 
although the reason for the poor purification of L1/L2 chimaeras is not clear. 
There are two HPV-16 L1 basic C-terminal regions which contain positively 
charged residues: aa 473-488 and 492-505 (Zhou et al., 1991b; Sun et al., 
1995, 2010). The L2 sequence insertions did not overlap the major basic 
regions in the C-terminal of L1 and replaced a maximum of 26 residues at 
aa 414-439. A possible explanation is that the overall surface charge of L1 
was affected, either by the aa composition of the inserted L2 epitopes, or by 
differences in protein assembly. In addition, the crude plant extract may have 
contained several contaminating proteins which bound more strongly to the 
columns and out-competed HPV L1 binding. 
 
3.4.2 Purification of the vaccine antigens 
Vaccine antigens were purified using heparin chromatography (described by 
Joyce et al., 1999; Bazan et al., 2009; Johnson et al., 2009; Kim et al., 2009, 
2010) for subsequent immunogenicity studies in mice (Figure 2). Heparin 
reversibly bound both the L1 and L1/L2 chimaeras in a similar manner (data 
not shown), and all antigens eluted with 0.75M NaCl. This is comparable to 
other studies where heparin-bound HPV-16 L1 eluted between 
0.5 - 1.2M NaCl (Bazan et al., 2009; Kim et al., 2010; Baek et al., 2011).  
 
Heparin selectively purifies assembled L1 protein by binding to a 
conformational motif which is not present on the C-terminal of L1 
(Fleury et al., 2009) and is unaffected by the L2 sequence replacements. 
This is particularly beneficial for vaccine production, as denatured L1 does not 
elicit the production of neutralising antibodies (Kirnbauer et al., 1992; Suzich 












demonstrated that purification of HPV-16 L1 using heparin chromatography 
gave high recovery yields (~60%) and produced immunogenic VLPs 
(25-65 nm in diameter). 
 
The purity of the heparin-purified samples was examined by Coomassie 
staining and western blot detection of L1 using CamVir1 (Figure 3). The 
purified samples were enriched with L1 or L1/L2 chimaeras, as there was a 
significant decrease in total protein with a relatively small decrease in antigen 
yield when compared to the crude samples. This was confirmed by H16.J4 
capture ELISA and TSP assays (Figure 4).  
 
Samples were partially-purified and contained several contaminating plant 
proteins (V1 and V2, Figure 3A), also present in the purified negative control 
(V5, Figure 3A). Contaminants were also observed in the purification of 
yeast-expressed HPV-16 L1 using heparin chromatography (Kim et al., 2010). 
As a result, a single step method using heparin chromatography is not 
sufficient to obtain highly-purified HPV L1 and L1/L2 chimaeras. Kim et al. 
(2010) demonstrated that co-purified contaminating proteins from yeast were 
not completely removed by additional cation-exchange and hydrophobic 
interaction chromatography steps, suggesting many of the contaminants have 
similar isoelectric points and hydrophobicity profiles to L1. Furthermore, the 
additional chromatographic steps reduced L1 recovery to ~10%. However, 
pure HPV-16 L1 was obtained by ammonium sulphate precipitation of 
yeast-expressed HPV-16 L1 prior to heparin chromatography, a method which 
should be examined in further purification studies using plant-expressed HPV 
L1-based proteins. 
 
3.4.3 Western blot quantification of antigens 
The purified antigens were quantified by western blot analysis (discussed by 
Heidebrecht et al., 2009) using densitometry to measure the intensity of the 
CamVir1-detected L1 bands and the commercial vaccine Cervarix as the 













L1 degradation was detected in some of the batches of purified antigen, 
particularly after several freeze-thaw cycles. This was seen at high 
concentrations of V1, V2 and V4 in Figure 5. However, the majority of the 
antigen proteins were not degraded and only the full-sized 56 kDa L1 band 
was quantified to ensure mice were immunized with similar doses of 
full-length antigen. Other groups have reported similar HPV-16 L1 degradation 
patterns when expressed in insect cells (Kirnbauer et al., 1992), yeast (Cook 
et al., 1999) and bacteria (Zhang et al., 1998). A consideration for future 
purification studies is the salt concentration of the extraction and diafiltration 
buffers, as VLP disassembly occurs in low-salt conditions (Murata et al., 
2009). Increasing the salt concentration to 0.5 or 1M NaCl may stabilize VLPs 
(Mach et al., 2006) and reduce degradation observed in the purified samples 
(Figure 5). 
 
3.4.4 Assembly of the vaccine antigens 
The assembly of plant-derived HPV-16 L1 and the L1/L2 chimaeras was 
analysed using immunocapture electron microscopy (Figure 6). Purification 
appeared to remove some background protein and all the plant-expressed 
L1/L2 chimaeras and the L1 positive control assembled into higher-order 
structures such as capsomeres, aggregates and VLPs.  
 
Plant-expressed HPV-16 L1 VLPs are typically 30-65 nm in size (Biemelt et 
al., 2003; Varsani et al., 2003b; Liu et al., 2005; Varsani et al., 2006a; 
Maclean et al., 2007), with the majority of VLPs reported as 50-60 nm in 
diameter when localised to the tobacco chloroplasts (Maclean et al., 2007; 
Fernández-San Millán et al., 2008; Lenzi et al., 2008). In this study, HPV-16 
L1 assembled into full-sized VLPs (~50 nm, Figure 6Dii). 
. 
Assembly of chimaeras into VLPs appears to be affected by the length of the 
L2 epitope, with L1/L2(108-120), L1/L2(17-36) and L1/L2(56-81) containing 
13, 20 and 26 residue epitope replacements respectively.  Plant-expressed 
L1/L2(108-120), with the shortest L2 epitope, successfully assembled into 












al., 2000) and varied greatly in size (25-40 nm, Figure 6A). In contrast, 
L1/L2(17-36) predominantly formed capsomere aggregates, although the 
presence of larger amorphous VLP-like structures suggest there may be 
partial-assembly of VLPs (Figure 6C). Finally, L1/L2(56-81) with the longest 
L2 epitope predominantly assembled into capsomeres, with no VLP-like 
structures observed (Figure 6B).  
 
L1/L2(108-120) has also been expressed in insect cells and the CsCl-purified 
chimaera was shown to assemble into amorphous VLPs and capsomere 
aggregates (Varsani et al., 2003a). It is not clear why HPV VLPs produced in 
various hosts are of different diameters, although it is postulated that 
differences between prokaryotic and eukaryotic systems may be a result of 
post-translational modifications (Varsani et al., 2006b). However, the VLPs 
formed by the plant-expressed L1/L2(108-120) chimaera resemble insect 
cell-expressed HPV-33 L1 VLPs purified using a two-step chromatography 
strategy (Baek et al., 2011), suggesting the morphology may be a result of 
chromatography purification and not the expression system. 
 
Capsomere assembly was expected as the deletion of L1 residues 428-465 or 
a mutation of the cysteine residue at aa 428 eliminated assembly of 
capsomeres into VLPs (Varsani et al., 2006b). Both the L1/L2(17-36) and 
L1/L2(56-81) chimaeras contain L2 sequence replacements which overlap this 
region, with epitopes replacing aa 414-433 and 414-439 respectively. 
Furthermore, the L2 epitopes replaced the h4 region which is involved in VLP 
assembly (Varsani et al., 2003a). However, capsomeres are immunogenic 
(Rose et al., 1998; Yuan et al., 2001; Fligge et al., 2001; Schädlich et al., 
2009) and provide an alternative thermastable antigen for second-generation 
HPV vaccines.  
 
3.4.5 Conclusions  
Plant-expressed HPV-16 L1 and L1/L2 chimaeras were purified using heparin 
chromatography and quantified by anti-L1 western blot analysis. The vaccine 












such as capsomeres, aggregates and VLPs, which rendered size-based 
purification techniques non-reproducible between antigens. Plant-expressed 
HPV-16 L1 assembled into full-sized VLPs which were similar in size and 
morphology to those expressed in other systems. The L1/L2(108-120) 
chimaera assembled into small cVLPs, which were regular in shape but varied 
in size, while the L1/L2(17-36) chimaera predominantly assembled into 
capsomere aggregates. L1/L2(56-81) did not assemble into cVLPs and 
appeared to exist exclusively as capsomeres. These results provide further 
evidence that the C-terminal h4 region plays a role in VLP assembly and that 
sequence replacements >13 residues negatively affects VLP assembly. 
Assembled L1 protein, existing either as VLPs or capsomeres, has been 
shown to elicit neutralising antibodies and the immunogenicity of the vaccine 













Chapter 4: Immunogenicity of L1/L2 chimaeras 
4.1 Introduction 
Vaccines antigens are selected on the basis of their immunogenicity. The 
humoral immune response, which involves the production of neutralising 
antibodies (NAb) against foreign antigens, is the most important factor in 
prevention of PV infection (Breitburd et al., 1995; Suzich et al., 1995; 
Kirnbauer et al., 1996). Immunisation with VLPs elicits Nabs, which are 
predominantly directed against immunodominant L1 epitopes (Kirnbauer et 
al., 1992; Roden et al., 1994; Roden et al., 2000), although low-titre 
antibodies against L2 have been shown to neutralise pseudovirions in vitro 
(Roden et al., 2000, Kawana et al., 2003).  
 
VLPs are comprised of assembled L1 capsomeres (Buck et al., 2008; Chen et 
al., 2000), and L1 modifications may influence assembly into higher-order 
structures. This is of particular interest in the development of L1-based 
chimaera vaccines, as L1 immunogenicity is dependent on L1 assembly into 
capsomeres and VLPs (Thönes et al., 2008; Schädlich et al., 2009) and 
denatured L1 does not elicit detectable immune responses (Fernández-San 
Millán et al., 2008; Schädlich et al., 2009) 
 
L1/L2 chimaeras containing L2 epitopes in the h4 region of L1 has been 
shown to affect VLP assembly (Varsani et al., 2003a; Bischop et al., 2007a; 
Schädlich et al., 2009; Murata et al., 2009). However, capsomeres elicit the 
production of NAbs and protect against challenge in animal models (Rose et 
al., 1998; Yuan et al., 2001; Ohlschläger et al., 2003; Dell et al., 2006; Thönes 
et al., 2008), and the low immunity of capsomeres can be improved by use of 
an adjuvant (Thönes et al., 2008; Schädlich et al., 2009; Jagu et al., 2010). In 
addition, assembly of L1 into “small” T=1 VLPs (30-40 nm) enhances humoral 
immunity and elicits antibody levels comparible to full-sized T=7 VLPs 













The host-specificity of papillomaviruses (PV) has complicated the 
development of HPV candidate vaccines, as the demonstration of protective 
efficacy in animal systems is a pre-requisite for human clinical trials (Rybicki, 
2009). Animal PV vaccines can be used in live animal challenge studies to 
directly test the protective ability of a vaccine provide a proof of concept.  
 
Two studies using cotton tail rabbit papillomavirus (CRPV) have demonstrated 
proof of efficacy for plant-produced PV L1 vaccines in a rabbit model. 
Immunisation with partially-purified CRPV L1 capsomeres (Kohl et al., 2006) 
and chimaeric tobacco mosiac virus (TMV) particles carrying a CRPV L2 
peptide (Palmer et al., 2006) successfully protected rabbits against CRPV 
challenge and prevented papilloma formation. Furthermore, the efficacy of 
plant-derived CRPV L1 compared favourably with insect cell-produced CRPV 
L1 VLPs used as a positive-control (Kohl et al., 2006) and in a parallel study 
(Govan et al., 2006).  
 
Antisera from immunized animals can be assayed to detect antibody 
responses against HPV L1 and L2 and thus give an indication of vaccine 
immunogenicity. Analysis of several plant-derived HPV immunogenicity 
studies revealed that low doses of plant-derived HPV-16 L1 elicited weak 
immune responses when administered subcutaneously (0.04 – 4 µg; Biemelt 
et al., 2003; Varsani et al., 2003b; Varsani et al., 2006a). However, 1-3 doses 
of 5-11 µg L1 co-administered with Freund‟s adjuvant is sufficient to elicit 
detectable immune responses in mice (Maclean et al., 2007; Fernández-San 
Millán et al., 2008; Paz De la Rosa et al., 2009).  
 
Although a challenge model for HPV does not exist, the antibody-mediated 
neutralisation of HPV pseudovirions (PsVs) in vitro can be used to detect 
HPV-specific antibody responses in antisera, and give an indication of vaccine 
immunogenicity. PsVs can be produced in mammalian cells and consist of the 
co-assembled L1 and L2 capsid proteins encapsidating a reporter plasmid 
(Pastrana et al., 2004). Human embryonic kidney cells over-expressing the 
SV40 large T antigen (HEK293TT) are co-transfected with a plasmid encoding 












plasmid, both containing a SV40 origin of replication. Expression of L1 and L2 
results in the assembly of PsVs and the encapsidation of the small reporter 
gene plasmid (Buck et al., 2004). The PsVs can be harvested from the cells 
and purified for use in a neutralisation assay. 
 
PsV infection of the HEK293TT cells occurs in a similar manner as infection 
with native HPV virions and ultimately results in the expression of the reporter 
gene. The reporter gene used in this study was secreted alkaline phosphatase 
(SEAP) and the enzyme can be detected in the extracellular medium by the 
addition of a substrate (Buck et al., 2004). In the assay, PsVs are 
pre-incubated with sera and antibodies against HPV neutralise the PsVs and 
thus prevent subsequent cell infection and SEAP expression. As a result, the 
antibody-mediated neutralisation of PsVs is indirectly detected as a reduction 
in SEAP activity using a highly sensitive chemiluminescent reporter system 
(Pastrana et al., 2004). 
 
Previous studies have shown that plant-derived HPV-16 L1 (Maclean et al., 
2007; Fernández-San Millán et al., 2008) and L1-based chimaeras (Paz De la 
Rosa et al., 2009) assembled into immunogenic VLPs and elicited the 
production of NAb, the gold standard for demonstrating the potential of 
prophylactic HPV candidate vaccines (Rybicki, 2010). Furthermore, insect 
cell-produced L1/L2 chimaeras were immunogenic and elicited both anti-L1 
and anti-L2 humoral responses (Varsani et al., 2003a). As a result, 
plant-derived L1/L2 chimaeras with L2 epitopes inserted in the same h4 
region of L1 may also be immunogenic and elicit the production of both NAb 
against homologous HPV-16 and cross-neutralising antibodies against other 
HPV types.  
 
In this study, mice were immunized with plant-derived L1 and three L1/L2 
chimaera candidate vaccines containing the cross-neutralising L2 epitopes 
aa 108-120, 56-81 and 17-36. The immunogenicity of the chimaeras was 
analysed with respect to chimaera assembly and their ability to elicit anti-L1, 
anti-L2 and protective NAb against homologous HPV-16 and heterologous 












4.2 Materials and Methods 
4.2.1 Immunisation of mice 
Female C57/BL6 mice from the South African Vaccine Producers Animal Unit 
(Johannesburg, South Africa) were maintained under Biosafty Level 2 (BSL-2) 
conditions in the Animal Unit in the Health Science Faculty, University of Cape 
Town. Permission for this study was granted by the Research Ethics 
Committee, University of Cape Town (AEC 008/037).  
 
Mice (7-8 weeks old) were immunised to test humoral antibody responses to 
plant-derived HPV-16 L1/L2 candidate vaccines. The controls included 
plant-expressed HPV-16 L1 (positive control) and NSs-infiltrated plant extract 
(negative control). The L1/L2(108-120) chimaera (published as SAF; Varsani 
et al., 2003a) has been shown by our laboratory to illicit anti-L1 responses and 
thus served as an additional positive control. The vaccination details are 
shown in Table 1.  
 
Table 1: Plant-derived vaccine antigens used in the immunogenicity study 
Vaccine 









L1/L2(108-120) V1 G1 & G2 10 0.12 
L1/L2(56-81) V2 G3 & G4 10 0.14 
L1/L2(17-36) V3 G5 & G6 10 0.09 
HPV-16 L1 (+) V4 G7 & G8 10 0.33 
Plant extract (-) V5 G9 & G10 N/A 0.16 
*n = number of mice  
†TSP = total soluble protein 
 
The purified vaccine antigens were adjusted to contain a 10 µg dose in 100 µl 
Dulbecco‟s PBS (DPBS; Sigma). The total soluble protein (TSP) in each 
vaccine was assessed using a Bradford protein assay (Chapter 2, Section 
2.2.9) to ensure the negative vaccine control contained a similar TSP in 
comparison to the other HPV vaccines (Table 1). The vaccine was prepared 
by homogenization of the vaccine antigen in Freund‟s Incomplete Adjuvant 
(FIA) in a 1:1 volume ratio using the syringe-extrusion technique (Koh et al., 













Mice were divided up into 2 groups of 5 mice per vaccine and were 
subcutaneously injected into the right flank, left flank or the inguinal site. 
Pre-bleeds were taken 12 days prior to vaccination (Day 0) and mice were 
boosted on Day 13, 27, 41 and 48 (approximately every 2 weeks, except for 
Day 48 when it was decided to boost rather than obtain a test bleed) before 
obtaining the final bleeds at Day 62 (~9 weeks post-vaccination). Serum was 
isolated and stored at -70°C. 
 
4.2.2 ELISA detection of anti-L1 antibodies in mouse sera 
 
4.2.2.1 Preparation of the insect cell-produced HPV-16 L1  
Insect cell-produced HPV-16 L1 (provided by Gillian de Villers) was used as 
an ELISA antigen to detect anti-L1 antibodies in the mouse sera. Insect 
cell-expressed L1 was used instead of plant-expressed L1 to avoid the 
background detection of antibodies against contaminating plant proteins. 
Spodoptera frugiperda (Sf-9) cells were grown shaking in SF90011 
serum-free medium (Gibco) at 27ºC and infected at a multiplicity of infection 
(MOI) of 1.0 and a cell density of 1x106 cells/ml. Cells were harvested after 
96 hrs by centrifugation (1000 x g for 5 min) and pellets were washed with 
DPBS and stored at -70ºC.  
 
HPV-16 L1 was extracted by resuspending cells to 4 x 106 cells/ml in high-salt 
PBS (0.8M NaCl 1x PBS) containing protease inhibitor (Roche Complete 
EDTA-free) and sonicating on ice for 5x 20s intervals of sonication and rest 
(Microtip sonication; Level 5; Heat Systems – Ultrasonics, Inc. Sonicator Cell 
Disruptor Model W-225 R). The cell lysate was clarified by centrifugation 
(5000g for 5 min) to remove cell debris and the centrifugation step was 
repeated using the supernatant. The commercial vaccine Cervarix (20 µg 
HPV-16 L1) was used as a HPV-16 L1 standard for western blot quantification 
of HPV-16 L1 (as described in Chapter 3, Section 3.2.5) and L1 was detected 














4.2.2.2 ELISA detection of anti-L1 antibodies 
The anti-L1 antibody titre was determined by direct ELISA. A 96-well Maxisorp 
microtitre plate (Nunc) was coated with 100µl/well (30 ng) of insect 
cell-produced HPV-16 L1 antigen diluted in 1x PBS and incubated overnight 
at 4°C. Plates were blocked with blocking buffer (1% skim milk in 1x PBS; 
200ul / well) for 2 hrs at room temperature and then washed 4x with PBS.  
 
Mouse sera were pooled into vaccines (10 mice / vaccine) for analysis. Final 
bleed mouse sera were diluted in blocking buffer in a 4-fold series in triplicate, 
ranging from a dilution of 1:50 to 1:51200. Pooled pre-bleed sera were tested 
at 1:50 dilution and served as a negative control. Diluted sera was added to 
the wells (100µl / well) and incubated for 2 hrs at room temperature. Positive 
controls wells contained 1:50 dilution of anti-L1 antibodies; both CamVir1 
(Abcam®), which binds both linear and conformational epitopes (McLean et 
al., 1990), and H16.V5 MAb, which binds specifically to conformational 
epitopes (Christensen et al., 1996). Blank wells with no antibody were 
included as a background control.  
 
After a 4x PBS washing step, goat anti-mouse horseradish peroxidase 
conjugate (1:2000; Sigma) diluted in blocking buffer was added to the wells 
(100 ul / well) and incubated for 1 hr at 37ºC. Plates were washed 4x with 
PBS (200µl / well) and 100 ul of O-phenylenediamine dihydrochloride (OPD) 
(DAKO; Denmark) was added per well. Plates were developed in the dark for 
30 min at room temperature, the reaction was stopped with 0.5M H2SO4 and 
the absorbance at 490nm was detected. The anti-L1 binding titres were 
expressed as a reciprocal of the maximum serum dilution which produces 
higher absorbance readings than that of the corresponding pre-bleed serum 
diluted at 1:50. 
 
4.2.2.3 Statistical analysis 
A two-tailed, non-paired t-test was used to calculate statistical significance of 
the final bleed anti-L1 response, as compared to the negative control vaccine 












vaccines and the Fisher LSD, Turkey HSD and Bonferroni tests were used to 
determine the significance (p = 0.01). 
 
4.2.3 Western blot detection of anti-L2 antibodies 
 
4.2.3.1 Preparation of E. coli-produced HPV-16 L2 
His-tagged HPV-16 L2 protein produced using the pProEX htb vector in E. coli 
(provided by David Mutepfa) was used for the western blot detection of anti-L2 
antibodies in mouse sera. E. coli cultures were grown shaking at 37ºC to an 
OD600 of 0.6 and then induced by the addition of 0.6 mM 
iso-propyl-β-thiogalactoside (IPTG). After 3 hrs, cells were harvested by 
centrifugation (3800g for 15 min at 4ºC) and the pellet was retained and 
weighed.  
 
The inclusion bodies were extracted by resuspension of the cells in 4 volumes 
of lysis buffer (50 mM Tris pH 8.5, 5 mM β-mercaptoethanol) and 
phenylmethanesulfonyl fluoride (PMSF) and lysozyme (Roche) was added to 
a final concentration of 0.4 mM and 0.08 µg/µl respectively. The cells were 
incubated on ice for 20 min, Triton-X was added to 1% and cells were further 
incubated for 20 min at 37ºC until the solution was viscous. DNase and 
RNase were added to 4 µg/ml and 40 µg/ml respectively and cells were 
incubated for 30 min at room temperature until viscosity cleared.  
 
The inclusion bodies were collected by centrifugation at 13,000 rpm in a 
microcentrifuge for 15 min at 4ºC and the pellet resuspended in 1ml lysis 
buffer (2.5 mM Tris pH 8.0, 3.125 mM β-mercaptoethanol, 0.2 mM EDTA, 
0.0025% Triton-X) and left to lyse for 10 min at room temperature. The 
sample was centrifuged at 13,000 rpm for 15 min at 4ºC and pellets were 
washed 4x with PBS. The pellet was resuspended in 1 volume PBS of the 
weight of pellet, quantified by Coomassie staining using a bovine serum 














4.2.3.2 Western blot detection of anti-L2 antibodies 
The E. coli-produced HPV-16 L2 antigen was incubated at 95°C for 5 min in 
5x loading buffer and was loaded into a 10% SDS-PAGE gel. Instead of using 
a 10-well comb, a 2-well comb was used: a small well for the protein marker 
and a large well consisting of the 9 wells fused together, thus producing a 
single wide well which allowed the protein to spread equally across the width 
(Figure 1).  
 
 
Figure 1: Schematic diagram of the western blot technique used to detect anti-L2 (~80 kDa) 
antibodies in mouse sera. M = protein marker with the protein sizes indicated on the left. Strip 
1-12 = membrane strips used to individually probe mouse sera.  
 
 
E. coli-expressed His-tagged HPV-16 L2 antigen (2.5 mg) was separated on a 
10% SDS-PAGE gel (Sambrook et al., 1989) and transferred onto a 
nitrocellulose membrane by semi-dry electroblotting as described in Chapter 
2, Section 2.2.8. The western blotting protocol was then modified, whereby 
the portion of the membrane between 55-130 kDa containing the L2 protein 
(~80 kDa) was divided into 12 similar-sized strips to probe with different sera. 
The membrane strips were transferred into individual wells in a 25-well tissue 
culture plate and incubated in blocking buffer for 4 hrs at room temperature. 
 
Individual pre-bleed and final bleed mouse sera were pooled into vaccines (10 
mice per vaccine) and the membrane strips were probed with positive control 
mouse anti-His antibody (1:2000, Serotech) or pooled mouse sera diluted 
1:100 in blocking buffer. Sera were added to different wells and incubated 
shaking overnight at room temperature. The strips were then washed 4x 10 
min with blocking buffer and then probed with secondary goat anti-mouse IgG 












room temperature. The individual strips were washed again for 4x 10 min with 
wash buffer and then developed with NBT/BCIP (Roche).  
 
Densitometry (GeneTools, Syngene, Synoptics, Ltd) was used to measure the 
absorbance intensity of each L2 band. Values were normalized for non-
specific background absorbance using the value associated with the negative 
control vaccine. Sera with L2 bands having absorbance values >2x the value 
observed in the HPV-16 L1 final bleeds elicited an anti-L2 response.  
 
4.2.4 HPV pseudovirion neutralisation assays 
 
4.2.4.1 Preparation for the neutralisation assays 
The protocols used for the HPV pseudovirion (PsV) neutralisation assays are 
taken from Dr John Schiller‟s Lab of Cellular Oncology technical files 
(Website 3: http://home.ccr.cancer.gov/Lco/) and the HPV L1/L2 pSheLL 
plasmids and the pYSEAP reporter plasmid were kindly provided by Dr John 
Schiller.  
 
The pYSEAP plasmid was checked using a SalI and BamHI restriction 
enzyme digest (as described in Chapter 2, Section 2.2.4.3). The HPV L1/L2 
pSheLL plasmids were similar in size and have similar restriction enzyme 
sites, thus the plasmids were sequenced to confirm their identity using two 
sets of pSheLL vector-specific primers which bind upstream and downstream 
of the HPV L1 and L2 genes (Table 2). Sequences were aligned with the HPV 
L1/L2 pSheLL plasmid sequence and HPV L1 or L2 gene sequences using 




















Table 2: pSheLL vector-specific sequencing primers 
Sequencing target Primer Sequence Tm (°C) Size (nt) 
HPV L1 L1 Fwd TGACCTTATGGGACTTTCCTAC 56.3 22 
  L1 Rvs CACCATAAGCAGCCACAAT 55.5 19 
HPV L2 L2 Fwd TACCACCACGAACAAGCAC 57.5 19 
  L2 Rvs AAGCCATACGGGAAGCAA 55.4 18 
 
 
Plasmids maps of pYSEAP and the HPV L1/L2 pSheLL plasmids used in PsV 
production is shown in Figure 2. The restriction enzymes sites and the 
location of the sequencing primers (L1 and L2 Fwd and Rvs) are indicated on 
the pYSEAP and pSheLL plasmids. 
 
       
Figure 2: Schematic maps of the plasmids used in the HPV pseudovirion assays. A) pYSEAP 
reporter plasmid, showing the BamHI and SalI sites used in the restriction digest analysis. 
B) Generalized map of the HPV L1/L2 pSheLL plasmid vectors. The p16, p18, p45 and p52 
SheLL plasmids are similar in structure, containing both L1 and L2 genes as well as the 
antibiotic markers for Zeo and Amp resistance. They differ in that they contain the HPV 
type-specific L1 and L2 genes, and p16 and p45 SheLL contain an enhancer element not 
present in p18 and p52 SheLL. The primers used to sequence the L1 and L2 genes are 
shown. The map colours represent the following: blue = CDS region, dark blue = mature 
peptide, green = origin of replication, red = poly A signal, turquoise = enhancer element, 
yellow = promoter, grey = repeat region, purple = intron and pink = exon. 
 
 
Endotoxin-free plasmid DNA (NucleoBond® Xtra Midi EF, Macherey-Nagel) 
was prepared from E. coli cultures grown under the appropriate antibiotic 
selection for both the pYSEAP plasmid and HPV-16, 18, 45 and 52 pSheLL 













Table 3: HPV PsV neutralisation assay plasmid vectors used in this study 
Plasmid HPV type Gene of interest Size (bp) Antibiotic resistance 
p16 SheLL HPV-16 L1 & L2 10827 Ampicillin (100 µg/ml) 
p18 SheLL HPV-18 L1 & L2 10723 Ampicillin (100 µg/ml) 
p45 SheLL HPV-45 L1 & L2 10814 Ampicillin (100 µg/ml) 
p52 SheLL HPV-52 L1 & L2 10725 Ampicillin (100 µg/ml) 
pYSEAP - SEAP 5297 Blasticidin (75 µg/ml) 
 
 
4.2.4.2 Transfection of HEK293TT cells 
The HEK293TT cell line was kindly provided by Dr John Schiller. HPV PsVs 
were produced as described in the “Production of Papillomaviral Vectors 
(Pseudoviruses)” protocol revised in June 2010.  
 
HEK293TT cells were cultured in complete high glucose Dulbecco‟s Modified 
Eagle Medium (cDMEM) containing 1% GlutaMAXTM (Gibco) and 10% fetal 
calf serum (Gibco). The cDMEM media was supplemented with 1% 
non-essential amino acids (Gibco), 100 units/ml penicillin (Gibco), 100 µg/ml 
streptomycin (Gibco), 10 µg/ml FunginTM (InvivoGen) and 250 µg/ml 
Hygromycin B (Roche) to select for the TT antigen (cDMEM-Ab). The thawing 
and passaging of cells was done as described in the protocol.  
 
Cells were pre-plated in cDMEM (without antibiotics or Hygromycin B) in a 
175cm2 flask to reach 50-70% confluence the following day. On the day of 
transfection, fresh cDMEM was added to the cells and aliquots of 
endotoxin-free plasmid DNA were thawed on ice. The transfection mix was 
prepared as follows: 175 ul FuGene6 (Roche) was added to 5.7 ml DMEM 
with GlutaMAX (serum-free media) in white-capped conical tubes (Sterilin) 
and incubated for 5 min at room temperature. A total of 40 ug DNA was added 
(20 ug of each plasmid), the mixture was incubated for a further 30 min at 
room temperature and then added dropwise to the cells. Flasks were 
incubated for 40-48 hrs at 37ºC in a 5% CO2 humidified incubator and the 













4.2.4.3 Extraction of pseudovirions 
Pseudovirions were harvested 40-48 hrs post-transfection. Cells were 
collected by trypsinisation with 0.05% Trypsin-EDTA (Gibco) and inactivated 
by the addition of cDMEM. The cells were transferred to a conical-bottomed 
polystyrene Sterilin tube (as pseudovirions adsorb non-specifically to 
polypropylene tubes), counted and centrifuged at 1200 rpm x 8 min. The pellet 
was washed with 0.5ml DPBS (Invitrogen) and resuspended in 1.5 pellet 
volumes of DPBS-Mg (DPBS with an additional 9.5 mM MgCl2) to achieve a 
high cell density of >100 x 106 cells/ml.  
 
10% Brij-58 (Sigma) was added to the resuspended pellet to a final 
concentration of 0.5% (w/v) and both Benzonase (Sigma) and Plasmid-SafeTM 
ATP-dependent DNase (Epicentre) were added to 0.5% (v/v) and 0.2% (v/v) 
respectively. Using Chris Buck‟s “Improved Maturation of HPV and 
Polyomavirus” protocol, sterile ammonium sulphat  (1M, pH 9.0) was added 
to a final concentration of 25 mM to promote the formation of intermolecular 
L1 disulphide bonds. The mixture was incubated at 37ºC for 15 min to allow 
lysis and then transferred to the preferred temperature for pseudovirion 
maturation overnight (25ºC for HPV-16 and 18, 37ºC for HPV-45 and 52).  
 
The matured lysate was chilled on ice for 5 min and the final NaCl 
concentration of the lysate was adjusted to 850 mM and incubating on ice for 
a further 10 min. The lysate was clarified by centrifuging 3000 x g for 10 min 
at 4ºC. The supernatant was collected and the pellet was re-extracted by 
resuspending in an equal pellet volume of high salt DPBS (0.8M NaCl) and 
re-centrifuging. The supernatants were pooled, re-centrifuged and transferred 
into white-capped polystyrene tubes and kept on ice. 
 
4.2.4.4 Purification of pseudovirions 
PsV are purified by Optiprep density gradient centrifugation. Optiprep 
(60% w/v iodixanol solution; Sigma) was diluted in DPBS to a 46% (w/v) 
Optiprep stock solution, and supplemented with 0.625M NaCl to a final 












2.1mM. High salt DPBS (0.8M NaCl) was used to dilute the stock solution to 
27%, 33% and 39% Optiprep, and the 3-step gradient was prepared by 
underlaying the Optiprep dilutions (27 – 39%) in 1.5ml steps in thin wall 5ml 
polyallomer ultracentrifuge tubes (Beckman). The gradient was left to diffuse 
at room temperature for 4 hrs. Double-clarified cell supernatant was layered 
onto the linearized Optiprep gradient and centrifuged in a Beckman SW55ti 
rotor at 50,000 rpm (234,000 x g) for 3.5 hrs at 16ºC. The bottom of the tube 
was punctured with a syringe needle and fractions were collected in white-
capped polystyrene tubes: the first fraction was ~0.75 ml, fraction 2-11 was 
~0.25 ml each and fraction 12 contained the remainder of the gradient. 
 
The protocol for screening fractions was modified to detect the presence of 
HPV L1, the major protein present in the capsid (Buck et al., 2008), using 
HPV type-specific anti-L1 dot blots. Each fraction was spotted onto 
nitrocellulose membrane (0.5 µl) and Cervarix (HPV-16 L1), E. coli-produced 
His-tagged HPV-16 L2, or the clarified HPV-16, 18, 45 or 52 supernatant 
initially loaded onto the gradient was used as positive controls.  
 
The membranes were blocked in blocking buffer for 30 min at room 
temperature and then probed overnight at room temperature with an 
appropriate primary anti-L1 antibody diluted in blocking buffer. CamVir1 
(1:5000; Abcam) was used to detect HPV-16. In addition, rabbit anti HPV-16 
L2 sera was available and used to detect L2 in the HPV-16 fractions (1:2000). 
The H16.I23, H45.N5, H52.C1 and H52.D11 MAb kindly provided by Dr Neil 
Christensen were used to detect HPV-18, 45 and 52 respectively (1:2000; 
Christensen et al., 1996). Membranes were probed with 1:10,000 secondary 
antibody (goat anti-mouse IgG conjugated to alkaline phosphatase or goat 
anti-rabbit alkaline phosphatase conjugate; Sigma), washed and developed 
as previously described (Chapter 2, Section 2.2.8). Peak fractions containing 
a high concentration of L1 were pooled in polystyrene tubes and stored at 














4.2.4.5 Electron microscopy of pseudovirions 
Purified HPV PsV were analyzed using electron microscopy. The PsV‟s 
(1:1000) were trapped on glow-discharged carbon-coated copper grids, 
stained with 2% uranyl acetate and viewed using a Zeiss EM 912 CRYO 
EFTEM.  
 
4.2.4.6 Pseudovirion titration 
The PsV titrations and neutralisation assays were based on the 
“Papillomavirus Neutralisation Assay” protocol, with the exception that no NAb 
were included in the titration. PsV stocks were titrated prior to the 
neutralisation assays in order to determine the minimum amount of PsV 
required for a robust signal in the SEAP assay.  
 
HEK293TT cells were grown in cDMEM-Ab to 70-80% confluence, collected 
as described, washed with DPBS and diluted to 3.0 x 105 cells/ml in 
neutralisation media (High glucose cDMEM with HEPES and without phenol 
red or sodium pyruvate, supplemented with 10% fetal calf serum; Gibco). 
Cells were pre-plated into 96-well tissue culture treated plates (Corning 
Costar) with 100µl cell suspension in each internal well and 150µl DMEM with 
phenol red in the external wells to avoid evaporation from the inner wells. 
Cells were incubated for 3-4 hrs at 37ºC before the addition of the PsVs.  
 
Serial dilutions of PsVs were prepared in neutralisation media (doubling 
dilutions from 1:250 to 1:64000) in non-treated sterile 96-well polystyrene 
plates (Nunc) and tested in triplicate. The PsV dilutions were added to the 
pre-plated cells (100µl / well) as outlined in the Schiller protocol, and each 
plate contained 6 negative control wells with no pseudovirions (cell control). 
Plates were incubated for 72 hrs at 37ºC in a humidified CO2 incubator.  
 
SEAP activity was detected using the Great EscAPeTM SEAP 
Chemiluminescence Kit 2.0 (Clontech Laboratories, Inc.) according to manual 
instructions, except volumes were adjusted to 0.6 volumes of those given in 












Supernatant (125µl) was transferred into sterile untreated 96-well polysterene 
plates (Nunc) and centrifuged at 1000 x g for 5 min. Clarified supernatant 
(15µl) was transferred into a white 96-well Optiplate (96F white maxisorb 
luminometer plates; Nunc), 45µl 1x dilution buffer was added to each well and 
the plate was incubated at 65°C for 30 min. Plates were chilled for 5 min on 
ice and then 60µl substrate was added per well and incubated at room 
temperature for 20 min. SEAP production was detected using a microplate 
luminometer (Digene DML 2000). The PsV dilution chosen for the 
neutralisation assay was one that used the minimum amount of PsVs 
occurring within the linear range of the titration curve. As the HPV-52 titre was 
very low, it was re-titred from 1:125 to 1:4000. 
 
4.2.4.7 Pseudovirion neutralisation assay 
An in vitro neutralisation assay was used to detect HPV-specific antibody 
responses in mouse sera and to determine endpoint neutralisation titres.  
 
Controls included:  
(a) Cell control (negative infection control): Cells were incubated with 
neutralisation media only (no sera or pseudovirions) to give a background 
reading of the cell culture supernatant. The luminescent values associated 
with this control represented 0% PsV neutralisation. 
(b) PsV control (positive PsV infection control): PsVs were pre-incubated in 
neutralisation buffer prior to cell infection. The values associated with this 
control represented 100% PsV neutralisation. 
(c) MAb or antisera known to neutralise the HPV-type PsV used in the assay 
(positive neutralisation assay control): PsV‟s were pre-incubated with 
6 dilutions which should span the pre-determined neutralisation titre (0-100% 
neutralisation). 















The NAb positive controls (Table 4) were titrated prior to the test sera 
neutralisation assay in order to determine the neutralisation dilution range to 
be used in the PsV neutralisation assays. The HPV-16, 45 and 52 
neutralisation controls were H16.V5, H45.N5, H52.C1 and H52.D11 MAb. The 
HPV-18 control was rabbit anti-Cervarix sera from our laboratory. 
 
 
Table 4: HPV type-specific neutralising antibodies 
Positive control antibody HPV type neutralised Fold dilution Dilution range 
Mouse H16.V5 ascites HPV-16 10-fold 2x102 – 2x107 
Rabbit anti-Cervarix sera HPV-18 4-fold 50 – 51200 
Mouse H45.N5 ascites HPV-45 4-fold 800 – 819200 
Mouse H52.C1 supernatant HPV-52 10-fold 2x102 – 2x107 




Sera from mice immunized with plant-produced HPV-16 chimaera candidate 
vaccines were pooled (10 mice/vaccine) and tested for neutralisation of 
HPV-16, as well as HPV-18, 45 and 52. Pooled vaccine sera was diluted 
4-fold in triplicate in the range 1:50 to 1:12800. Pre-bleeds were also pooled 
and tested in triplicate as a negative control at the lowest dilution of 1:50. 
Serial dilutions of sera were prepared in sterile non-treated 96-well tissue 
culture plates (1:10 to 1:2560).  
 
PsVs were diluted in neutralisation buffer to the concentration pre-determined 
in the titration assay. In another untreated 96-well plate, 100µl diluted PsVs 
were added to each well and 25µl of diluted sera (or neutralisation buffer for 
the PsV control wells) were added to the triplicate wells, resulting in a further 
1:5 dilution of pre-diluted sera. The PsVs and sera were incubated at 4°C for 
1hr to allow for the neutralisation of infectious PsVs, and then 100µl were 
added to each well in the pre-plated HEK-293TT plate (neutralisation buffer 
for the cell control wells). The plates were incubated for a further 72 hrs in a 













The supernatant was harvested as described above and assayed for the 
presence of SEAP. The neutralisation titre was stated as the reciprocal of the 
maximum serum dilution which reduces SEAP activity by at least 50% in 




4.3.1 Humoral immune response against HPV-16 L1 
The detection of antibodies elicited against HPV-16 L1 was done by direct 
ELISA, using insect cell-expressed HPV-16 L1 as the coating antigen 
(Figure 3). The anti-L1 titres were expressed as the reciprocal of the 
maximum serum dilution containing higher absorbance readings than that of 
the corresponding pre-bleed serum at 1:50. 
 
No anti-L1 response was detected for the L1/L2(56-81) chimaera and the 
negative control vaccine (V2 and V5; Figure 3A) as well as the vaccine 
pre-bleeds (Figure 3C). In comparis n, the ELISA MAbs (H16.V5, CamVir1, 
Figure 3B) and the plant-derived L1 positive controls (V4, Figure 3A) showed 
a good response and both the plant-derived L1/L2(17-36) and L1/L2(108-120) 
chimaeras elicited anti-L1 titres of 200 and 12800 respectively (V3 and V1, 
Figure 3A). Although HPV-16 L1 elicited the highest anti-L1 titres 
(12800-51200), L1/L2(108-120) showed a similar response (V4 and V1 
respectively, Figure 3A), suggesting the insertion of the L2 aa 108-120 
epitope had less of an effect on L1 immunogenicity in comparison to the other 
chimaeras. Furthermore, the L1/L2(108-120) and HPV-16 L1 anti-L1 response 
was statistically significant from their corresponding pre-bleeds and the 

















Figure 3: Direct ELISA of mouse sera using insect cell-produced HPV-16 L1 as the coating 
antigen. V1 = L1/L2(108-120), V2 = L1/L2(56-81), V3 = L1/L2(17-36), V4 = HPV L1 
(+ vaccine control), V5 = plant extract (- vaccine control). A) Titration of the mouse antisera 
for all the vaccines. B) Graph showing the values obtained for the ELISA positive control 
MAbs H16.V5 and CamVir1. C) Vaccine pre-bleed absorbance values at 1:50 dilution. 




4.3.2 Humoral immune response against the HPV-16 L2 epitopes 
The anti-L2 response against the E. coli-produced His-tagged HPV-16 L2 
protein was determined using western blotting. Individual mouse sera were 





























Figure 4: Western blot detection of E. coli-expressed His-tagged HPV-16 L2 by mouse sera 
at a dilution of 1:100. M = protein marker with the protein size in kDa. V1 = L1/L2(108-120), 
V2 = L1/L2(56-81), V3 = L1/L2(17-36), V4 = HPV L1 (+ vaccine control), V5 = plant extract 
(- vaccine control). PB = pre-bleed sera. FB = final bleed sera. For the western blot controls: 
+ve = mouse anti-His (1:2000; Serotec), -ve = no primary antibody. The black arrow indicates 
L2 (~80 kDa). 
 
 
A non-specific band similar to the ~80 kDa L2 band was detected in both the 
antisera from the negative vaccine control (V5; plant extract) and the L1 
vaccine control (V4; plant-expressed HPV-16 L1) which serves as an 
additional negative L2 control in this experiment (Figure 4). All chimaera 
vaccines (V1-3) appeared to give an anti-L2 response, as strong L2 bands 
were detected using the chimaera antisera (Figure 4). However, only the 
L1/L2(108-120) and L1/L2(17-36) chimaeras (V1 and V3 respectively) gave a 
definitive anti-L2 response, with L2 bands >2X intensity of HPV-16 L1 (V4).  
 
4.3.3 Neutralisation assays 
 
4.3.3.1 Plasmid analysis 
The identity of the pYSEAP and the HPV-16, 18, 45 and 52 L1/L2 pSheLL 
plasmids was confirmed using restriction enzyme digestion and sequencing 
(data not shown). 
 
4.3.3.2 Optiprep purification and HPV PsV detection in purified fractions 
HPV PsVs were purified from the clarified cell supernatant by density gradient 
ultracentrifugation on a 27-39% Optiprep linear gradient. A light grey band 
was faintly visible a third of the way up from the gradient and the fractions 














Figure 5: Purified HEK293TT-produced HPV PsVs. The arrow indicates the purified HPV 
PsV. A) Photograph of an Optiprep density gradient after ultracentrifugation of clarified 




Fractions were screened for the presence of PsVs using HPV type-specific 
anti-L1 dot blots (Figure 6). CamVir1 and rabbit antisera against HPV-16 L2 
was used to detect HPV-16 L1 and L2 (Figure 6A), using Cervarix and 
E. coli-produced His-tagged HPV-16 L2 as controls. The H16.I23, H45.N5, 
H52.C1 and H52.D11 MAb were used to detect HPV-18, 45 and 52 
respectively (Figure 6B-D), using the initial clarified cell supernatant as the 
HPV type-specific control.  
 
HPV-16 was detected in fraction 3-5 using H16.V5 and weakly detected with 
the HPV-16 L2 antisera, as the L2 protein is located internally to the L1 capsid 
surface in co-assembled L1/L2 VLPs (Buck et al., 2008). HPV-18, 45 and 52 
L1 was strongly detected in fractions 5-7, 4-6 and 6-10 respectively. PsV 


















Figure 6: Dot blot detection of purified HEK293TT-produced HPV PsVs in the Optiprep 
fractions. A) HPV-16 PsVs were detected with anti-L1 MAb CamVir1 and anti-L2 MAb rabbit 
sera. B) HPV-18 PsVs were detected with H16.I23. C) HPV-45 PsVs were detected with 
H45.N5. D) HPV-52 PsVs were detected with H52.C1 and H52.D1. Fractions 1-12 were 
tested, using the clarified PsV supernatant layered onto the gradient as the +ve control (top 
right corner of each blot), and the PsV supernatant of the other PsV types as –ve controls 















4.3.3.3 Electron microscopy analysis 
The pooled PsV samples were examined by transmission electron microscopy 
to determine their assembly, morphology and purification (Figure 7). All HPV 
types assembled into spherical PsVs (55 nm). HPV-45 PsVs appeared to exist 
exclusively as fully-assembled PsV particles (Figure 7D). HPV-16 and 18 
PsVs were predominantly assembled, although some capsomeres and 
aggregates were visible (Figure 7A-B). HPV-52 PsVs (Figure 7D) contained a 
large proportion of capsomere aggregates and partial PsVs, possibly as a 




Figure 7: Electron microscopy of purified HEK293TT-produced HPV PsVs viewed on a Zeiss 
EM 912 CRYO EFTEM. A) HPV-16, B) HPV-18, C) HPV-45 and D) HPV-52 PsV. The red 
arrows indicate HPV PsV (~55 nm), the blue arrows indicate capsomere aggregates 
















4.3.3.4 HPV PsV titration 
The purified PsVs were titrated (Figure 8) to determine the PsV dilution to be 
used for the neutralisation assays. The dilution used was the minimum 
amount of PsVs giving a robust signal within the linear range of the titration 
curve.  
 
For HPV-16 and 18 PsVs, the linear range of the titration curve occurred 
between dilutions 1:250 to 1:1000 (Figure 8A), and thus 1:500 was chosen for 
the neutralisation assays. HPV-45 PsVs had the highest titre, with the linear 
range occurred between dilutions of 1:500 and 1:2000 (Figure 8A), thus 
1:1000 was chosen for further work. HPV-52 PsVs had to be re-titred using 
lower dilutions (poor titre yield has also been reported by Schiller‟s group). 
The linear range occurred between dilutions 1:125 to 1:250 (Figure 8B), and a 




Figure 8: HPV PsV titration curves. A) High-yielding HPV-16, 18 and 45 PsV titrations. 




4.3.3.5 Titration of the positive control neutralising antibodies 
The NAb positive controls were tested prior to the neutralisation assays with 












determine a suitable dilution range. All positive control antibodies were 




Table 5: Titration of the positive control neutralising antibodies 
HPV PsV type Positive control Dilution range PsV neutralisation (%) 
HPV-16 H16.V5 2x102 – 2x107 19 – 100 
HPV-18 anti-Cervarix sera 50 – 51200 34 – 99 
HPV-45 H45.N5 800 – 819200 29 – 100 
HPV-52 H52.C1 2x102 – 2x107 0 – 98 
 H52.D11 2x102 – 2x107 0 – 98 
 
 
4.3.3.6 HPV PsV neutralisation assays 
Sera from mice immunized with plant-produced HPV-16 L1 and L1/L2 
chimaeras were tested for homologous neutralisation of HPV-16 PsVs and 
heterologous cross-protection against HPV-18, 45 and 52 PsVs (Figure 9-12). 
All positive control NAbs successfully neutralised the HPV-16, 18, 45 and 52 
PsVs (Figure 9-12F), demonstrating that the neutralisation assay results were 
valid. The neutralisation titre was defined as the highest dilution of serum 
which reduces SEAP activity by >50% in comparison to the control sample, 
which was not treated with serum. 
 
HPV-16 
The results from the HPV-16 PsV neutralisation assays are shown in Figure 9. 
Plant-derived HPV-16 L1 sera (V4; Figure 9D) mimicked the H16.V5 positive 
control (Figure 9F) and strongly neutralised HPV-16 PsV, followed by 
L1/L2(108-120) with a similar neutralisation curve (V1; Figure 9A). Both 
L1/L2(56-81) and L1/L2(17-36) did not appear to elicit HPV-16 NAb 
(V2-3; Figure 9B-C) showing similar neutralisation curves to the negative 














Figure 9: HPV-16 PsV neutralisation assay. Pooled sera from mice vaccinated with V1-V5 
were tested for their ability to neutralise HPV-16 PsVs. A) V1 = L1/L2(108-120), 
B) V2 = L1/L2(56-81), C) V3 = L1/L2(17-36), D) V4 = HPV-16 L1 (+ve vaccine control), 
E) V5 = NSs-infiltrated plant extract (-ve vaccine control). F) H16.V5 = +ve neutralisation 
control. Cell control = -ve infection / SEAP expression control. PsV control = +ve 
infection / SEAP expression control. Samples were assayed in triplicate and error bars 





The antisera from all the vaccines did not neutralise HPV-18 PsV (Figure 10). 
The L1/L2(56-81) and L1/L2(17-36) chimaeras (V2-3, Figure 10B-C) produced 












negative control (V4-5, Figure 10D-E). L1/L2(108-120) appeared to have 
some neutralising activity, with reciprocal sera dilutions of <800 reducing 
luminescent readings below that of the pre-bleed and the unneutralised HPV-
18 PsV control (V1; Figure 10A). However, the chimaera did not reduce SEAP 




Figure 10: HPV-18 PsV neutralisation assay. A) V1 = L1/L2(108-120), B) V2 = L1/L2(56-81), 
C) V3 = L1/L2(17-36), D) V4 = HPV-16 L1, E) V5 = NSs-infiltrated plant extract (-ve vaccine 

















The results from the HPV-45 PsV neutralisation assay (Figure 11) suggest 
that none of the L1/L2 chimaera vaccines (V1, V2 and V3; Figure 11A-C) 
elicited significant titres of HPV-45 NAb, with neutralising curves similar to 





Figure 11: HPV-45 PsV neutralisation assay. A) V1 = L1/L2(108-120), B) V2 = L1/L2(56-81), 
C) V3 = L1/L2(17-36), D) V4 = HPV-16 L1, E) V5 = NSs-infiltrated plant extract (-ve vaccine 














The HPV-52 PsV neutralisation assays (Figure 12) provide evidence that 
L1/L2(56-81) sera did not neutralise HPV-52 (L2; Figure 12C), as seen for 
HPV-16 L1 and the negative control sera (V4-5; Figure 12D-E). 
L1/L2(108-120) and L1/L2(17-36) chimaera vaccines appeared to have some 
neutralising activity at low reciprocal dilutions (50-200), reducing SEAP levels 
by >50% in comparison to the unneutralised HPV-52 PsV control (V1 and V3; 




Figure 12: HPV-52 PsV neutralisation assay. A) V1 = L1/L2(108-120), B) V2 = L1/L2(56-81), 
C) V3 = L1/L2(17-36), D) V4 = HPV-16 L1, E) V5 = NSs-infiltrated plant extract (-ve vaccine 













Although the assay was successful, as shown by the H52.C1 NAb control 
(Figure 12F), there was a great deal more variation between triplicates 
samples and trend lines were difficult to establish. This may be attributed to 
the partial purification and low concentration of HPV-52 PsVs which may have 
exaggerated small differences between replicates. The values for the HPV-52 
PsV infection control differ between vaccines as V1, V2 and V4 (Figure 12A-B 
and D) were analyzed on a different plate from V3, V5 and H52.C1 
(Figure 12C and E-F). Time constraints prevented this assay from being 
repeated. 
 
Table 6 summarizes the HPV-16, 18, 45 and 52 PsV neutralisation antibody 
titres elicited by the plant-derived vaccines. L1/L2(108-120) elicited 
homologous HPV-16 NAb and the antisera cross-neutralised heterologous 
HPV-52 PsV, suggesting this vaccine has the most potential for protection. 
L1/L2(17-36) chimaeras elicited low levels of cross-neutralising HPV-52 NAb, 
but homologous HPV-16 NAb were not detected, suggesting the 
immunogenicity against HPV-16 L1 may be compromised. L1/L2(56-81) did 
not elicit NAb and does not appear to have potential as a prophylactic 
vaccine. None of the HPV vaccines elicited cross-neutralising antibodies 
against phylogenically-related HPV types 18 and 45. 
 
 
Table 6: Summary of the neutralisation titres for plant-derived L1 and the L1/L2 chimaera 
candidate vaccines  
  
PsV neutralisation assay titres*   
Vaccine Chimaera HPV-16 HPV-18 HPV-45 HPV-52 
V1 L1/L2(108-120) 50-500 0-50 0-50 50-200 
V2 L1/L2(36-58) 0-50 0-50 0-50 0-50 
V3 L1/L2(17-36) 0-50 0-50 0-50 50-200 
V4 HPV-16 L1 500-5000 0-50 0-50 0-50 
V5 Plant extract 0-50 0-50 0-50 0-50 
+ control H16.V5 2x105 – 2x106       
  α-CamVir1   12800-51200     
  H45.N5     3200-12800   
  H52.C1       2x104 – 2x105 













4.3.4 Overview of vaccine immunogenicity 
The structural assembly (Chapter 3, Section 3.3.3), the anti-L1 and L2 
humoral responses and the HPV-type NAb detected in the L1/L2 chimaera 
antisera are summarized in Table 7. Assembly into VLPs appears to be 
associated with higher anti-L1 and HPV-16 PsV neutralisation titres, 
suggesting assembly is associated with L1 immunogenicity. 
 
 















V1 L1/L2(108-120) VLPs Y 12800 Y HPV-16/52 
V2 L1/L2(56-81) C / CA N 0-50 N None 
V3 L1/L2(17-36) CA / VLPs Y 200 Y HPV-52 
V4 HPV-16 L1 (+) VLPs Y >12800 N HPV-16 
V5 Plant extract (-) N/A N 0-50 N None 
 
* TEM antigen assembly: C = capsomeres, CA = capsomere aggregates, VLPs = virus-like particles. 
** ELISA detection of anti-L1 antibodies. Y = yes, N = no.  




Plant-derived HPV-16 L1 (Maclean et al., 2007; Fernández-San Millán et al., 
2008) and L1-based chimaeras (Paz De la Rosa et al., 2009) assemble into 
immunogenic VLPs and elicit the production of neutralising antibodies (NAb), 
In this study, the immunogenicity of three plant-derived L1/L2 chimaeras 
containing cross-neutralising HPV-16 L2 aa 108-120, 56-81 or 17-36 epitopes 
in the h4 region of HPV-16 L1 were analysed. Mice were subcutaneously 
immunized with 10 µg of plant-derived antigen in Freund‟s incomplete 
adjuvant, and received 4 booster vaccinations within 7 weeks. 
 
4.4.1 Humoral immune responses 
Insect cell-expressed L1/L2 chimaeras with the L2 aa 108-120 substituted into 
the h4 region of L1 (Varsani et al., 2003a) or L2 aa 17-36, 18-31, 35-75, 












loop (aa 133-134) elicited anti-L1 and L2 responses in mice (Slupetzkey et al., 
2007; Schellenbacher et al., 2009), suggesting L1/L2 chimaeras may be an 
effective strategy to broaden the protection of HPV prophylactic vaccines. As 
a result, the humoral anti-L1 and L2 responses elicited by the plant-derived 
L1/L2 chimaeras were analysed in this study, to determine if the L2 peptides 
are displayed and whether the L2 insertions compromise L1 immunogenicity.  
 
The detection of L1 and L2 antibodies in mouse antisera was done by direct 
ELISA (Figure 3) and western blotting (Figure 4) respectively, using either 
insect cell-expressed HPV-16 L1 or E. coli-expressed His-tagged L2 antigen. 
Plant-derived HPV-16 L1 served as the anti-L1 positive control in the study 
and elicited the highest anti-L1 response, with titres of 12800 - 51200 (Figure 
3A). These results are similar to other mouse immunogenicity studies using 
partially-purified plant-derived HPV-16 L1 VLPs (Titres = 20000 – 40960; 
Maclean et al., 2007; Fernández-San Millán et al., 2008).  
 
The negative control vaccine (V5: NSs-infiltrated plant extract) and the 
vaccine pre-bleeds (V1-5 PB) did not give anti-L1 responses (Figure 3). 
However, antisera from the negative controls (V4-5, Figure 4) did detect the 
E. coli-expressed His-tagged HPV-16 L2 antigen, thus demonstrating the 
presence of non-specific antibodies in the sera which bound the His-tagged 
L2 protein. This is possibly due to the partial purification of antigens, which 
resulted in the vaccines containing contaminating plant proteins. 
Nevertheless, the negative control bands were less distinct than the bands for 
the L1/L2(108-120) and L1/L2(17-36) chimaeras, suggesting these L1/L2 
chimaeras elicited an anti-L2 response. 
 
L1/L2(108-120) assembled into distinctive cVLPs and was the most 
successful chimaera vaccine (Table 7), eliciting the highest anti-L1 response 
with titres of ~12800 (Figure 3A) and an anti-L2 response (Figure 4). 
Furthermore, only the L1/L2(108-120) and HPV-16 L1 antisera demonstrated 
significant anti-L1 responses (p = 0.01) in comparison to the pre-bleeds and 
the NSs-infiltrated plant extract (negative control). The insect cell-expressed 












anti-L1 titres (>204800) in comparison to the plant-derived chimaera, however 
a 10x higher dose was used (100 µg vs. 10 µg). Taken together, there is 
strong evidence that the L2 aa 108-120 peptide is effectively displayed on the 
surface of the L1 cVLPs. 
  
The L1/L2(17-36) vaccine elicited a relatively weak anti-L1 response with 
titres of ~200 (Figure 3A) but elicited a strong anti-L2 response (Figure 4), 
suggesting that the L2 peptide is displayed on the surface of assembled L1.  
Similarly, fusion of a L2 aa 20-38 peptide to bacterial thioredoxin (Trx) elicited 
strong anti-L2 reponses in comparison to other Trx-L2 peptides comprising of 
aa 56-120 (Rubio et al., 2009) and the RG-1 MAb directed against the 
HPV-16 L2 aa 17-36 peptide has been shown to detect L2 in western blotting 
and ELISA (Gambhira et al., 2007b). 
 
The L1/L2(56-81) capsomere vaccine did not elicit a detectable anti-L1 
response at the lowest sera dilution 1:50 (Figure 3A) and the anti-L2 response 
was inconclusive (Figure 4), with both the anti-L1 and L2 responses similar to 
the vaccine pre-bleeds (V1-5 PB) and the negative controls (Figure 3-4). As a 
result, plant-derived L1/L2(56-81) do not appear to be immunogenic,  unlike 
E. coli-expressed Trx-L2 fusion peptides (Rubio et al., 2009) and insect 
cell-expressed L1/L2 chimaeras containing similar L2 epitopes in the DE loop 
of BPV-1 L1 VLPs (Slupetzkey et al., 2007; Schellenbacher et al., 2009).  
 
4.4.2 Pseudovirion neutralisation assays 
The L1/L2 chimaeras, containing L2 epitopes aa 108-120, 56-81 and 17-36, 
were examined for their ability to elicit antibodies which neutralise HPV-16, 
18, 45 and 52 PsVs. All the L2 epitopes analysed in this study have been 
shown to elicit antibodies which neutralise homologous HPV-16 and 
cross-neutralise HPV-52 (Kawana et al., 2003; Slupetzky et al., 2007; 
Kondo et al., 2007, 2008; Gambhira et al., 2007b; Schellenbacher et 
al., 2009). Additionally, L2 aa 56-81 cross-neutralises HPV-18 and L2 












Kondo et al., 2007, 2008; Alphs et al., 2008; Schellenbacher et al., 2009; 
Rubio et al., 2009). 
 
HPV-16 was chosen as HPV-16 L1 is the backbone of the chimaeric 
candidate vaccines and it causes the majority of cervical cancers, followed by 
phylogenically-related HPV-18 and HPV-45. HPV-16, 18 and 45 are 
associated with 48%, 23% and 10% of cervical cancers in Africa, and 61%, 
10% and 6% of cervical cancers worldwide (de Sanjosé et al., 2010). Although 
HPV-52 is only ranked 5th in Africa (3%) and 6th worldwide (6%), HPV-52 has 
been shown to be highly prevalent in low and high-grade cervical lesions in 
South African women and thus HPV-52 cross-neutralisation is of local 
significance (Allan et al., 2008).  
 
4.4.2.1 Homologous HPV-16 neutralisation 
Plant-derived L1/L2(56-81) and L1/L2(17-36) did not elicit detectable HPV-16 
NAb titres, giving results similar to the pre-bleeds and the NSs-infiltrated plant 
extract (Figure 9). Previous work has shown L1/L2 chimaeras containing 
HPV-16 L2 peptides aa 17-36, 18-38, 56-75 or 69-81 located in surface 
regions of BPV-1 or HPV-16 L1 elicted HPV-16 NAb (Slupetzkey et al., 2007; 
Kondo et al., 2008; Schellenbacher et al., 2009); however, the insertion sites 
differed from those used in this study and the chimaeras assembled into 
cVLPs. Furthermore, MAb directed against HPV-16 L2 aa 73-84 were found to 
be non-neutralising and did not neutralise HPV-16 PsV (Gambhira et al., 
2007b), similar to the results obtained for the L1/L2(56-81) chimaera in this 
study. 
 
In this study, only L1/L2(108-120) and HPV-16 L1 neutralised HPV-16 PsV in 
a similar manner to H16.V5 (positive neutralisation control), giving titres of 
50-500 and 500-5000 respectively (Table 6). These results are consistent with 
other mouse immunogenicity studies using plant-derived HPV L1 antigens. 
A similar or higher dose of plant-derived HPV-16 L1 VLPs elicited HPV-16 
NAb titres of 400-1600 (Maclean et al., 2007; Fernández-San Millán et al., 












using a hemagglutination assay (Paz De la Rosa et al., 2009). Furthermore, 
immunisation of humans with the HPV-16 L2 aa 108-120 peptide has shown 
to elicit HPV-16 NAb titres of 100-1000 (Kawana et al., 2003) and mouse 
antisera from L1/L2 chimaeras containing the L2 epitopes aa 108-120 
(Slupetzkey et al., 2007) or L2 aa 75-112 and 115-154 (Schellenbacher et al., 
2009) neutralised homologous HPV-16 PsVs with titres <1000. Therefore the 
titres obtained in the study are within the range reported by L1/L2 chimaera 
vaccines produced in other expression systems. 
 
4.4.2.2 Heterologous HPV-18, 45 and 52 neutralisation 
Neutralising activity against phylogenically-related HPV-18 and 45 PsV was 
not detected for all the HPV vaccines (Figure 10-11). Similarly, the 
L1/L2(56-81) antisera did not neutralise HPV-52 PsV (Figure 12). Although 
L1/L2(108-120) and L1/L2(17-36) appeared to elicit low HPV-52 NAb titres 
(50-200), there was a great deal of variation in the assay, possibly due to the 
purification of partially-assembled PsVs (Figure 7D), and the assay should be 
repeated to confirm results.  
 
Previous work has demonstrated that L1/L2 chimaeras containing the L2 
aa 56-81 peptide cross-neutralises both HPV-18 and 52 (Kondo et al., 2008). 
However, the chimaeras were assembled into cVLPs unlike L1/L2(56-81), 
suggesting VLP assembly is important to induce the production of high NAb 
titres. Furthermore, L1/L2 chimaera containing L2 aa 17-36 or 18-36 (Kondo 
et al., 2008; Schellenbacher et al., 2009) elicits NAb against HPV-18, 45 and 
52. However, the L2 peptides were inserted into the DE loop (Schellenbacher 
et al., 2009) and the dosage was not stated for the study conducted by Kondo 
et al. (2008). In this study, the low HPV-52 NAb titres elicited by plant-derived 
L1/L2(17-36) in mice were comparible to titres elicited by a similar L1/L2 
chimaera expressed in insect cells (Schellenbacher et al., 2009), suggesting 














Plant-derived L1/L2(108-120) chimaera appeared to elicit HPV-52 NAb and 
may have potential as a cross-protective HPV vaccine, supported by evidence 
that the L2 aa 108-120 peptide has been shown to elicit HPV-52 NAb titres of 
50-1000 respectively in humans (Kawana et al., 2003). There is no evidence 
that HPV-16 L2 aa 108-120 cross-neutralises HPV-45, however L1/L2 
chimaeras containing similar L2 aa 96-115 or 75-112 epitopes 
cross-neutralised phylogenically-related HPV-18 (Kondo et al., 2008; 
Schellenbacher et al., 2009). However NAb titres reported in the studies were 
low (<100) and it is possible that elicited HPV-18 NAb were too low to detect 
in the L1/L2(108-120) antisera.  
 
4.4.3 Conclusion 
Plant-derived HPV-16 L1 VLPs elicit the highest anti-L1 and HPV-16 NAb 
titres in mice. Although both L1/L2(108-120) and L1/L2(17-36) chimaeras elicit 
anti-L1 and L2 responses, L1/L2(108-120) assembled into cVLPs and 
appears to be the best candidate vaccine, as it elicits high anti-L1 responses 
and was the only chimaera to elicit both HPV-16 NAb and cross-neutralise 
heterologous HPV-52. L1/L2(56-81) did not appear to be immunogenic and 













Chapter 5: Transgenic expression of L1 chimaeras 
5.1 Introduction 
One of the main strategies employed in the production of plant-derived HPV 
antigens is transgenic expression. Stable transformation of plants involves the 
integration of a foreign gene into the nuclear or plastid genome (Fischer and 
Emans, 2000). Several studies have expressed HPV-16 L1 in transgenic 
plants (Appendix A), either by nuclear transformation (Biemelt et al., 2003; 
Varsani et al., 2003b; Liu et al., 2005; Maclean et al., 2007) or transplastomic 
chloroplast transformation (Fernández-San Millán et al., 2008; Lenzi et al., 
2008; Waheed et al., 2011), and the first plant-expressed HPV-16 L1/E6/E7 
chimaera has recently been expressed in transgenic tomatoes (Paz De la 
Rosa et al., 2009). 
 
Low expression yields (<1% TSP) have been consistently reported for 
HPV-16 L1 expressed in nuclear-transformed transgenic plants, possibly due 
to post-transcriptional gene silencing (PTGS) and adverse position effects 
(Rybicki, 2009). Similarly, the L1/E6/E7 chimaera also demonstrated low 
yields of 0.1% TSP in transgenic tomatoes (Paz De la Rosa et al., 2009). 
However, human codon-optimisation of the HPV-16 L1 gene and targeting the 
protein to tobacco chloroplasts has significantly improved transgenic yields to 
>1% TSP, with yields of 500 – 650 mg/kg plant tissue reported for the L1 
transgenic lines (Maclean et al., 2007). This suggests that the nuclear 
transformation of tobacco still has potential for the high-level expression of 
HPV-16 L1 and may be viable for commercial exploitation.  
 
HPV-16 L1 expressed in tobacco chloroplasts via transplastomic 
transformation produced yields of 3000 mg/kg (24% TSP), the highest 
plant-expressed HPV-16 L1 yields recorded to date (Fernández-San Millán 
et al., 2008). However, other transplastomic HPV-16 L1 expression studies 
have reported less impressive yields of 1.5% TSP (Lenzi et al., 2008; Waheed 
et al., 2011) and there are several important limitations of this system to 












transformation and selection, the limited choice of susceptible host plants, the 
prokaryotic-like post-translational processing and negative pleiotropic effects, 
which was recently reported for HPV-16 L1 (Waheed et al. 2011). As a result, 
transplastomic expression systems require further development in order to be 
utilized for commercial vaccine production, and the molecular processes 
responsible for the high-level accumulation of foreign protein in chloroplasts 
appear to be similar irrespective of whether the recombinant protein is 
transported to the chloroplast by a signal sequence or expressed from a 
plastid transgene (Fernández-San Millán et al., 2008).  
 
The transgenic expression of three human codon-optimised HPV-16 L1 
chimaeras was investigated by nuclear transformation of tobacco plants. The 
chimaeras were targeted to the chloroplast and contained either the L2 
epitope aa 108-120 (Kawana et al., 1999), the mouse-restricted E7 CTL 
epitope aa 49-57 (Feltkamp et al., 2003), or both the L2 and E7 epitopes. The 
L1/L2(108-120), L1/E7M and L1/L2/E7M chimaeras were specifically chosen 
to examine the effect of the L2 or E7 sequence replacement on chimaera 
expression. Furthermore,  the E7 chimaeras containing the mouse-restricted 
E7 CTL epitope (E7M) was chosen as vaccine efficacy is first demonstrated in 
animal models (Rybicki, 2009).  
 
 
5.2 Materials and Methods 
5.2.1 Plant transformation and regeneration 
The plant line used for transformation and transgenic expression of the L1 
chimaeras was Nicotiana tabacum cv. Petit Havana SR1. Leaf discs were 
transformed as described by Horsch et al. (1985). Sterilized leaf discs 
(~0.5 cm2) were incubated for 20 min in the pTRAkc-rbcs1-cTP chimaera 
Agrobacterium GV3101 cultures (OD600 = 1.0), grown overnight at 27ºC in 
induction medium with antibiotics (30 µg/ml kanamycin, 50 µg/ml rifampicin 
and 50 µg/ml carbenicillin). Leaf discs were placed on co-cultivation medium 












sucrose; 10 g/L plant agar, Sigma; pH 5.8 with KOH) for 2 days at 22ºC under 
constant light. The tranformation negative controls consisted of leaf discs 
dipped in induction medium, or dipped in the kanamycin-sensitive 
Agrobacterium GV3101 culture.  
 
Leaf discs were transferred to regeneration media containing kanamycin 
(300 mg/L) and cefotaxime (400 µg/L; Claforan®) and incubated at 26ºC, 16 
hrs light / 8 hrs, until small shoots developed (4–6 weeks). Shoots were 
separated from the original leaf discs and transferred to rooting medium after 
4-8 weeks (4.421 g/L MS nutrients and vitamins, Highveld Biological; 1 mg/L 
NAA; 30 g/L sucrose; 10 g/L plant agar, Sigma; pH 5.8 with KOH) with 
kanamycin and cefotaxime selection. When roots and shoots were 
established (4-6 weeks), regenerated plantlets were transplanted into soil and 
grown to maturity. Flowers were self-pollinated and the seeds were collected. 
 
5.2.2 PCR detection of the L1 gene 
Plant genomic DNA (gDNA) was extracted using the Doyle and Doyle (1987) 
protocol. After 2 weeks post-transplantation into soil, putative transgenic 
gDNA was extracted from 3 leaf discs per transgenic plant and plant gDNA 
was screened for the presence of the HPV chimaera gene by PCR using the 
HPV L2 or E7 epitope-specific primers and the PCR profile described in 
Chapter 2 (Section 2.2.4.2). PCR products were separated on a 2% TBE 
agarose gel and detected using ethidium bromide. 
 
5.2.3 Selection and generation of T1 transgenic lines 
Seeds were collected from each of the regenerated plants (R0 generation), 
surface-sterilized and germinated on regeneration medium under kanamycin 
selection (100 mg/L) for 1 week at 22ºC under constant light, in order to test 
seed viability and verify the presence of kanamycin-resistant chimaera 
transgene. To determine the % seed germination, 3 plates containing 
50-100 seeds were prepared for each transgenic line. The number of 












and the values were averaged. Wild-type Petit Havana SR1 seeds 
(kanamycin-sensitive) were included as a negative control. Seedlings 
(T1 generation) were transferred to soil when the shoots and roots were 
established and allowed to fully mature. 
 
5.2.4 Protein extraction and chimaera quantification 
Protein was extracted from R0 and T1 transgenic plants 4 weeks 
post-transplantation into soil (plants ~20 cm in height). The protein extraction, 
anti-L1 western blot detection and quantification of the total soluble protein 
(TSP) in each transgenic plant extract was performed as described for the 
transient-expressed chimaeras in Chapter 2 (Section 2.2.9).  
 
Supernatants were screened for HPV chimaera expression by CamVir1 
(1:10000) western blot analysis.  The wild-type Petit Havana SR1 plant extract 
was included as a negative control. A transiently-expressed L1/L2(108-120) 
sample (previously quantified using Cervarix), was run as a positive control 
and a standard on each blot. The density of the bands detected on anti-L1 
western blots was measured using GeneTools (SYNGENE) and estimated 
relative to the western blot standard. The relative chimaera yield was 
calculated by expressing the total chimaera yield (mg/kg plant tissue) as a 
percentage of the TSP, and the fold decrease in % TSP yield for the 
T1 transgenic lines was calculated relative to the higher-expressing R0 lines. 
 
5.2.5 Electron microscopy analysis 
The structural assembly of transiently and transgenically-expressed L1/L2, 
L1/E7M and L1/L2/E7M chimaeras was analyzed using immunocapture 
transmission electron microscopy. For transient chimaera expression, 
pTRAkc-rbcs1-cTP chimaeras co-expressed with NSs and extracted from 
N. benthamiana 5 days post-infiltration (dpi) was analysed (described in detail 
in Chapter 2, Section 2.2.6). The highest expressing transgenic line for each 
chimaera was examined for both the R0 and T1 generation (4 weeks 












included as a negative control. Crude plant extract was immunotrapped with 
CamVir1 antibody (1:1000) on carbon-coated copper grids, negatively stained 




5.3.1 PCR detection of the L1 gene in R0 transformants 
Several plant lines were regenerated from the transformation of leaf discs with 
the HPV chimaeras, mediated by A. tumefaciens. A few plant lines showed 
abnormal growth and phenotypical characteristics and were not transplanted 
into soil. Regeneration of 5-7 primary transformants (R0) was obtained for 
each HPV chimaera and regenerated plants displayed normal phenotypical 
characteristics. The negative control leaf discs on kanamycin-selective 
regeneration plates show no growth. Transformant gDNA was screened for 
the presence of the HPV chimaera gene by PCR, using L2 or E7 
epitope-specific primers (Figure 1). 
 
Band detection using the plant gDNA was difficult, even after several attempts 
to optimize the reaction using different concentration of gDNA template, MgCl2 
concentrations and DMSO. A commercial “Extract „n Amp” gDNA extraction kit 
was also utilized with no additional success (data not shown). Faint PCR 
bands were detected for four transgenic lines for the L1/L2, L1/E7M and 
L1/L2/E7M chimaeras, thus confirming the presence of the transgene. The 
















Figure 1: PCR detection of the L1 gene in the R0 putative transgenic lines for the A) L1/L2, 
B) L1/E7M and C) L1/L2/E7M chimareas. Labels: M = DNA marker with size in bp indicated on 
the left. –ve control = no template water control with the appropriate primer set. 
+ve control = pTRAkc-rbcs-cTP chimarea construct DNA. Numbers 1-7 indicate the putative 
transgenic lines tested. Black arrows represent the L2 or E7 epitope-specific chimaera PCR 
products. The white arrow represents a non-specific PCR product. Transgenic lines without a 
distinct chimaera-specific PCR band are indicated with a star (*) 
 
 
Southern blotting is required to determine gene copy number and to verify that 
the transgenic lines are not genetic clones (Warzecha et al., 2003; Paz De la 
Rosa et al., 2009). Furthermore, RNA detection using northern blotting 
(Biemelt et al., 2003; Warzecha et al., 2003; Paz De la Rosa et al., 2009) or 
RT-PCR (Varsani et al., 2003b; Kohl et al., 2007) would also be useful to 
detect transcription of the chimaera transgene. However, this was not done in 













5.3.2 Production of the T1 transgenic lines  
 
5.3.2.1 T1 seed germination 
Seeds from each transgenic line were germinated under kanamycin selection, 
in order to test seed viability and verify the presence of kanamycin-resistant 
chimaera transgene. Wild-type Petit Havana SR1 seeds (kanamycin-
sensitive) were included as a negative control. Although the wild-type seeds 
initially germinated, the seedlings died after 6 weeks, unlike the putative 
transgenic T1 seedings. The comparison is shown in Figure 2, using a 





Figure 2: T1 seed germination of a transgenic L1/L2 line (kanamycin-resistant) in comparison 
to the wild-type (WT) Petit Havana SR1 negative control (kanamycin-sensitive) under 
kanamycin selection. Both seeds germinated at 1 week (2A-B). However, the WT seedlings 














All HPV chimaera transgenic lines germinated (an example of the seedling 
regeneration plates for each of the HPV chimaeras is shown in Figure 3A-C), 




Figure 3: T1 seed germination of transgenic chimaeras under kanamycin selection. Each 
chimaera line was tested and examples of germinating transgenic A) L1/L2, B) L1/E7M and 
C) L1/L2/E7M chimaera seeds are shown, with D) the fully developed T1 plants. The wild-type 
Petit Havana SR1 seeds (negative control) initially germinated but did not survive under 
kanamycin selection.  
 
 
5.3.2.2 R0 and T1 HPV chimaera expression and quantification 
Protein was extracted from R0 and T1 transgenic plants and supernatants 
were screened for L1 chimaera expression by CamVir1 (1:10000) western blot 
analysis, using the transiently-expressed L1 chimaeras as positive expression 
controls (Figure 4A-C). The wild-type Petit Havana SR1 plant extract, included 













Figure 4: Expression of A) L1/L2, B) L1/E7M and C) L1/L2/E7M chimaera R0 and T1 putative 
transgenic lines. Chimaera expression was detected by anti-L1 western blot analysis for both 
the i) R0 and ii) T1 crude plant extracts. Labels: M = protein marker with size in kDa indicated 
on the left. –ve control = wild-type Petit Havana SR1 crude plant extract. +ve control 
= chimaeras transiently-expressed using pTRAkc-rbcs-cTP and co-infiltrated with NSs (5 dpi). 
Numbers 1-7 indicate the chimaera putative transgenic lines tested. Black arrows represent 
the detected chimaera (~56 kDa). Transgenic lines without a distinct HPV chimaera band are 
indicated with a star (*). 
 
 
A quantified L1/L2(108-120) chimaera standard was included in all the 
western blots (data not shown), in order to estimate chimaera expression 
yields and determine the relative chimaera yield (expressed in mg/kg plant 
tissue and % TSP) for each transgenic line (Table 1). The fold decrease in 
% TSP yield for the T1 transgenic lines was calculated relative to the 













Table 1: Summary of the HPV chimaera putative transgenic lines 











% TSP*** % seed 
germination 
Fold decrease 
in % TSP** 
L1/L2 1 Y Y 110 1.2 71 1.1 
  2 N N - - 69 - 
  3 Y Y 590 4.4 78 4.4 
  4 Y Y 730 7.4 64 12.3 
  5 Y Y 760 6.4 76 5.3 
  Summary 4/5 lines 4/5 lines 110 – 760 1.2 - 7.4 60 – 80 1 – 12 
L1/E7M 1 N N - - 91 - 
  2 Y Y 180 1.7 89 17.0 
  3 Y Y 220 2.3 79 4.6 
  4 Y Y 50 0.5 85 1.3 
  5 Y Y 210 1.8 78 3.0 
  Summary 4/5 lines 4/5 lines 50 – 220 1.7 - 2.3 80 – 90 1 – 17 
L1/L2/E7M 1 N Y 15 0.06 83 - 
  2 N N 10 0.02 89 - 
  3 Y Y 40 0.10 84 9.0 
  4 Y Y 10 0.02 91 30.0 
  5 Y Y 30 0.10 67 6.0 
  6 N N 5 0.01 68 - 
  7 Y N 10 0.01 90 - 
  Summary 4/7 lines 4/7 lines 5 – 40 0.01 - 0.10 70 – 90 6 – 30 
 
*Detection of the HPV chimaera genes by PCR (Y = yes, N = no). 
**Detection of the HPV chimaera protein by western blotting (WB). 
***TSP = Total soluble protein 
 
 
PCR detection of the chimaera transgenes identified four putative transgenic 
lines for each of the L1 chimaeras (Figure 1, Table 1). Western blot detection, 
using the anti-L1 MAb CamVir1, confirmed these transgenic lines for both the 
L1/L2 chimaera (Figure 4A: line 1 and 3-5) and L1/E7 chimaera (Figure 4B: 
line 2-5).  
 
The results for L1/L2/E7M were conflicted. Only 3 putative transgenic lines 
appeared to contain both the L1/L2/E7M gene and the expressed protein 
(Figure 4C: line 3-5). However, expression in line 4 was not present in the 
T1 generation, indicating that the gene may have been lost or experienced 












but expressed protein was not detected (Figure 4C), suggesting the transgene 
may have also been silenced. In contrast, line 1 was not detected by PCR 
(Figure 1C), although very low levels of protein were expressed (Figure 4C). It 
is possible the L1/L2/E7M transgene is present in line 1 and was not detected 
by PCR, suggesting further work is needed to optimize the PCR experiments 
and confirm the presence of the transgene. 
 
As described for transient expression (Chapter 2), the L1/L2 chimaera was 
generally expressed to higher levels than the E7M chimaeras, with higher 
yields obtained for the L1/E7M than L1/L2/E7M (Figure 4A-C, Table 1). The 
maximum L1/L2 yield was 4-fold higher than the maximum L1/E7M yield, 
suggesting the sequence and length of the sequence insertion affects 
expression. L1/L2 was up to 19-fold higher than the highest L1/L2/E7M yield. 
This suggests that the insertion of 2 epitopes within the L1 structure appears 
to negatively impact protein expression. All transgenic chimaeras showed 
higher expression levels in the R0 generation, with a decrease in the % TSP 
yield in the T1 generation (Table 1).  
 
The L1/L2 R0 transgenic lines produced yields of 110 – 760 mg/kg plant tissue 
(Table 1). Although the T1 generation shows a up to a 12-fold reduction in 
yield, transgenic lines 1, 4 and 5 still have yields >1% TSP (data not shown), 
considered the threshold for the commercial production of antigens (Fischer 
et al., 2004). The L1/E7M R0 transgenic lines demonstrated lower yields, with 
only line 2 and 3 containing yields >1% TSP (Table 1). However, yields were 
<1% TSP in the L1/E7M T1 generation (0.1 – 0.6 %TSP; data not shown) and 
in all the L1/L2/E7M transgenic lines (<0.1% TSP), suggesting the L1/E7M 
and L1/L2/E7M transgenic plants are not suitable for commercial exploitation. 
 
All T1 putative transgenic seeds germinated (64-91% germination), even for 
the lines which don‟t appear to contain the transgene (L1/L2 line 2, L1/E7M 
line 1, L1/L2/E7M line 2 and 6). The reason for this may be because the 
kanamycin concentration was too low to allow for efficient transgene selection, 












wild-type Petit Havana SR1 seeds (negative control), and thus higher 
kanamycin concentrations need to be utilized in the future. 
 
5.3.3 Electron microscopy analysis of L1 chimaera assembly 
Immunocapture electron microscopy was used to analyze the structural 
assembly of the L1 chimaeras targeted to the tobacco chloroplasts (Figure 5). 
The highest-expressing transgenic line was examined for each of the L1 
chimaeras and transiently-expressed L1 chimaeras were included for 
comparative purposes. Wild-type Petit Havana SR1 crude plant extract was 
included as a negative control. 
 
Figure 5A shows the L1/L2 chimaera assembled into cVLPs. Transiently-
expressed L1/L2 assembled into distinctive small cVLPs and capsomere 
aggregates, as observed in Chapter 3 (Section 3.3.3). The transgenic 
expression of L1/L2 resulted in chimaeras assembling into more distinctive 
cVLPs (~50 nm) and a variety of secondary structures, including non-uniform 
capsomere aggregates and partially-formed cVLPs.  
 
The transgenic L1/E7M chimaeras assembled into distinct, regular-sized 
cVLPs. In contrast, the majority of transiently-expressed L1/E7M chimaeras 
assembled into capsomeres (Figure 5B), although a few cVLPs were observed 
in the crude plant extract (inset in Figure 5B).  
 
The low-expressing L1/L2/E7M chimaeras (Figure 5C) assembled into 
distinctive cVLPs when expressed either transgenically or transiently, although 
the majority of the chimaeras formed capsomeres and aggregates, particularly 














Figure 5: Transmission electron micrographs of immunotrapped A) L1/L2, B) L1/E7M and 
C) L1/L2/E7M chimaeras, either transiently-expressed in the presence of NSs and extracted 
5 dpi, or expressed transgenically in tobacco plants. For the transgenic chimaeras: the 
transgenic line with the highest expression yields (L1/L2 line 5, L1/E7M line 5 and L1/L2/E7M 
line 2) was examined for both the R0 and T1 generations. D) Wild-type Petit Havana SR1 
crude plant extract served as the negative control. The insets emphasize the distinctive 
chimaeric VLPs observed in the samples. Red arrows indicate full-size VLPs (50-55 nm). Blue 
arrows indicate capsomeres (~10 nm) and white arrows indicate capsomere aggregates or 
small VLPs (20-45 nm). Scale bar = 50 nm. The chimaeras were analyzed on a Zeiss 912 













Transgenic expression of L1 or L1-based chimaera candidate vaccines is a 
potential strategy for the cost-effective production of HPV vaccines (Biemelt et 
al., 2003; Varsani et al., 2003b; Liu et al., 2005; Paz De la Rosa et al., 2009) 
and three L1 chimaeras (L1/L2, L1/E7M and L1/L2/E7M) were expressed in 
transgenic tobacco plants and analysed in this study. 
 
5.4.1 Production and genetic analysis of the putative R0 transgenic lines 
PCR detection of the chimaera genes identified four putative transgenic lines 
for each chimaera (Figure 1). Several problems were experienced with PCR, 
despite using similar primers and reaction conditions for the detection of 
E. coli and A. tumefaciens-expressed L1 chimaera genes (Chapter 2, Section 
2.2.4.2). Optimisation experiments using a range of template DNA, MgCl2, 
DMSO concentrations were largely unsuccessful, suggesting the plant gDNA 
may contain extract contaminants that inhibit PCR. However, another 
commercial extraction method was similarly unsuccessful and further work is 
warranted. Time constraints prevented further PCR optimisation, as well as 
Southern blotting and RNA analysis. 
 
5.4.2 Production of L1 chimaera T1 transgenic plants 
To assess the inheritance of the trangene in the T1 generation, 5-7 plant lines 
for each HPV chimaera were self-pollinated and the seeds were screened by 
kanamycin-resistance to select the lines containing the chimaera transgenes. 
All lines germinated (Table 1), including the kanamycin-sensitive negative 
control (wild-type Petit Havana SR1 seeds), which suggests the kanamycin 
concentration may not have been sufficiently high to select for antibiotic 
resistance. However, the negative control seedlings did not continue to 
develop after initial germination (Figure 2) and died within 6 weeks using the 
kanamycin-supplemented media, unlike the putative transgenic T1 seedings. 
 
5.4.3 Transgenic expression of the L1 chimaeras 
Four L1/L2 and L1/E7M transgenic lines expressed the chimaeras at 












observed for both the R0 and T1 generation (Figure 4, Table 1), suggesting the 
L1/L2 and L1/E7M transgene is stably integrated in the T1 generation. There 
appears to be at least four L1/L2/E7M transgenic lines (Table 1: Line 3-5 &7), 
although chimaera expression was not detected for line 7, and in the 
T1 generation for line 4 (Figure 4C), possibly due to position effects, gene 
silencing or even gene instability. As a result, it appears that the L1/L2/E7M 
chimaera transgene is less stable in tobacco plants.  
 
The transgenic expression of the L1 chimaeras was more successful than the 
plant-derived L1/E6/E7 chimaera recently expressed in transgenic tomatoes 
(Paz De la Rosa et al., 2009). All the L1/L2 and L1/E7 transgenic lines and 
two of the L1/L2/E7M lines (line 3 & 5) gave yields similar or greater than 
0.1% TSP (Table 1), the highest yield for a plant-derived L1-based chimaera.  
 
The L1/L2 chimaera was expressed to higher levels than L1/E7M in both 
transient (Chapter 2) and transgenic expression systems (Figure 4, Table 1). 
Transient expression of L1/L2(108-120) and L1/E7M gave yields of 
~1000 mg/kg and 30 mg/kg plant tissue respectively (Chapter 2, Figure 12 
and Table 4), and expression of L1/L2 in 3 of the 4 transgenic lines 
demonstrated higher expression yields than the highest-expressing L1/E7M 
line (L1/L2 Line 3-5: 590-760 mg/kg, vs. L1/E7M Line 3: 220 mg/kg). This 
suggests the sequence and the length of the epitope insertion may affect the 
expression of L1-based chimaeras when epitopes are located in similar L1 
positions. Furthermore, the maximum L1/L2 transgenic yields 
(Table 1: 760 mg/kg) are similar to the HPV-16 L1 yields (500 - 650 mg/kg) 
expressed in transgenic tobacco plants by Maclean et al. (2007), suggesting 
the L2 epitope may have a smaller affect on expression and protein stability in 
comparison to the E7 epitope.  
 
The L1/L2/E7M chimaera, containing 2 epitope insertions, was poorly 
expressed in both transient and transgenic systems, with yields of 5-40 mg/kg 












L1/L2 chimaera produced yields up to 19-fold higher than L1/L2/E7M 
(Table 1), suggesting that the second epitope insertion is not well-tolerated.  
 
5.4.4 Structural assembly of the L1 chimaeras 
Transmission electron microscopy was used to analyze the structural 
assembly of transiently and transgenically-expressed L1/L2, L1/E7M and 
L1/L2/E7M chimaeras (Figure 5). Wild-type Petit Havana SR1 plant extract 
was included as a negative control and no capsomere-like or VLP-like 
structures were observed in this sample. 
 
All the L1 chimaeras assembled into higher-order structures (Figure 5), with 
transgenic plant-derived L1/L2, L1/E7M and L1/L2/E7M assembling into 
cVLPs (~50 nm), similar to the HPV-16 L1 VLPs derived from transgenic 
plants (Biemelt et al., 2003; Varsani et al., 2003b). Transiently-expressed L1 
chimaeras assembled into capsomere aggregates and cVLPs of various sizes 
(25-50 nm). As a result, sequence replacements of ≤13 residues into the h4 
region and 9 residues into the coil between the h4 and β-J structural region do 
not appear to prevent capsomere and VLP assembly in transgenic plants, 
although the cVLPs are not morphologically similar to native virions. 
 
5.4.5 Conclusions 
Four putative tobacco transgenic lines were obtained for each of the HPV-16 
L1/L2, L1/E7M and L1/L2/E7M chimaeras, although one L1/L2/E7M line did 
not express detectable levels of protein, possibly as a result of position effects 
or PTGS. Chimaera expression was reduced in the T1 generation, suggesting 
that the transgenes were silenced by PTGS. 
 
The L1/L2 chimaeras gave higher expression levels than L1/E7M chimaeras 
and only low expression was detected for L1/L2/E7M. This suggests the 
length and sequence of the epitope insertion affects protein expression and a 
second 9 residue epitope insertion in the h4 and β-J structural region has a 
negative impact on expression, a factor which should be considered in the 












The L1/L2 and L1/E7M transgenes appear to be stably inherited in the 
T1 generation, while the L1/L2/E7M transgene appears to be less stable and 
may have been lost in one of the transgenic lines. All L1 chimaeras 
assembled into cVLPs of various sizes, although the morphology was 
irregular. Only the L1/L2 chimaera produced yields >1% TSP in the T1 
generation (Table 1: Line 1, 4 & 5), considered the threshold for the economic 
production of antigens (Fischer et al., 2004). Further analysis of the L1/L2 
chimaera lines is needed to determine long-term transgene stability and 
PTGS effects, as well as the immunogenicity and safety of the plant-derived 
candidate vaccine. However, the L1/E7M and L1/L2/E7M transgenic plants 
are not currently viable for commercial exploitation and the use of alternative 












Chapter 6: Conclusions 
Cervical cancer is a global concern and is the third most common cancer 
among women worldwide, with the majority of cases occuring in developing 
countries (Ferlay et al., 2010). Southern Africa is considered a high-risk region 
(Parkin and Bray, 2006) and cervical cancer is the most prevalent cancer in 
black South African women (Mqoqi et al., 2004). Therefore HPV vaccine 
development is a priority in preventative cervical cancer research, both 
globally and locally. 
 
There is an incentive to develop cheaper second-generation HPV vaccines 
which are broadly protective against multiple oncogenic types and therapeutic 
to treat pre-existing HPV infections and associated disease. This study 
examined the expression of eight HPV-16 L1-based chimaeras containing 
cross-neutralising L2 epitopes and therapeutic E7 CTL epitopes in plants and 
analyzed the immunogenicity of three plant-derived L1/L2 chimaera candidate 
vaccines in mice.  
 
Three types of HPV-16 L1 chimaeras were analyzed: the L1/L2, L1/E7 and 
L1/L2/E7 chimaeras. The L1/L2 chimaeras consisted of the South African 
HPV-16 L1 sequence containing cross-neutralising L2 epitopes; either 
HPV-16 L2 aa 108-120, 56-81 or 17-36, or the BPV-1 L2 aa 1-88 epitope. The 
L1/E7 chimaeras contained HPV-16 E7 CTL epitopes comprising of either the 
mouse-restricted E7 aa 49-57 epitope (E7M) or human-restricted E7 aa 86-93 
epitope (E7H). The L2 or E7 epitopes in the L1/L2 and L1/E7 chimaeras 
replaced the h4 region of L1 at aa 414, with the exception of the L1/L2 
chimaera containing the BPV-1 L2 epitope which replaced the entire L1 
C-terminal. The L1/L2/E7 chimaeras contained L2 aa 108-120 epitope in the 
same h4 region and the E7 epitope in the coil between the h4 helix and ß-J 
structural region at aa 433/434. These two insertion positions were chosen as 
they have been shown to successfully display L2 epitopes and elicit both 













6.1 Expression of L1 chimaeras in plants 
Plant expression systems present a cost-effective alternative for the 
production of vaccine antigens. However, optimisation of protein expression is 
necessary to obtain yields >1% TSP, considered the threshold for commercial 
production of recombinant proteins in plants (Fischer et al., 2004). 
 
6.1.1 Transient expression 
The highest HPV-16 L1 yields obtained thus far in an Agrobacterium-mediated 
transient expression system was 530-550 mg/kg plant tissue. These yields 
were acheived by human codon-optimisation of the L1 gene and by two 
strategies: targeting the expressed protein to the chloroplast (Maclean et al., 
2007) or using an agroinfiltration-delivered self-replicative BeYDV vector 
(Regnard et al., 2010). This is the first study which directly compared these 
strategies using eight human codon-optimised L1 chimaeras. 
 
All the HPV L1/L2, L1/E7 and L1/L2/E7 chimaeras were expressed in 
N. bethamiana using an Agrobacterium-mediated transient system. 
Optimisation experiments indicate that co-expression of the NSs silencing 
suppressor increased expression levels and the use of a BeYDV-based 
self-replicative vector increases the accumulation of L1/L2 chimaeras in the 
cytoplasm in comparison to a non-replicative vector. However, targeting the 
expressed chimaeras to the chloroplast is the best strategy for the high-level 
accumulation of chimaeras in plants and improved yields by up to 28-fold.  
 
The L1/L2 chimaeras, containing the HPV-16 L2 epitope sequences aa 
108-120, 56-81 or 17-36, were highly-expressed and produced commercially 
viable yields of ~1200 mg/kg (>1% TSP) which were 2-fold higher than the 
maximum HPV-16 L1 yields reported in a similar plant expression study 
(Maclean et al., 2007). However, the L1/L2 chimaera with the BPV L2 aa 1-88 
epitope was not well-expressed and degradation was detected, suggesting 












The low-expressing L1/E7 and L1/L2/E7 chimaeras produced maximum yields 
of 30 – 80 mg/kg plant tissue (<1% TSP) and thus require further optimisation 
in this expression system.  
 
6.1.2 Transgenic expression 
Transgenic expression of HPV-16 L1 or L1-based chimaeras is a strategy for 
the production of HPV vaccine antigens. Although nuclear expression of 
HPV-16 L1 is traditionally associated with low yields (<1% TSP), human 
codon-optimisation of the HPV-16 L1 gene and targeting the protein to 
tobacco chloroplasts significantly improved yields to 500 - 650 mg/kg plant 
tissue in L1 transgenic lines (>1% TSP, Maclean et al., 2007), suggesting 
nuclear transgenic expression of HPV antigens may still be viable for 
commercial exploitation.  
 
Three types of L1-based chimaeras were transgenically-expressed in 
nuclear-transformed tobacco plants: L1/L2(108-120), L1/E7M and L1/L2/E7M. 
The chimaeras were all targeted to the chloroplasts and were specifically 
chosen to examine the effect of the L2 or E7 sequence replacement on 
chimaera expression.  
 
Four transgenic lines were obtained for each of the HPV chimaeras. Similar to 
transient expression, L1/L2(108-120) was expressed to higher levels than 
L1/E7M and low expression was detected for the L1/L2/E7M, with maximum 
yields of 760, 220 and 40 mg/kg plant tissue respectively. Chimaera 
expression was reduced in the T1 generation, possibly as a result of PTGS, 
and only the L1/L2(108-120) chimaera lines continued to produce 
commercially viable yields >1% TSP.  
 
6.1.3 The effect of epitope insertions on expression 
The replacement of the L1 C-terminal with the BPV-1 L2 aa 1-88 epitope 
resulted in low expression levels and degradation in the plant cytoplasm, 
suggesting that the replacement of a large portion of the HPV-16 L1 protein 












The C-terminal plays a role in the assembly of capsomeres and VLPS (Zhou 
et al., 1991b; Varsani et al. 2006b; Bishop et al. 2007a), thus it is likely that 
the protein did not assemble and was degraded by cellular proteases (Chen 
et al., 2000). As a result, the production of L1/L2 BPV(1-88) chimaera 
production in plants was not pursued further.  
 
In contrast, the L1/L2 chimaeras containing the HPV-16 L2 epitopes 
aa 108-120, 56-81 and 17-36 (13-26 residues) were highly-expressed and 
produced yields up to 20-fold higher than the other chimaeras in a transient 
expression system. HPV-16 L1 demonstrated higher yields than the L1/L2 
chimaeras, although the differences were not statistically significant. This 
suggests the L2 epitope substitutions do not affect the expression and 
accumulation of HPV protein in chloroplasts.  
 
The L1/E7 and L1/L2 chimaeras, containing different epitopes inserted into 
similar L1 regions, demonstrated different expression levels. This provides 
further evidence that the expression of recombinant proteins in plants is 
empirical (Rybicki, 2010). In addition, both transient and transgenic 
expression of the L1/L2/E7 chimaeras provide evidence that the insertion of a 
second epitope into the coil between h4 and the β-J structural region in 
HPV-16 L1 appears to have a negative impact on expression and decreases 
yields by up to 19-fold in comparison to L1/L2(108-120), a factor which should 
be considered in the further design of HPV chimaera candidate vaccines. 
Furthermore, the inheritance of the L1/L2/E7M transgene appears to be less 
stable in transgenic plants and L1/L2/E7M demonstrated the greatest 
decrease in expression between the R0 and T1 transgenic lines.  
 
6.2 Structural assembly of the L1/L2 chimaeras 
The three highly-expressed L1/L2 chimaeras containing the HPV-16 L2 
epitopes aa 108-120, 56-81 and 17-36 were chosen as vaccine antigens for 
the mouse immunogenicity studies and the assembly of the L1/L2 chimaera 













Plant-derived HPV-16 L1 and the L1/L2 chimaeras were bound by the 
conformational-specific MAb H16.V5 (Christensen et al., 1996), suggesting 
the chimaeras assembled into higher-order structures (Carter et al., 2003; 
Wang et al. 2003; Ryding et al., 2007). Electron microscopy confirmed 
chimaera assembly; however, it was apparent that the L1/L2 chimaeras 
assembled into a variety of heterologous structures such as capsomeres, 
aggregates and VLPs. As a result, size-based purification methods were 
inefficient and HPV-16 L1 and L1/L2 chimaeras were purified using heparin 
chromatography. 
 
The L1/L2 chimaeras contained L2 epitopes which varied in length. 
L1/L2(108-120, L1/L2(56-81) and L1/L2(17-36) contained L2 epitope 
sequence replacements of 13, 26 and 20 residues respectively. Unmodified 
plant-expressed HPV-16 L1 assembled into T=7 VLPs (~50 nm), which were 
similar in size and morphology to those expressed in other studies (Biemelt 
et al., 2003). The L1/L2(108-120) chimaera assembled into smaller cVLPs 
which varied in size (25-40 nm) while the L1/L2(56-81) chimaera, with the 
largest sequence replacement, assembled exclusively into capsomeres 
(~10 nm). The majority of L1/L2(17-36) chimaeras assembled into 
capsomeres and aggregates, although a low concentration of amorphous 
cVLPs were observed.  
 
These results suggest the length of the L2 epitope affects the assembly of 
chimaeras, with epitopes >13 residues having a significant impact on VLP 
assembly. This is further supported by the electron microscopy results for 
plant-derived L1/E7M. The chimaera contained a 9 residue E7 epitope and 
also assembled into VLPs when expressed in transient or transgenic plant 
systems. 
 
This phenomenon is explained by the presence of a disulphide bond between 
the highly conserved cysteine residue 175 and 428 in VLPs (Li et al., 1998; 












the formation of capsomeres rather than VLPs (Li et al., 1998; McCarthy et al., 
1998; Sapp et al., 1998; Fligge et al., 2001; Varsani et al., 2006b) and thus 
the L1/L2(108-120) and L1/E7M chimaeras, with the epitope located at 
aa 414-426 and aa 417-425 respectively, does not replace the cysteine at  
residue 428 and does not affect assembly into cVLPs. As a result, the length 
of the epitope in the h4 region of L1 is an important factor to consider in the 
future design of L1/L2 chimaera vaccines. 
 
6.3 Immunogenicity of the L1/L2 chimaeras 
Plant-derived HPV-16 L1 and L1-based chimaeras have been shown to 
assemble into immunogenic higher-order structures and elicit the production 
of NAb (Maclean et al., 2007; Fernández-San Millán et al., 2008; Paz De la 
Rosa et al., 2009), widely considered the gold standard for demonstrating the 
potential of prophylactic HPV candidate vaccines (Rybicki, 2010) as protection 
is predominantly mediated by NAb directed against conformational epitopes 
(Breitburd et al., 1995; Jansen et al., 1995; Suzich et al., 1995; Christensen 
et al., 1996; Kirnbauer et al., 1996). Furthermore, insect cell-produced L1/L2 
chimaeras with the L2 epitope substituted into the h4 region of L1 were 
immunogenic and elicited the production of anti-L1 and anti-L2 humoral 
responses (Varsani et al., 2003a). As a result, the immunogenicity of 
plant-derived HPV-16 L1 and three L1/L2 chimaeras was investigated in this 
study. 
 
Plant-derived HPV-16 L1 elicited the highest anti-L1 titres, followed by 
L1/L2(108-120) and L1/L2(17-36). In addition, both L1 and L1/L2(108-120) 
elicited NAb against homologous HPV-16, which is detected in 61% of 
invasive cervical cancers worldwide (de Sanjosé et al., 2010). L1/L2(108-120) 
and L1/L2(17-36) demonstrated anti-L2 responses, which suggests the L2 
peptides were effectively displayed on the surface of the chimaeric protein. 
Although none of the antisera cross-neutralised HPV-18 or 45 pseudovirions, 
both L1/L2(108-120) and L1/L2(17-36) elicited cross-neutralising antibodies 












al., 2008; Schellenbacher et al., 2009). This result is particularly significant in 
a local context, as HPV-52 is highly prevalent in low and high-grade cervical 
lesions in South African women (Allan et al., 2008).  
 
As a whole, L1/L2(108-120) appears to be the best candidate vaccine as it 
elicited high anti-L1 titres, elicited an anti-L2 response and was the only 
chimaera to elicit both HPV-16 NAb and cross-neutralise heterologous 
HPV-52, unlike the type-specific L1 vaccine. L1/L2(56-81) did not appear to 
be immunogenic and this chimaera does not show potential for further 
development as a HPV vaccine. 
 
6.4 The effect of chimaera assembly on immunogenicity 
There appears to be a correlation between VLP assembly and L1 
immunogenicity. This was demonstrated by Thönes et al. (2008), where 
immunisation with VLPs elicits 20 to 40-fold higher humoral responses than 
capsomere vaccines. Similarly, plant-derived L1 VLPs elicited the highest 
anti-L1 response and HPV-16 NAb titres in comparison to the L1/L2 
chimaeras, comprising of smaller cVLPs, aggregates and capsomeres. 
Furthermore, L1/L2(108-120) cVLPs elicited higher anti-L1 titres than 
L1/L2(17-36) assembled into a mixed population of capsomeres, aggregates 
and cVLPs, which in turn elicited higher anti-L1 titres than the L1/L2(56-81) 
capsomeres.  
 
Only L1/L2(108-120) elicited detectable levels of HPV-16 and 52 NAb. 
Although the L2 aa 17-36 and L2 aa 56-81 have been shown to neutralise the 
HPV-16, 18, 45 and 52 types used in the neutralisation assays (Gambhira 
et al., 2007b; Kondo et al., 2007, 2008; Alphs et al., 2008; Schellenbacher 
et al., 2009; Rubio et al., 2009) the partial assembly of the plant-derived L1/L2 
chimaeras may have affected L2 immunogenicity. L2 peptides fused to 
keyhole limpit haemocyanin (KLH) rather than displayed on the surface of 
HPV-16 L1 cVLPs demonstrated lower HPV-16 and 18 NAb titres (Kondo 












aa 17-36 reduced both homologous HPV-16 and heterologous HPV-18, 45 
and 52 NAb titres to such an extent that HPV-45 and 52 NAb were not 
detected in the rabbit antisera (Schellenbacher et al., 2009). As a result, there 
is strong evidence that assembly of L1/L2 chimaeras into cVLPs elicits 
stronger immune responses than capsomeres and unassembled L1.  
 
6.5 Conclusions and future work 
Eight HPV L1-based chimaeras were transiently expressed in plants using an 
Agrobacterium-mediated transient system. However, the L1/L2 chimaera 
containing a C-terminal BPV-1 L2 aa 1-88 epitope replacement was unstable 
in plants and was eliminated as a potential candidate vaccine. The dual 
prophylactic and therapeutic L1/E7 and L1/L2/E7 chimaera candidate 
vaccines demonstrated low expression yields and require further optimisation. 
Transient expression of three HPV-16 L1/L2 chimaeras containing the L2 
aa 108-120, 56-81 and 17-36 epitopes in the h4 position in L1 accumulated to 
high levels in the chloroplasts and were chosen for further analysis in mouse 
immunogenicity studies. 
  
Plant-derived HPV-16 L1 and the L1/L2 chimaeras assembled into 
higher-order structures, with distinctive differences in assembly for the L1/L2 
chimaeras. The L1/L2(108-120), L1/L2(17-36) and L1/L2(56-81) chimaeras, 
with 13, 20 and 26 residue sequence replacements, assembled into small 
cVLPs, capsomere aggregates and capsomeres respectively. As a result, the 
insertion and the length of the L2 sequence replacement affects assembly 
and should be considered in the future design of chimaeras. 
 
Mice immunised with partially-purified L1/L2 antigens demonstrated that L1 
VLPS and L1/L2(108-120) cVLPs elicited higher anti-L1 responses in 
comparison to the other chimaeras assembled into capsomeres and 
aggregates. Overall, L1/L2(108-120) chimaera is the best candidate vaccine, 













Future work includes the optimization of L1/E7 and L1/L2/E7 chimaera 
expression in plants, possibly by combining the two high-yielding strategies 
and fusing chloroplast signal sequences to transgenes expressed using a 
self-replicative vector. In addition, the stability and expression of 
L1/L2(108-120) in the transgenic lines should be monitored over several 
generations to determine if the expression system remains commercially 
viable. Further analysis of L1/L2 chimaera cross-protection remains a priority; 
the HPV-52 neutralisation assay should be repeated and future assays should 
include HPV-31 and 35 (which is of particular concern in Africa and South 
Africa), and HPV-33 and 58 (which are highly prevalent worldwide). Finally, 
the L1/L2 chimaeras should be re-designed to allow cVLP assembly and 
improved L2 peptide display. Assembly into cVLPs may enhance both the L1 
and L2 immunity and stronger L2 responses may improve the cross-protection 














Table A1: Plant-expressed HPV-16 L1 antigens and HPV fusion proteins containing HPV-16 L2 and E7 
 








%TSP mg/kg plant tissue 
HPV-16 L1 Tobacco/leaf, Potato/tuber Transgenic 
0.5% (tobacco) 
0.2% (potato) 12 (potato) 
Human & plant codon-optimisation, 
TMV-derived translational enhancer Ω  
Capsomeres, 
VLPs 
Biemelt et al., 
2003 
  Tobacco/leaf Transgenic < 0.01% < 0.01 C-terminal truncation (NLS removed) Capsomeres, VLPs*** 
Varsani et al., 
2003b 
  Tobacco/leaf Transgenic 0.08% - None VLPs Liu et al., 2005 
  Tobacco/leaf Transienta < 0.01% 0.04 None Capsomeres, VLPs 
Varsani et al., 
2006a 
  Tobacco/leaf Transgenic & transientb 11 - 17% 530 – 890 
Human & plant codon-optimisation, 
ER & chloroplast localization 
Capsomeres 
VLPs*** 
Maclean et al., 
2007 
  Tobacco/leaf Transientc - 550 Human codon-optimisation Not examined 
Regnard et al., 
2010 
  Tobacco/ chloroplasts Transplastomic 1.5% - 
 Plant-codon optimisation, 
5' UTR & N-terminal plastid gene 
sequence (downstream box) 
VLPs Lenzi et al., 2008 
  Tobacco/ chloroplasts Transplastomic 20 - 26% 2100 – 3700 Used the light-regulated psbA 5‟-UTR VLPs 
Fernández-
San Millán et 
al., 2008 
  Tobacco/ chloroplasts Transplastomic 1.5% - 
Mutated with Cys replaced by Ser 
residues at aa 175 and 428 Capsomeres 
Waheed et al., 
2011 
HPV-16 
L1/E6/E7  Tomato/fruit Transgenic 0.1% - 
C-terminal truncation (NLS removed), 
Fusion of E6/E7 epitopes, 
ER-localisation sequence 
cVLP 
Paz de la 
Rosa et al., 
2009 
          
a Transient expression via tobacco mosaic virus (TMV) or potato virus X (PVX) viral vectors 
b Agrobacterium-mediated transient expression 
c Transient expression via agroinfiltration-delivered replicative Bean yellow dwarf virus (BeYDV)-based vector 
** Maximum yield expressed as a percentage of the total soluble protein (TSP) and/or expressed as mg of antigen per kg of plant tissue (mg/kg) 













Table B1: Pilot experiments to optimize the purification of plant-expressed HPV-16 L1 and L1-based vaccine antigens  
 
Strategy Method Details Results Reference 
Extraction *Crude protein 
extraction 
Mechanical methods, sonication, 
filtration 
Antigen soluble and localised in the 
supernatant. 
Chapter 3, Section 3.2.1 
Size-based purification Microfiltration Cross-flow microfiltration 
cartridges (0.45 & 0.65um) 
Process timely. 
Low antigen recovery: although the 
majority of the antigen was detected in 
the permeate, antigens were retained, 
even using the larger 0.65um cartridge. 
The technical extract from "The Innovation 
Fund Final Report: Novel Papillomavirus 
Vaccines, January 2007" (Rybicki, 2007; 
unpublished), and Cook et al. (1999) 
 Ultracentrifugation 40% sucrose cushion + 30% 
CsCl gradient 
No distinct bands visible, protein 
broadly detected in several fractions & 
method not reproducible for different L1 
chimaeras. 
Varsani et al. (2003a & b); Fernández-San 
Millán et al. (2008); Schellenbacher et al. 
(2009) 
  5-30% continuous sucrose 
gradient + 30% CsCl gradient 
No distinct bands visible in either 
gradient & protein broadly detected in 
several fractions. 
Large loss in recombinant protein 
yields. 
Based on method 5B, except a continuous 





POROS 50HS column Majority of antigen did not bind column.  
A small proportion of antigen bound 
strongly and irreversibly to the column 
As per manufacturer‟s instructions. 
Described by Cook et al. (1999) to purify 
yeast-expressed HPV-11 L1 
  HiTrap SPFF column Majority of antigen did not bind column.  As per manufacturer‟s instructions 
 Heparin 
chromatography 
*HiTrap Heparin HP column All chimaeras and L1 bound the column 
and eluted with a high salt PBS. 
As per manufacturer‟s instructions. 
Described by Johnson et al. (2009) and Kim 
et al. (2009, 2010) for the purification of L1 
from HPV-5, 16, 18, and 31. 
     Concentration/ buffer 
exchange 
Ultrafiltration Cross-flow ultrafiltration cartridge 
(300 kDa MWCO) 
Process timely. 
Degradation detected.  
Antigen successfully concentrated. 
The Innovation Fund Final Report: Novel 
Papillomavirus Vaccines, January 2007 
(Rybicki, 2007; unpublished) 
   *Macrosep® ultafiltration spin 
tubes (10 kDa MWCO) 
 Rapid concentration and desalting of 
chromatography fractions 
 As per manufacturer‟s instructions 
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